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In higher eukaryotes, the DNA base Cytosine can exist in a variety of modified forms when in the 
dinucleotide CpG. Although a methylated form tends to dominate within the genome, approximately 
1% of all CpG dinucleotides are found unmodified at high densities spanning around 1Kb and tend to 
co-localise to the 5’ ends of around 60% of annotated gene promoters. These unique DNA sequences 
are known as CpG islands (CGIs) and their role within the genome to date is largely unknown. 
Methylation of CGIs in cancers however has been linked to silencing of associated genes implying a 
role in gene regulation. Furthermore these sites are also interesting as they remain specifically non-
modified within a genome rich in methylated CpG. 
 
We set out to better understand the roles for CGIs through the characterisation of any specific CGI 
binding proteins. Digestion of nuclei with methyl sensitive restriction enzymes facilitates the 
purification of CGI fragments. Subsequent immunohistochemistry on the CGI chromatin fragments 
along with ChIP-PCR over several CGIs revealed an enrichment of the “active” histone modifications 
including H3K4me3, a depletion of the “silencing” marks such as H3K27me3, as well as a group of 
CGI specific binding factors. These latter proteins contained a domain previously shown to bind to 
non-methylated CpG dinucleotides (the CXXC domain) and as such were ideal candidates for CGI 
specific factors, in particular a protein called Cfp1. Genome wide sequencing revealed a striking 
correlation between Cfp1 and H3K4me3 which were both seen at around 80% of islands. 
Furthermore, the presence of Cfp1/H3K4me3 at islands tended to have a negative correlation with the 
presence of chromatin rich in the silencing histone modification H3K27me3. Closer investigation of 
the Cfp1 protein reveals it to be a true non-methyl CGI binding factor in vivo and shRNA reduction of 
Cfp1 levels to around 10% of wild type resulted in a precipitous drop in H3K4me3 levels over CGIs 
without a dramatic reduction in global H3K4me3 levels. As Cfp1 has been shown to be part of the 
Set1 histone H3K4 methyltransferase complex responsible for this modification, this CXXC protein 
may be attracting this histone modifying complex and as such represents a method whereby the 
underlying DNA sequence (CpG) can drive the overlying epigenetic state. This study may go some 
way to understanding the functional significance of CGIs within the genome. 
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Chapter 1: Introduction 
In biology, the term epigenetics is generally described as the phenomenon whereby the overall 
phenotype and gene expression profiles of a cell or organism are controlled by mechanisms other than 
the underlying DNA sequence. This name, derived from the Greek “epi” meaning over or above, 
describes the observation that the DNA sequence is under a higher level of control outside of its 
sequence. This control is brought about both by the direct chemical modification of the DNA itself 
along with the regulation of DNA binding proteins known as the histones. The wrapping of DNA 
around these histone proteins form an octameric protein structure called the nucleosome and the 
subsequent compaction of these structures packages the DNA into the nucleus of a cell. Therefore to 
gain access or to attract and repel certain enzymatic complexes to the DNA these nucleosomes must 
be regulated tightly. 
 
Epigenetic control is most prominent during development as pluripotent embryonic stem cells (ES 
cells) containing the same DNA sequences, differentiate into many functionally diverse cell types. 
These differentiated cells contain the same DNA sequence as the ES cells, barring any mutations 
picked up during differentiation; however the gene expression profiles of these cell types will vary 
massively. Many changes in gene expression are brought about through epigenetic mechanisms such 
as the modification of the local chromatin structure (through modulation of nucleosome positioning or 
modification of histone tails) or through epigenetic modification of the DNA without changes to the 
sequence itself.  In turn, these modifications can bring about changes in gene expression through the 
attraction or exclusion of specific binding factors which can facilitate or repress the transcriptional 
machinery. As the field of epigenetic research has grown, the importance of such control mechanisms 
has become apparent in a range of developmental disorders and diseases (Egger, Liang et al. 2004). 
These include many of the autism spectrum disorders (Schanen 2006) as well as carcinogenesis and 
the progression to tumourogenesis (Jones 2002). Furthermore several disorders have been found to 
contain “epimutations” which occur without any detectable changes or mutations in the DNA 
sequence itself (Horsthemke 2007). Investigating the links between specific histone modifications, 
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chemical modifications to the DNA sequence and the proteins recruited to such modified sites should 
lead to a better understanding of epigenetic gene control. 
 
1.1 Chromatin structure and post translational modification 
of the nucleosome 
The basic repeating structure of chromatin is that of the nucleosome; consisting of ~146 base pairs of 
DNA wrapped around a octamer of the four histone proteins H2a, H2b, H3 and H4
i
. This octamer is 
made up of two dimers of H3 and H4 and two dimers of H2a and H2b (each forming tetramers). These 
two tetramers then combine with ~146bp of DNA to form the octameric nucleosomal structure (fig 
1.1-1, A; right). This nucleosomal unit is responsible for the compaction of the DNA sequence of an 
organism into chromosomes through the folding of these DNA:protein complexes into higher order 
structures (fig1.1-1, A; left). Not only does the nucleosome facilitate the packaging of the DNA, it 
also plays a critical role in the regulation of the genetic code by restricting the access of sequences 
within these compact structures.  This is thought to primarily occur through the modification of the 
histone proteins which can affect the compaction of local nucleosomes. The histone proteins consist of 
both a globular domain and an N terminal flexible tail. Whislt the globular domains interact with one 
another to form the octameric histone core complex, the tails protrude out from this structure and act 
as platforms for chemical modification by a host of enzymatic complexes (Figure 1.1-1, B). Chemical 
modification of certain residues in these tails results in changes to both the overall compaction of the 
chromatin as well as attracting or repelling specific protein complexes. Thus the higher order fibers 
can be decompacted (forming a “euchromatic” environment) allowing proteins to access and exert an 
effect on the DNA, or tightly compacted (forming a “heterochromatic” environment) resulting in 
inaccessible DNA sequences. This form of regulation when placed upon the DNA is regarded as 








i. Although typical nucleosomes consist of the histones mentioned in the text, nucleosomes are found which 






Figure 1.1-1. The structure and modification of the mammalian nucleosome. A.The structure of a 
typical nucleosome is shown on the right. Histones H2A (yellow), H2B (light red), H3 (green) and H4 (blue). 
Residues comprising the charged pocket are shown in dark red. Not shown are the flexible N terminal histone 
tails which are freely associable outside the nucleosome. These nucleosomes are packaged into higher order 
structures as shown on the left, which finally results in the formation of the chromosome.B. Schematic of selected 
histone tail modifications along with the organisation of the nucleosome. Some of the key post translational 
modifications are shown across the four histone tails (see key for colour coding).  
 







Study of these histone tail modifications and their effector proteins as well as the distribution of these 
marks throughout the genomes of multiple organisms has resulted in a greater understanding of 
epigenetic regulation. Nevertheless many of these findings are purely correlative and as such require 
further investigation. The most commonly investigated histone modifications are the incorporation of 
methyl or acetyl groups into lysine and arginine residues or the phosphorylation of serine residues 
across the four histone tails. The specific modifications placed upon certain residues in turn exert a 
particular effect upon the regulation of genes. 
 
1.1.1 Selected histone tail modifications 
The N terminal tails of the four histone proteins can be post translationally modified at many residues 
(Figure 1.1-1). Some of these modifications have been studied more extensively than the others; 
largely due to the roles such modifications appear to play in the regulation of several key processes 
such as gene regulation, cell cycle progression and overall chromatin compaction. Some of the more 
frequently researched modifications are explained below in greater detail.  
 
i) Methylation at lysine 4 of Histone H3 
Methylation of the fourth lysine residue on the N terminal tail of Histone 3 (H3K4me) was first 
identified in trout testes in 1975 (Honda, Dixon et al. 1975) and is found to exist in three states; mono-
, di- and trimethylated H3K4. This methylation is progressive from the mono-methylated state 
(H3K4me1) through to a fully tri-methylated form (H3K4me3) which is generally found to be 
associated with transcriptionally active chromatin (Bernstein, Kamal et al. 2005). Studies in yeast 
have shown that the mono- and di-methyl marks occur at both active and inactive genes (Santos-Rosa, 
Schneider et al. 2002) often peaking in the body of genes (Pokholok, Harbison et al. 2005). Recent 
high resolution sequencing studies in the human genome revealed a somewhat contrasting pattern for 
the H3K4 mono- and di methylation in vertebrates (Barski, Cuddapah et al. 2007). Here it was found 
that although the mono- and di- methyl marks positively correlate with gene transcription they tend to 
peak at around -900 and +1000bp for mono H3K4me1 and -500 and +700bp for di-methyl over 
relative to the transcriptional start site (TSS) of genes (Figure 1.1-2 ) (Barski, Cuddapah et al. 2007).  
The trimethylated form of the modification is known to associate specifically with genes which are 
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active or destined to be so (Bannister, Schneider et al. 2002; Bernstein, Humphrey et al. 2002; Santos-
Rosa, Schneider et al. 2002; Schubeler, MacAlpine et al. 2004).  In budding yeast the H3K4me3 mark 
is seen at the 5’ end of genes during transcription and is thought to be set up through a combination of 
factors including RNA polymerase II (RNAP II) and a histone methyltransferase (HMTase) complex 
called COMPASS (Miller, Krogan et al. 2001; Ng, Robert et al. 2003). Studies on mammalian cells 
reveal a tight correlation between the TSS and H3K4me3 modified histones, with this modification 
found enriched from -300 to +100bp over promoters (Figure 1.1-2 ) (Barski, Cuddapah et al. 2007).  
 
This modification may provide a platform for the binding of chromatin modifying complexes which 
contain a PHD domain specific for methylated H3K4 residues. One such protein is the “bromodomain 
PHD finger transcription factor” (BPTF) which is part of the nucleosome remodelling factor (NURF) 
complex (Mizuguchi, Tsukiyama et al. 1997). Attraction of BPTF results in the formation of an 
accessible euchromatic state, allowing the binding of the transcriptional machinery to the DNA 
sequence. The H3K4me3 mark can also attract the Inhibitor of growth (ING) protein via its PHD 
domain. This protein has been shown to bind to both a histone actetyltransferase (HAT) complex as 
well a histone deacetylase (HDAC) complex, providing a potential link between histone acetylation 
and H3K4 methylation (Russell, Berardi et al. 2006). Finally, the histone H3 lysine 9 (H3K9) 
demethylase Kdm3a has been shown to bind to the H3K4me3 modification and removes any 
methylation from H3K9 residues, a mark normally associated with silencing. This results in the 
perpetuation of an active chromatin state, not only through the attraction of activating complexes, but 
through the loss of attraction of repressive complexes (Yamane, Toumazou et al. 2006). As studies 
into these H3K4me3 binding proteins are limited much is still left to learn regarding the downstream 
effects of this histone modification.  
 
ii) Methylation of lysine 27 on histone H3 
Methylation of lysine27 on histone H3 is a repressive histone modification associated with 
heterochromatic regions of the genome as well as at the promoters of silenced genes (Boyer, Plath et 
al. 2006; Roh, Cuddapah et al. 2006; Barski, Cuddapah et al. 2007). To date the trimethylated from of 
this modification is the best understood and histones rich in H3K27me3 tend to be found over much 
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larger domains (averaging 5-20kb) than the discrete peaks averaging 3kb seen for H3K4me3 (Figure 
1.1-2) (Bernstein, Mikkelsen et al. 2006). Recent work has also revealed the presence of “bivalent” 
regions of chromatin containing both H3K4me3 and H2K27me3 marks, most frequently found at a 
proportion of promoters in pluripotent ES cells (Bernstein, Mikkelsen et al. 2006). These bivalent 
domains are thought to represent regions “poised” for later transcription. It appears that during 
differentiation either the H3K4me3 or H2K27me3 modification is lost from such sites depending on 
the expression of the gene in the differentiated cell type. 
 
The H3K27me3 modification is bound by a chromodomain containing protein termed Polycomb (Pc) 
which is part of a larger complex of proteins called the polycomb repressive complex 1 (PRC1,  
(Messmer, Franke et al. 1992). This complex contains the aforementioned polycomb protein along 
with stoichiometric amounts of three other proteins; Posterior sex combs (Psc), Polyhomeotic (Ph) 
 
Figure 1.1-2. The patterns of selected histone methylations over human TSS. ChIP sequencing 
across the human genome generating high resolution plots for H3K4me1, 2 & 3, H3K27me3 and H3K36me3 
modifications. The plots are grouped based on the relative activity of the associated gene (see key, bottom right). Each 
signal is plotted over a region spanning the TSS (“0”). H3K27me3 and H3K36me3 plots are plotted over a larger region 
than the H3K4 methylations as these modifications tend not to form discrete peaks. Signals are displayed as normalised 
counts revealing peaks and troughs for each of the histone modifications. For more on ChIP-sequencing see chapter 4.4. 


































and Sex combs extra (Sce) (reviewed by (Gil and Peters 2006). Although this complex is relatively 
simple in Drosophila, multiple orthologues of these proteins exist in mammals (Figure 1.1-4 below). 
As PRC1 binding occurs over large regions of H3K27me3 the end result is a large region of 
inaccessible and compacted chromatin which provide stable, long term and heritable silencing of 
underlying genes.  
 
iii) Methylation of lysine 36 on histone H3 
The methylation of histone tails at lysine 36 (H3K36me3) is mechanistically linked to the progression 
of the transcriptional machinery through the gene body. This mark is generally enriched within the 
coding regions of genes whilst low or absent over the 5’ promoter regions (Figure 1.1-2) (Barski, 
Cuddapah et al. 2007; Blackledge, Zhou et al. 2010). The functional significance of this modification 
is thought to be mediated through the attraction of specific effector proteins. During transcription the 
RNAP II complex passes through the gene body in a process termed transcriptional elongation. As the 
body of genes are thought to be found in a compacted chromatin state, the progression of the RNAP II 
complex relies on the localised de-compaction of this chromatin environment. This is brought about 
through the acetylation of histone tail residues (see section 1.1.1 iv below). In order to prevent 
spurious transcription, the state of the chromatin must be tightly regulated once the RNAP II complex 
has passed. This regulation is thought to be modulated through the H3K36me3 modification, which 
attracts the EAF3 chromodomain containing protein (Joshi and Struhl 2005). This H3K36me3 binding 
factor in turn attracts the histone deactylase complex Rpd3S which removes the acetyl groups from 
the histones once the transcriptional machinery has passed. The removal of acetyl groups from the 
histone tails results in a “closed” chromatin state preventing the initiation of internal transcripts. As 
such, the H3K36me3 modification is often used as a method to identify actively transcribed genes. 
Promoters however, are strictly devoid in this histone modification, presumably as they are required to 
become acetylated during transcriptional initiation.  
 
iv) Acetylation of residues on the H3 tail 
The addition of acetyl groups to histone tails can occur at a large number of the arginine and lysine 
residues on both histones H3 and H4 (Figure 1.1-1).  These modifications are tightly associated with 
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transcriptional activity and are found at the promoters of actively transcribed genes (Figure 1.1-2) as 
well as associated with the elongating RNAP II complex during transcription (Liang, Lin et al. 2004; 
Schubeler, MacAlpine et al. 2004). The mechanisms by which this modification brings about a 
decondensed chromatin state is not known however several models have been proposed. A likely 
mechanism is that the neutralisation of positively charged lysine residues in the histone tails by the 
addition of acetyl group reduces the interaction between the histone and the negatively charged DNA. 
Alternatively, the attraction of chromatin modifying complexes containing a bromodomain specific 
for the acetyl mark may result in a change in the local chromatin state. Evidence exists suggesting that 
the chromatin remodelling complex Swi/Snf, is bound to acetylated H3K23 residues resulting in 
nucleosomal remodelling (Awad and Hassan 2008). Additionally the TATA box protein associated 
factor (Taf1), which is part of the RNA polymerase II complex, is seen to bind to acetylated H4 tails 
through its bromodomain, resulting in a recruitment of the complex to modified histone tails 
(Matangkasombut and Buratowski 2003). 
 
1.1.2 Regulation of the histone tail modifications 
As the post translational modifications placed on the histone tails give rise to important regulatory 
mechanisms, these marks must be tightly regulated. As such, each modification is regulated to ensure 
the coordinated addition and removal in a temporal fashion. Some of these modifications are relatively 
simple in their regulation whilst for others several multiprotein complexes act.   
 
i) Regulation of H3K4 methylation by the Trithorax group of proteins 
The enzymes responsible for the methylation of histone H3K4 were first identified in Drosophila as 
having essential roles in the maintenance of gene expression (Byrd and Shearn 2003). This protein, 
known as “Trithorax” (TRX) and “Absent Small or Homeotic discs 1” (Ash1) contains a catalytic 
SET methyltransferase domain responsible for the methylation at H3K4 residues. Enzymatic 
complexes containing this conserved SET domain were also found in the yeast and mammalian 
genomes indicating that similar methylation role existed for these proteins (Miller, Krogan et al. 
2001). The yeast homologue of trithorax, Set1, is part of a large multiprotein complex called 
COMPASS. Characterisation of this 400kd complex revealed six other proteins (Figure 1.1-3), 
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CPS60, 50,40,35,30 and 25 (Miller, Krogan et al. 2001; Shilatifard 2008) in addition to the catalytic 
Set1 protein. Further work on this complex found that the Set1 protein is able to bind to the 
phosphorylated carboxy-terminal domain (CTD) of RNA Pol II and catalyse the methylation of H3K4 
residues (Ng, Robert et al. 2003). Of the other proteins, CPS50, 35 and 30 contain WD40 repeats 
(Figure 1.1-3). WD40 domains are around 40 amino acids long and are thought to be important within 
the formation of multi-protein complexes (Li and Roberts 2001). Other interesting proteins include 
CPS60 (also known as Bre2) and CPS40, also known as Spp1. These two proteins have been shown to 
be important for the progression of the methylated lysine from a dimethylated form to a trimethylated 
form (Schneider, Wood et al. 2005). Furthermore as Spp1 contains two PHD domains it is thought to 
be important in targeting the complex to chromatin (Figure 1.1-3). Removal of this protein results in a 
reduction in H3K4me3 levels arguing that its role may be to tether the COMPASS complex to specific 
regions of chromatin. Alternatively this loss in H3K4me3 may represent an essential role for Spp1 in 
the enzymatic viability of this complex.  
 
In the mammalian genome, H3K4 methylation seems to be a more complex affair. Whilst one SET 
complex appears to be responsible for the control of H3K4 methylation in yeast, multiple histone 
methyltransferases (HMTases) appear fill this role in the mammalian genome. Although it is unknown 
why such a number of H3K4 HMTases are required in higher eukaryotes, likely explanations are that 
the complexes are either functionally redundant or that each modify particular regions of the genome. 
Evidence exists to support the latter hypothesis as specific deletions and truncations of three different 
H3K4 HMTase genes in mice all give rise to distinct phenotypes (Yu, Hess et al. 1995; Glaser, Schaft 
et al. 2006). Mammalian H3K4 HMTases all contain a highly conserved SET methyltransferase 
domain, similar to those seen in the yeast Set1 and Drosophila TRX proteins. The best characterised 
of these histone methyltransferases belonging to a family of proteins called the MLL proteins (Milne, 
Briggs et al. 2002; Wysocka, Myers et al. 2003; Yokoyama, Wang et al. 2004). This family contains 
the members MLL1, 2, 3 and 4 as well as Set1A and 1B (Figure 1.1-3) and exist in multi-protein 
complexes containing the mammalian homologues of the COMPASS complex found in 
Saccharomyces cerevisiae (reviewed by (Shilatifard 2008).  
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These multi-protein complexes share a common set of subunits to the S.Cerevisiae COMPASS 
complex such as the CPS homologues ASH2, WDR5 and RbPB5 (Wysocka, Myers et al. 2003; Lee 
and Skalnik 2005) . These proteins are essential for enzymatic activity, as removal of just one of the 
aforementioned subunits results in loss of activity in vitro and in vivo (Dou, Milne et al. 2006). 
Several of these subunits have been studied in greater detail such as the yeast CPS30 homologue, 
WDR5. This protein, as in yeast, contains WD40 repeats responsible for the formation of protein-
protein interactions. Furthermore it has been shown to be responsible for the binding of H3K4 MTase 
complexes to histone tails already carrying the H3K4me3 modification (Wysocka, Swigut et al. 2005). 





Figure 1.1-3. The Trithorax proteins in yeast and human. The components of the yeast COMPASS 
complex and the homologues in human. The core components are conserved between the human hSet1, Mll1, 
Mll2 &Mll3/4 complexes (purple text) with the catalytic SET domain protein as well as several other subunits 





























Although many of the subunits are shared between the mammalian H3K4 HMTase complexes, a few 
individual proteins vary. The Set1a and Set1b complexes are by and large identical in their protein 
content with the only difference being the catalytic methyltransferase present (either the Set1a or 1b 
protein). Presumably this allows for overlapping and non-redundant properties between complexes. 
Studies investigating the distribution of the Mll1 complex within cultured human cells found a tight 
correlation with sites of RNA polymerase occupancy (Guenther, Jenner et al. 2005). Mll1 was seen 
bound to 5,186 promoters which represent 23.3% of annotated protein coding promoters. Although 
the exact roles for the H3K4 HMTase complexes are not fully understood, each is thought to play an 
important role in the initiation and propagation of the H3K4me3 modification.  
 
 
ii) Regulation of H3K27 methylation by the Polycomb group of proteins 
The proteins responsible for the methylation of H3K27 residues were first discovered in Drosophila 
as proteins able to control the expression of genes responsible for the development of body segments 
(Lewis 1978). Subsequent work revealed that these proteins remodel the chromatin resulting in 
epigenetic maintenance of silenced gene state (reviewed by (Gil and Peters 2006; Sauvageau and 
Sauvageau 2008). In mammals these proteins, called the “polycomb proteins”, form two discrete 
groups. The complex responsible for the initial methylation of H3 tails at K27, termed Polycomb 
repressor complex 2 (PRC2), is made up of three core components; Enhancer of Zeste (EzH2), Extra 
sex combs (Esc also known as Eed) and Suppressor of Zeste-12 (Su(z)12), along with several other 
proteins likely to have roles in directing the complex to specific loci (Figure 1.1-4). 
 
The specific methylation of H3K27 residues occurs through the catalytic SET methyltransferase 
domain found in the EzH2 protein whilst chromatin binding is facilitated through interactions with the 
PHD zinc finger of Su(z)12 (Birve, Sengupta et al. 2001). The methylation of H3K27 tails leads to the 
attraction of a second complex of polycomb proteins, PRC1, which results in the compaction into 




              
Figure 1.1-4. Mammalian Polycomb repressor complexes A. Class II polycomb complex (PRC2) is 
made up of three proteins, Esc, Su(z)12 and the catalytic subunit E(z) responsible for the methylation of H3K27 
residues (B). C. PRC1 complexes are more complex in their formation than PRC2. Although consisting of four 
subunits, multiple forms of each exist as shown by the boxed lists. D. PRC1 complexes bind to the H3K27me3 
modifications set by the PRC2 complex. These PRC1 complexes form compacted and repressed chromatin. 
(Figure from (Gil and Peters 2006) 
 
 
iii) Dynamic regulation of methyl groups from lysine 36 of histone H3 
As H3K36me3 modified tails are involved in the progression of transcription through the gene body in 
conjunction with acetylation, this modification is somewhat dynamic (see 1.1.1 part iii above). It is 
therefore important that this modification can be removed as well as deposited. The protein Set2 
interacts with RNAP II and specifically methylates lysine 36 on histone H3. Set2 is recruited to 
phosphorylated serine 2 residues on the RNAP II C-terminal domain facilitated by the Ctk1 protein 
(Xiao, Shibata et al. 2007). This in turn ensures that the processes of transcriptional elongation and 
H3K36 methylation are tightly coordinated. Once the transcriptional machinery has passed the H3K36 
methylation must be removed. The removal of methyl groups is carried out by two classes of proteins; 





each demethylate specific lysine residues such as the affinity of Kdm5s for H3K4me3 and Kdm3a for 
H3K9me3 demethylation (Klose, Kallin et al. 2006; Ingvarsdottir, Edwards et al. 2007). Recent work 
has revealed the Kdm2a protein as the demethylase responsible for the removal of methylation from 
H3K36 residues (Blackledge, Zhou et al. 2010) 
 
iv) Regulation of acetylation across the histone H3 tail 
The acetylation and deacetylation of arginine and lysine residues on histone tails is thought to be a 
dynamic process tightly linked to transcription (Hebbes, Clayton et al. 1994). This dynamic nature 
requires the coordinated addition and removal of acetyl groups from histone tails which is a process 
carried out by a group of histone acetyl transferases (HATs) and histone deacetylases (HDACs) 
(Wang, Zang et al. 2009). Three major families of HATs have been found in mammals: the Gcn5 
related acetyltransferases (GNATs) which specifically target H3 tails, the MYST family of HATs 
which target the H4 tails and the CBP/p300 family which can target both tails. (Glozak, Sengupta et 
al. 2005). Although functionally similar, structural analysis reveals that each group of HATs are 
distinct from one another (Vetting, LP et al. 2005). The HDAC proteins fall into four main groups 
based on their catalytic activity. Type I, II and IV HDACs have a related mechanism for deacytlation 
whilst the third group, type III, require the cofactor nicotinamide adenine dinucleotide (NAD) 
(Kurdistani and Grunstein 2003; Vaquero, Sternglanz et al. 2007). Thus it can be seen that the 
regulation of acetylated histone tails is a highly complex process facilitated by multiple protein 




1.2 Epigenetic modification of the DNA 
The epigenetic mechanisms discussed so far have all involved modifications to the tails of the 
abundant DNA binding proteins; the histones. However the DNA can also be directly modified by the 
incorporation of a methyl or hydroxymethyl group (Figure 1.2-1). To date the majority of work has 
focused around the methylation of DNA and although the distribution of this covalent modification is 
seen to vary between many organisms the functional implications remain the same. 
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1.2.1    DNA methylation across organisms  
i) DNA methylation in bacteria 
In E.coli, methylation can occur at the 6
th
 nitrogen of the adenine base and 4
th
 nitrogen and 5
th
 carbon 
of the cytosine base (Noyer-Weidner and Trautner 1993). Interestingly this modification appears to act 
as a defence system against invading bacteriophages as exogenous sequences lacking such methyl 
marks are vulnerable to degradation by methylation sensitive restriction enzymes encoded by the 
bacteria (Meselson, Yuan et al. 1972; Bestor 1990). Further to this role, methylation has also been 
implicated in the regulation of transcription as removal of DNA methylation in bacteria led to the 
overexpression of many genes (Low, Weyand et al. 2001). 
 
ii) DNA methylation in fungi 
The presence and distribution of methylated DNA varies widely between members of the fungi 
family. This epigenetic modification has not been detected in the ascomycetes S.cervisiae and 
S.pombe (Proffitt, Davie et al. 1984) however high levels of methylated cytosine (methylated at the 5
th
 
carbon) are found in the filamentous fungi Neurospora crassa at single cytosine bases (Selker, 
Tountas et al. 2003). Furthermore these 5 methyl cytosine (5meC) nucleotides are seen to associate 
specifically within transposable elements and removal of this methylation results in increased 
transposition.  
 
iii) DNA methylation in plants 
Methylation of the DNA is also found in plants, where as much as 6% of the Arabidopsis genome 
contains the 5meC nucleotide (Bender 2004). In contrast to the simpler organisms described above 
this modified base can exist within the context of CpG, CpNpG, and CpNpN sequences where N 
represents any nucleotide but guanine (Finnegan, Genger et al. 1998). The distribution of this 
modification throughout the Arabidopsis genome reveals that the majority of gene bodies are devoid 
in 5meC, whilst a minority of promoters contain this mark and tend to exhibit tissue specific 
expression profiles. Once again, removal of DNA methylation results in the expression of transposons 
 29 
(Zhang, Yazaki et al. 2006) suggesting that the major role for DNA methylation in plants is similar to 
the genome defence roles employed by bacteria and fungi.  
 
iv) DNA methylation in invertebrates 
DNA methylation in invertebrates such as Ciona intestinalis is a more complex affair. Generally 
methylation patterns are mosaic; occurring in domains interspersed with non-methylated domains. 
These non-methylated regions tend to co-localise to promoters, intergenic DNA sequences as well as 
transposons (Suzuki, Kerr et al. 2007). As such, methylation appears to be targeted to the bodies of 
genes and it is thought that the role of DNA methylation here is to prevent the spurious initiation of 
transcription from within a gene. Once again, DNA methylation is intrinsically linked to inaccessible 
and silenced chromatin.  It must be noted however that several invertebrate genomes are found to be 
completely devoid of DNA methylation such as the nemadote C.elegans or contain extremely low 
levels, as is the case with the fruit fly Drosophila (Bird 2002). As these organisms still contain defined 
regions of histone tail modifications and are able to silence transcription efficiently this argues that an 
alternative mechanism for gene silencing separate to DNA methylation exists in these organisms. 
Quite why DNA methylation is absent from C.elegans and Drosophila is not known. 
 
1.2.2    DNA methylation in mammals 
i) CpG as a signalling molecule 
In the mammalian genome, epigenetic modification of the DNA occurs at cytosine bases within the 
dinucleotide CpG (Figure 1.2-1). The most abundant form of this dinucleotide (representing around 
70% of methylated bases) is modified through the incorporation of a methyl group onto the fifth 
carbon in the cytosine base (5 methyl cytosine).  As in other organisms, this methylated cytosine base 
tends to be found within compacted chromatin and has links to the silencing of associated genes and 
transposable elements. Whether or not the methylation of DNA is directly responsible for these events 
or is a secondary event of heterochromatic compaction is as yet unknown.  
 
A second state in which the CpG dinucleotide is found contains a modified 5-hydroxy methyl cytosine 




 carbon on the cytosine base. Although first characterised in the bacteriophage in 1952 (Wyatt and 
Cohen 1952) it was only recently found in mouse and human (Kriaucionis and Heintz 2009) and as 
yet no known hydroxymethyl CpG (hmCpG) binding proteins have been identified. To date 5hmC has 
only been found in a few cell types such as the purkinje neurons in the brain and embryonic stem 
cells. Whether or not this modified base represents a unique signalling platform or is simply an 
intermediate in demethylation processes is as yet unknown.     
 
Although the majority of CpG dinuleotides exist in a methylated form, around 30% is non-modified 
and is of particular interest due to its unique distribution throughout the genome. These non-
methylated cytosine bases tend to be found over 1kb stretches of CpG rich DNA, often at discrete loci 
such at the 5’ ends of genes (Bird, Taggart et al. 1985; Bird 1986). In contrast to methylated cytosine, 
this non-modified form of the CpG dinucleotide is associated with the promoters of active genes and 




Figure 1.2-1. Cytosine bases within CpG dinucleotides exist in three forms. The cytosine base can 
exist in three distinct states within the dinucleotide CpG in the mammalian genome. Around 30% of cytosine is 
found in a non modified state which tends to occur in regions of high CpG density. The majority of CpG (~70%) 
exists in a modified form in which a methyl group is found at the carbon 5 position of the DNA base.  In contrast 
to these forms of cytosine, relatively little is known regarding cytosine containing a hydroxymethyl group 
however this base may represent an intermediate between methylated and non-modified cytosine. 
 
ii) Distribution of DNA Methylation  
Although the majority of CpG dinucleotides exist in a methylated state, they do so over a large 
fraction of the genome (~98%) at low densities around 1 per 100 base pairs of DNA (Bird 1980).This 






of the methylated cytosine base. As methyl CpG is relatively unstable, spontaneous deamination of 
this modified dinucleotide through a hydrolysis reaction converts the methyl cytosine into thymine. 
As the resulting conversion is not efficiently repaired by the DNA repair machinery this results in an 
under-representation of this dinucleotide.  Although deficient in CpG density, regions of high meCpG 
are typically found associated with transposable elements, intragenic regions and repeat sequences 
(Weber, Davies et al. 2005; Eckhardt, Lewin et al. 2006). In contrast to these methylated CpGs, the 
remainder of the genome (<2%) is rich in non modified CpG dinucleotides (typically 1 CpG per 10 
base pairs) at discrete loci. These unique regions, termed CpG islands or CGIs will be explained in 
greater depth below (see chapter 1.3)   
 
Methylation of the cytosine base has been associated with gene silencing events and the formation of 
localised heterochromatin across a host of organisms. Early experiments revealed that the gene 
encoding adenine phosphoribosyltransferase (aprt) was silenced by methylation of CpG dinucleotides 
over its promoter region upon transfection into cultured mammalian cells (Stein, Razin et al. 1982). 
Additional experiments revealed that removal of DNA methylation through the use of the drug 5-
azacytidine (5 Aza-C) resulted in the restored expression of genes on the inactive X chromosome 
which were previously identified as silenced by the methyl mark (Mohandas, Sparkes et al. 1981; 
Wolf, Jolly et al. 1984). Precisely how the addition of a methyl group results in the silencing of 
underlying genes is still subject to some debate. One possible explanation is that this silencing may 
arise through the direct steric hindrance of transcription factors and binding proteins by the methyl 
group itself. Alternatively meCpG can act as a signalling module for the binding of a series of proteins 
which contain methyl binding domains (MBDs). Many of these proteins can either directly, or 
indirectly influence local chromatin modifications resulting in a transcriptionally repressive 
environment.  
 
iii) DNA methylation as a heritable epigenetic mark 
The methylation of cytosine nucleotides is a heritable epigenetic mark in that it is copied over onto 
newly synthesised strands of DNA upon replication. Early work on establishing the methylation 
patterns in mammals was carried out through the use of methylation sensitive restriction enzymes 
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where the methyl mark protects the CpG site from digestion. In the context of double stranded DNA it 
was found that the cytosine within a CpG dinucleotide would be either be methylated on both strands 
or unmethylated on both, fitting with a model of a transmissible methylation mark (Bird 1978). The 
fact that the patterns are faithfully copied over during cell division give rise to a mechanism of cell 
memory which is essential for viability (Li, Bestor et al. 1992).  
 
1.2.3    Setting up the DNA methylation pattern: the de novo 
methyltransferases 
DNA methylation patterns in mammals are set up during gametogenesis and again in embryogenesis 
(Reik, Dean et al. 2001; Reik 2007; Weber and Schubeler 2007). Initially the genomes of mature 
sperm and egg cells contain high levels of methylated DNA, equivalent to those found in somatic cells 
(Bestor 2000). During the early stages of development the levels of DNA methylation drop 
precipitously. Analysis of global DNA methylation levels in the fertilised egg using an antibody 
against 5meC revealed that one chromosome appeared remarkably different from the other in its 
methylation content (Rougier, Bourc'his et al. 1998). Closer inspection of the zygote prior to the 
fusion of the maternal and paternal pronuclei revealed that although both were initially highly 
methylated, there was a dramatic loss of methylation from the paternal genome a few hours after 
fertilisation (Mayer, Niveleau et al. 2000; Oswald, Engemann et al. 2000). Intriguingly, this loss of 
methylation occurs in the absence of DNA replication and as such appears to be an example of an 
active demethylation, possibly facilitated through an as yet unidentified DNA demethylase enzyme. In 
contrast, the maternal genome also loses DNA methylation during early embryogenesis. However this 
loss is a passive event, occurring as a result of cell division in the absence of a DNA methyltransferase 
enzyme. In total more than half of the initial DNA methylation levels are lost at this stage prior to re-
methylation once implantation has occurred. 
 
The enzymes responsible for the methylation of DNA can be separated into two groups; those which 
can set up the patterns of methylation during development and those which maintain it in 
differentiated cells. So far four mammalian DNA methyltransferases (Dnmts) and one specific 
cofactor have been discovered all of which share at least a large part of a conserved catalytic domain 
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responsible for the methylation of the DNA (Figure 1.2-2). Two of these Dnmts have been shown to 
be essential for the setting up of the methylation patterns after the early developmental global 
demethylation events and as such are termed the “de novo Dnmts”. This group consists of the 
enzymes Dnmt3a, 3b along with the 3a cofactor Dnmt3L. These de novo methyltransferases were first 
discovered through the observation that non-methylated DNA would remain in this non methylated 
state after multiple cell divisions. However non-methylated transgenes introduced into mouse 
preimplantation embryos were found to become stably methylated in the adult mouse (Jahner, 
Stuhlmann et al. 1982). Disruption of the gene for the previously discovered DNMT1 enzyme did not 
interfere with this de novo methylation and as such was excluded as a potential de novo 
methyltransferase. A search of EST databases using the catalytic domain of DNMT1 brought up three 
potential candidates, DNMT2, 3a and 3b (Okano, Xie et al. 1998). Further work on DNMT3a and 3b 
revealed that neither of these proteins were able to methylate hemimethylated DNA (unlike DNMT1), 
implying that these proteins act on non-methylated templates (Okano, Xie et al. 1998). Finally, 
disruption of both of these genes in embryos and ES cells led to a genome wide loss of methylation, 
leading to the conclusion that these complexes were indeed the de novo methyltransferases (Xie, 
Wang et al. 1999).  
 
Subsequent work has revealed that the protein DNMT3L is an important cofactor for DNMT3a and is 
required for the specific methylation at imprinted loci (Hata, Okano et al. 2002). Dnmt3L closely 
resembles the carboxy terminus of the other de novo methyltransferases but lacks critical sequence 
motifs required for catalytic activity (Bourc'his, Xu et al. 2001). Recent studies have identified the 
crystal structure of this interaction between Dnmt3a and the cofactor 3L revealing that the periodicity 
of methylation from this complex was in the range of 8 to 10 base pairs (Ooi, Qiu et al. 2007) which is 
in agreement with earlier biochemical predictions. Furthermore this study revealed that DNMT3L 
cannot bind histone H3 tails in which the 4
th
 lysine is methylated. As H3K4me3 is known to be linked 
to actively transcribed genes this may link the methylation of the DNA to histone modifications 
resulting in gene silencing. Additionally DNMT3L is able to bind to histone H3 tails modified by 
methylation at K27 and K9, both marks of gene silencing (Ooi, Qiu et al. 2007). These specific 
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interactions with histone tails might go some way to explain how such Dnmt complexes are targeted 
to specific loci thus setting up methylation profiles during development. 
 
 
Figure 1.2-2. The de novo methyltransferases. The two de novo Dnmts aligned with the Dnmt3L 
cofactor. Both Dntm3a and b contain PWWP domains which aids binding to DNA. All three proteins contain a 
chromatin binding PHD domain along with catalytic domains (grey box) although the catalytic domain of 
Dnmt3L lacks certain motifs leading to loss of catalytic ability. Shown is the region with which Dnmt3L interacts 
with Dntm3a and b. 
 
 
1.2.4    Maintaining the DNA methylation pattern 
As DNA methylation has roles in the regulation of transcription it is essential that the methylation 
patterns are faithfully propagated with every cell division. The copying of this pattern is carried out by 
another group of DNA methyltransferases, the maintenance methyltransferases. In fact, the first DNA 
methyltransferase discovered was the maintenance methyltransferase Dnmt1 (Bestor and Ingram 
1983). This methyltransferase progressively copies the methylation pattern from the parental strand 
onto newly synthesised DNA strands allowing faithful propagation during replication. Dnmt1 
preferentially binds to hemimethylated DNA (Yoder, Soman et al. 1997) such as that found at the 
replication forks. This preference for hemimethylated DNA is brought about through interactions 
between the amino terminal domain of this protein and the DNA. Removal of the N terminal region of 
Dnmt1 abolishes the specificity for hemimethylated DNA whilst increasing the normally limited de 
novo activity of the protein (Bestor 1992; Chuang, Ian et al. 1997). Not only does this affinity for 
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hemimethylated DNA help target Dnmt1 to sites of ongoing replication, direct interaction with the 
proliferating nuclear antigen (PCNA) protein ensures that Dnmt1 tracks along with the replication 
fork (Chuang, Ian et al. 1997) resulting in the copying of methylation patterns as replication is taking 
place.   
 
Interestingly Dnmt1 contains a CXXC domain within the N terminal half of the protein. Proteins 
containing this domain have been found to bind specifically to non-methylated CpG rich sequences 
(Voo, Carlone et al. 2000). This domain, absent in the de novo dnmts, may have a role in the 
hemimethylated binding exhibited by Dnmt1 as hemimethylated sites will indeed contain large 
amounts of non methylated CpGs.   
 
Dnmt1 is active only within the nucleus with targeting of this protein accomplished by a nuclear 
localisation sequence (NLS) (Figure 1.2-3) within the N terminus. Interestingly, modulation of this 
NLS can give rise to a further level of Dnmt1 control. Nuclear targeting does not occur during the 
early stages of embryonic development resulting in accumulation of Dnmt1 outside of the nucleus. 
This nuclear exclusion overlaps with passive global demethylation events in the female pronucleus of 
preimplantation embryos (Oswald, Engemann et al. 2000).  
 
 
Figure 1.2-3. The maintenance DNA methyltransferases. Dnmt1 and Dnmt2 domain architecture and 
interactions. The highly conserved catalytic domain shared by both proteins is represented by the grey box. In 
addition to the non-methyl binding CXXC domain (yellow box), Dnmt1 contains a nuclear localisation signal 
(NLS, red box), a region important in replication targeting (rep’ targeting, red box) and a polybromo domain 
involved in protein-protein interactions. In addition to these domains interactions with PCNA, PRC2 and 
Dnmt3a/b are represented underneath by black bars.  
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The second DNA methyltransferase discovered through the conserved catalytic domain was Dnmt2 
(Figure 1.2-3)  although this protein appears to lack methyltransferase activity (Schaefer and Lyko 
2010). Although the structure of Dnmt2 is closely related to that of Dnmt1 (Dong, Yoder et al. 2001), 
recent studies have found that a tyrosine residue found only in Dnmt2 and not Dnmt1 may  
prevent it from binding to DNA efficiently (Goll and Bestor 2005). However rather than act as a DNA 
methyltransferase this protein was found to instead methylate RNA, specifically to methylate position 
38 in aspartic acid transfer RNA (mC38 tRNA
Asp
). Following this finding, Dnmt2 is now more 
commonly referred to as tRNA aspartic acid methyltransferase 1 (TRDMT1). 
  
 
1.2.5    Mediators of methylation: The MBD proteins 
The dinucleotide meCpG can lead to long term stable gene repression; however this modification on 
the DNA must be translated into an overlying epigenetic change. As explained above this is likely to 
be brought about be either steric hindrance or through the recruitment of methyl binding proteins 
along with associated transcriptional repressors. Indeed the latter hypothesis has been the more 
thoroughly investigated. A group of methyl specific binding proteins have been identified which 
contain a highly conserved methyl binding domain or MBD (Figure 1.2-4). In addition, many of these 
proteins have been shown to interact with transcriptional repressor complexes (Bird and Wolffe 1999).  
These methyl binding proteins were first identified through band shift assays using methylated probes 
as bait. Using this method the protein complex MeCP1 was discovered (Meehan, Lewis et al. 1989). 
The first purified protein to be identified however was Methyl-CpG binding protein (MeCP2). 
Database searches for proteins containing similar methyl binding domains to that of MeCP2 gave rise 
to a further four proteins which together make up the MBD family of proteins (Figure 1.2.4) 




Figure 1.2-4. The MBD family of proteins. The MBD group of proteins are aligned by their methyl binding 
domain (blue). Two members, MeCP2 and Mbd1 contain a transcription repression domain (TRD, grey boxes). 
The protein Mbd1 also contains 3 non-methyl CpG binding domains (CXXC, yellow boxes). MbD4 is involved 
in DNA repair and as such contains a glycosylase domain (red box)  
 
 
The first of the MBD proteins to be discovered, MeCP2, was shown to contain both an MBD domain 
for specific meCpG binding as well as a carboxy terminal transcription repression domain (TRD). 
This domain interacts with the Sin3a complex which contains histone deacytalase activity (Nan, Ng et 
al. 1998). As such, recruitment to methylated CpGs results in removal of the acetyl groups from 
histone tails and as these modifications are essential for formation of a decondensed chromatin state, 
transcription is subsequently silenced.  The levels of this MeCP2 protein are highest within the 
neurons of the brain and this is consistent with the findings that MeCP2 deficiency results in cases of 
severe mental retardation known as Retts syndrome (Nan and Bird 2001). Recent work in the Bird 
laboratory focussing on the MeCP2 rich neuronal cells of the brain has shown that MeCP2 is bound 
globally to methylated DNA and not at specific methylated loci as once thought (Skene, Illingworth et 
al. 2010). Further to this, removal of this protein resulted in globally elevated levels of histone 
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acetylation linking modification of the DNA to changes in the chromatin state through this methyl 
binding protein.     
 
Another protein containing an MBD domain, Mbd1, interacts with the histone H3 lysine 9 
methyltransferase (H3K9 HMTase) SetDB1 (Hendrich and Bird 1998). As the H3K9me3 
modification is known to be associated with gene silencing events it is another example of the methyl 
binding proteins recruiting transcriptional repressors to methylated CpG rich sequences. This 
recruitment is thought to occur in parallel with replication due to the transient interaction between 
MBD1 and the chromatin assembly factor (CAF) during S phase (Reese, Bachman et al. 2003). 
MBD1 is of particular interest as not only does it contain a domain for specific methyl CpG binding, it 
also contains three CXXC domains with particular affinities for non methylated CpG dinucleotides. 
Investigations into the in vitro and in vivo binding properties of these three CXXC domains reveals 
that only the most 3’ of these is able to bind to non methylated DNA (Jorgensen, Ben-Porath et al. 
2004). Closer inspection of the sequences of these CXXC domains reveals that CXXC-3 contains high 
levels of conservation with previously verified functional CXXC domains, whereas the other two 
domains exhibit functionally important changes rendering these domains unable to bind non 
methylated CpGs. However the role of the functional CXXC domain of MBD1 is still largely 
unknown. One possible explanation is that during replication, MBD1 can bind to both the methylated 
and newly synthesised (and thus non-methylated) strand at the replication fork. This assumes that the 
copying of methyl groups onto the daughter strand by Dnmt1 occurs after the silencing histone 
modifications such as H3K9me3 have been deposited (Sarraf and Stancheva 2004). 
 
Another protein containing an MBD is the protein Mbd2. The MBD2 protein has been purified as part 
of the nucleosomal remodelling complex (NuRD) complex which also binds to HDACs 1 & 2, thus 
linking DNA methylation to changes in histone modifications (Zhang, Ng et al. 1999) Studies have 
shown that fibroblast cell lines derived from Mbd2 null mice exhibit a reduced ability to silence a 
methylated reporter gene highlighting a potential role in gene silencing (Hendrich, Guy et al. 2001). 
Further roles for Mbd2 have arisen through the finding that Mbd2 null mice have striking defects in 
the production of cytokines (Hutchins, Mullen et al. 2002). This appears to be due to the fact that 
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Mbd2 binds to the promoter of the Il4 gene responsible for the formation of TH2 T-helper cells 
involved in the immune response. Upon stimulation by antigen presenting cells, the naïve T helper 
cells express Il4 during differentiation into TH2 cells which occurs through the loss of Mbd2 binding 
from the Il4 promoter. As such Mbd2 appears to be a regulator of transcription however to date very 
few promoter specific binding sites have been found for this protein.  
 
These MBD proteins represent a mechanism of cross talk between methylated DNA sequences and the 
local chromatin structure. As the methylated CpG dinucleotide is acting as a signalling module for the 
binding of a specific set of proteins it will be interesting to determine whether or not similar 




1.3 CpG islands 
Although the majority of CpG dinucleotides in the mammalian genome exist in a methylated form, 
around 30 % is non-modified and plays a crucial role in the control of gene expression and localised 
chromatin state. Although the majority of non-methylated CpG dinucleotides are found dispersed 
across the majority of the genome a proportion (~8%) are found at discrete loci with a frequency of 
around one CpG per 10bp (Figure 1.3-1) (Bird, Taggart et al. 1985). Not only are such sites unique in 
the regards that they exist within a largely methylated genome but they tend to co-localise with the 5’ 
ends of genes (Figure 1.3-1). These CpG rich regions were first discovered as fractions of the genome 
which were cleaved unusually frequently by methyl sensitive restriction enzymes such as HpaII 
(Cooper, Taggart et al. 1983). This enzyme only cuts the sequence CCGG when unmethylated 
resulting in the digestion of the non-methyl CpG rich loci into many small fragments which were 
subsequently termed “HpaII tiny fragments” (HTFs). Cloning of these HTFs revealed that these 
fragments were derived from the 1kb stretches of non-methyl CpG rich DNA we now know today as 





Figure 1.3-1.  Distribution of CpG dinucleotides within the mammalian genome. The distribution of 
CpG states are shown for a typical mammalian cell. Percentage values represent proportion of total genomic 
DNA. White lollypops represent non methylated CpGs whilst black lollypops are methylated. Exons are 
represented underneath as blue boxes. Transcriptional states of these genes are represented by the green arrow 
(active) or the red cross (inactive). The majority of the genome (98-99%) contains low densities of CpG 
dinucleotides, mainly methylated. 1-2% however correspond to regions of high CpG density. These regions are 
generally non-methylated and associated with the 5’ ends of genes (CpG islands). A minority (~0.1% of total 
CpG dinucleotides) of these islands are methylated, corresponding with a loss of transcription. This figure does 
not represent the 40% of gene promoters which lack a CGI, most of which are tissue specific in function. 
 
1.3.1 Characterisation of the CpG Island 
Mapping studies across the promoter region of the gene for alpha 2 (type 1) collagen in chicken cells 
provided an early insight in the unique properties of CpG island DNA. Although the CpG rich regions 
over promoters had not been identified as the entities now known as CGIs it was noted that the CpG 
rich sequence remained unmethylated regardless of the transcriptional state of the gene whilst the gene 
body remained methylated. (McKeon, Ohkubo et al. 1982)  The majority of the early work on CGIs 
revolved around the use of digestion by methyl sensitive restriction enzymes. The human CGI fraction 
was first liberated in this way as digestion with HpaII or HinP1 was sufficient to separate the high 
molecular weight bulk DNA from the highly digested and thus small fragments of non-methylated 
CGI DNA. When carried out within the context of chromatin the resulting digestion profiles varied 
slightly, indicating that the presence of nucleosomes occludes many of the potential methyl and non 
methyl CpG cut sites (Antequera, Macleod et al. 1989; Tazi and Bird 1990). Purification of these CGI 
fragments along with their associated histones revealed high levels of H3 and H4 acetylation with 
depleted levels of the linker histone H1 (Tazi and Bird 1990). These early investigations outlined 
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CGIs as not only unique in their DNA sequence composition and cytosine methylation levels but in 
their chromatin modifications and levels of chromatin compaction. 
 
CGIs are found to correspond to the promoters of around 60% of human genes (Lander, Linton et al. 
2001; Saxonov, Berg et al. 2006; Weber and Schubeler 2007). Although the majority of these are 
highly active housekeeping genes, many genes with restricted tissue expression patterns also contain a 
CGI over their 5’ end. Tissue specific genes lacking CGIs tend to contain TATA boxes for the 
attraction of transcriptional machinery (Yang, Bolotin et al. 2007). These TATA boxes rely heavily on 
the coordinated presence of transcriptional activators and as such represent a more highly regulated 
mode of transcriptional control.   
 
1.3.2 Defining and Mapping CpG islands 
As the methods for CGI detection have developed, so too has our understanding of the distribution of 
islands. Initial predictions were made by extrapolating the results of observed CGI frequencies across 
the entire genome resulting in a predicted 45,000 Islands (Antequera and Bird 1993). This prediction 
was in fact very close to the number of Islands predicted through bioinformatic analysis of genomic 
sequences using a set of predefined parameters. Typically the criteria used for the identification of 
CGIs according to standards defined by Takai and Jones is to search the genome for DNA sequences 
with a base composition of Cytosine and Guanidine (“C+G”) greater than 50%, a CpG observed over 
expected ratio [o/e] of at least 0.6 (Takai and Jones 2002) over a length of either a 200 bases (“NCBI -
relaxed”) or 500 bases (“NCBI-strict”). As such depending on the parameters used, relaxed or strict, 
the number of CGIs identified changes with the stringency of the analysis. Analysis using the “NCBI-
relaxed” criteria gives over 300,000 predicted islands, however nearly 90% of these islands were 
unable to be identified through subsequent CGI mapping studies (Illingworth, Kerr et al. 2008). By 
contrast the “NCBI-strict” data set predicts around 24,000 islands. Although this generates a far more 
convincing data set, subsequent CGI mapping studies failed to identify a quarter of these predicted 




As computational prediction methods were not sufficient to generate complete CGI data sets more 
accurate studies were devised utilising the affinity of a protein domain for non-methylated CpG 
dinucleotides. This “CXXC domain”, so called due to conserved cysteine residues forming a DNA 
binding zinc finger, has been shown to harbour an affinity for non methylated CpG rich probes in 
vitro (see chapter 1.4)(Voo, Carlone et al. 2000). As such, columns containing the CXXC-3 domain 
from the Mbd1 protein were used to select for non-methylated CpG rich fragments of DNA such as 
those found at CGIs in a process termed “CAP” (CXXC affinity purification). The resulting purified 
DNA fragments were then hybridised to arrays to map the locations of such CGIs. Pools from human 
whole blood DNA gave rise to 25,200 unique CGIs (Illingworth, Kerr et al. 2008), 76% of which were 
within 1.5kb of the TSS of an annotated gene. Interestingly only half of these CGIs were seen directly 
over the transcriptional start sites of genes. Previous to this finding CpG islands were thought to be 
primarily promoter specific however this finding along with more recent studies using high resolution 
whole genome sequencing technology (Illingworth, Gruenewald-Schneider et al. 2010) reveals a more 
complex distribution of CGIs within the mammalian genome which be broken down into three 
classes; annotated promoter CGIs, intra-genic CGIs and inter-genic CGIs. The roles of such non-
promoter CGIs are as yet unknown but as these loci are often found associated with RNAPII one 
cannot rule out the possibility that they represent either non-annotated protein coding genes or non-
coding RNA (ncRNA) genes.  
 
 
1.3.3 Origins and maintenance 
Non-methylated CGIs are exceptions to the global CpG methylation patterns seen throughout the 
majority of the genome. This has lead to these discrete loci becoming the focus of many studies 
aiming to determine how CGIs are both set up during development and how they are subsequently 
maintained in this non-methylated state in differentiated tissues. 
 
CGIs as unmethylatable entities 
One of the simplest ways to explain how CGIs remain non-methylated in a highly methylated genome 
is that these sequences have some property which makes them refractory to incorporation of methyl 
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cytosine.  This hypothesis however is unlikely when one considers the fact that a fraction of islands 
can be methylated and silenced between differentiated cell types as well as being widely methylated 
on the inactive X chromosome (Park and Chapman 1994). Methylation of islands also occurs in many 
cancers leading to the silencing of certain genes (reviewed by (Bird 1996), therefore the underlying 
DNA sequences at CGIs are indeed capable of becoming methylated. 
 
CGIs as regions of abnormal DNA metabolism 
An alternative view is that non-methylated CGIs represent regions of the genome which are affected 
by abnormally high levels of DNA metabolism such as sites of origins of replication or regions of 
high DNA repair. These loci would result in high levels of turnover of the underlying DNA bases 
during replication firing or DNA repair which could result in the removal of methylated cytosine 
bases. However, thus far only limited and predominantly speculative studies have been carried out 
implying a link between origins of replication and CpG islands sites (Antequera and Bird 1999). 
Furthermore, how these putative sites of abnormal DNA metabolism would result in the exclusion of 
the Dnmt proteins is also unclear.   
 
Active demethylation 
An attractive model and one which has gained much support recently is that CpG islands are actively 
demethylated resulting in the removal of methyl groups from specific sites by an as yet unidentified 
enzyme. As a set of enzymes responsible for the methylation of DNA (Dnmts) have been identified it 
is widely believed that enzymes might exist that facilitate the opposite reaction. Indeed this is the case 
with many enzymes including the histone methyltransferases and demethylases. Studies in 
Arabidopsis have identified the candidate demethylase enzyme Ros1 (Agius, Kapoor et al. 2006). This 
protein contains a glycosylase domain which has roles in base excision during DNA repair. During 
base excision repair, the damaged base is flipped out from the DNA double helix before cleavage of 
the N-glycosidic bond (Liu, Prasad et al. 2007). It is predicted that this mechanism may be responsible 
for the active removal of 5meC bases from targeted sites. Interestingly loss of Ros1 leads to global 
hypermethylation with associated gene silencing events whilst overexpression in transgenic plants 
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results in reduction of 5meC levels along with increased expression of target genes (Agius, Kapoor et 
al. 2006). These findings demonstrate the likely existence of active demethylation at least in plants.  
 
Although a multitude of candidate proteins have been proposed, no mammalian demethylase has yet 
been convincingly identified. For some time the methyl binding protein MBD4 was thought to be a 
potential DNA demethylase due to the presence of a glycosylase domain towards the C terminus of 
the protein. This protein together with thymine DNA glycosylase (TDG), is responsible for the 
removal of thymine bases from T:G mismatches produced through deamination of meCpG 
dinucleotides (Yoon, Iwai et al. 2003). However removal of this protein does not affect global levels 
of methylation but instead leads to a three to four fold increase in mutations at CpG sites implying that 
MBD4s main role is that of a DNA repair protein and not that of a demethylase. The protein 
GADD45a was also highlighted as a potential DNA demethylase (Barreto, Schafer et al. 2007) 
however subsequent studies reveal that this protein was unable to demethylate methylated reporter 
plasmids even when overexpressed (Jin, Guo et al. 2008). 
 
As the search for a demethylase proved more difficult than first anticipated, attention turned to the 
methyltransferase enzymes themselves for further clues. Recent studies by two groups argue that the 
DNA methyltransferases responsible for the setting up of the methylation profiles, Dnmt3a and 3b, are 
also those responsible for the demethylation at CpG islands (Kangaspeska, Stride et al. 2008; 
Metivier, Gallais et al. 2008). These studies reveal that cyclical methylation of CpG dinucleotides 
occurs at the active promoter of the estradiol-estrogen receptor (E2-ERα) and that this coincides with 
the recruitment of the de novo methyltransferases to this site. These Dnmts are thought to be involved 
in the deamination of meCpG to TpG resulting in loss of methylation. However the efficiency of the 
Dnmt deamination reaction is likely to be insufficient to facilitate the observed levels (Ooi and Bestor 
2008). The most recent protein to be linked with roles as a DNA demethylase is that of the ten-eleven 
translocation-1 (Tet1) protein. This protein can bind to 5meC bases resulting in a conversion to 5hmC 
in both cultured cells and in vivo (Tahiliani, Koh et al. 2009). This protein may be catalysing the 
demethylation of cytosine nucleotides through a 5hmC intermediate however further work is required 
to determine whether or not this protein is indeed the elusive mammalian DNA demethylase. 
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CGIs as relics of early embryonic transcription 
The fact that CGIs are often found at the 5’ end of a gene may be an important factor in their origin 
and maintenance within a largely methylated genome. Early studies on CGIs first discussed the 
importance of transcription upon island methylation during early embryonic development. Particularly 
compelling evidence came from studies on the non-methylated CpG Island at the mouse adenine 
phosphoribosyltransferase (aprt) gene. In a transgenic experiment, binding sites for the transcription 
factor Sp1 were mutated at the aprt promoter resulting in a loss of transcription (Macleod, Charlton et 
al. 1994). Following pro-nuclear injection the resulting mice were seen to gain methylation over this 
CGI, presumably as a direct result of loss of transcription. Recent studies reveal that the majority of 
genes are indeed transcribed in ES cells, however only a subset of these genes produce viable full 
length transcripts. Subsequent ChIP-chip analysis (Chromatin immunoprecipitation followed by 
microarray detection) revealed that the initiating form of RNAP II is found at around 75% of 
promoters in ES cells (Guenther, Levine et al. 2007). The fact that similar numbers of ES cell 
promoters undergo transcription (be it abortive or full length) as contain CGIs indicates that early 
embryonic transcription may in some way protect these CGIs from the acquisition of methylation 
(Macleod, Ali et al. 1998). 
 
Protection of CGIs through protein interactions 
One of the simplest models for the origin and maintenance of non methylated CGIs is that they are 
bound by a group of proteins which results in protection from the Dnmts either directly or indirectly. 
To date studies have identified only a few candidate factors including the aforementioned 
transcription factor Sp1 (Braghetti, Piazzi et al. 1993). Even if CGIs are bound and protected by a 
specific group of proteins they are still highly accessible regions of the genome, as shown through 
DNA footprinting and nuclease sensitivity assays (Lin, Tomzynski et al. 2000).  
 
Recent studies have found that the DNA methyltransferase cofactor Dnmt3L is not able to bind to 
histone H3 tails where the lysine 4 is di- or tri- methylated (Ooi, Qiu et al. 2007). De novo 
methylation during development may therefore be excluded from regions of the genome containing 
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high levels of this histone modification. As the promoter regions of active genes have previously been 
shown to correspond with high levels of the H3K4me3 modification (Bernstein, Kamal et al. 2005; 
Kim, Barrera et al. 2005; Roh, Cuddapah et al. 2006; Barski, Cuddapah et al. 2007) these loci may not 
be targeted for methylation by the de novo methyltransferases.  
  
As CGIs are often found associated with the 5’ ends of genes the transcriptional machinery itself may 
act as a protective shield against the methylation seen elsewhere in the genome. The initiating form of 
RNA polymerase is shown to be present at around 75% of promoters in ES cells (Guenther, Levine et 
al. 2007) and CGIs may therefore remain methyl free due to the direct protection afforded by this 
protein complex and not transcription per se. This model is also valid within the contexts of the 
studies on the aprt CGI, as abolition of Sp1 sites would lead to loss of any RNAP machinery based 
protection. 
 
1.3.4 Methylation of CGIs 
Although CGIs are usually defined as non-methylated clusters of CpG dinucleotides, recent work has 
found that in a minority of cases these islands can become methylated. The methylation of islands 
occurs both naturally and abnormally with the end result of gene silencing.  
 
Dosage compensation in mammals is carried out through X chromosome inactivation to ensure that 
equal numbers of X linked genes are expressed in both sexes (Lyon 1961) . As females contain two 
copies of the X chromosome and males only one, lack of such a system would result in uneven levels 
of gene expression between males and females. To balance the expression levels of these genes, one 
of the X chromosomes in females is silenced (termed the Xi). Methylated CGIs tend to be associated 
with the promoters of silenced genes on this inactive X chromosome (Norris, Brockdorff et al. 1991), 
(Norris, Patel et al. 1994). The mechanisms by which methylation is targeted to such CGIs are 
unknown.  
 
Another example of CGI methylation resulting in the control of gene expression is that of imprinting. 
Imprinting a phenomenon whereby allele specific gene expression occurs depending on the parent of 
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origin (McGrath and Solter 1984; Surani, Barton et al. 1984) and is known to affect around 40 genes. 
These include the much discussed H19 and Igf2 loci. Allele specific methylation of the CGIs at these 
two genes corresponds with the silencing of either the paternal (H19 silencing) or maternal (igf2 
silencing) copy of the gene (Sasaki, Ishihara et al. 2000). As this imprinting mark must be erased and 
re-established depending on the sex of the individual this process is entirely epigenetic. 
 
Recent work has revealed that the methylation of CGIs also has a role to play in the differentiation of 
cell types. A class of methylated CGIs was first discovered by comparing the methylation profiles of 
promoter regions of differentiated whole blood cells to those of testis and ES cells (Shen, Kondo et al. 
2007). A subset of CpG island promoters (4%) were seen to gain methylation during differentiation 
and this was seen to correspond to the silencing of associated genes.  
 
Finally, abnormal methylation of CGIs is widely reported in many cancers. Both hypomethylation and 
hypermethylation have been associated with the progression of cancers however the latter has been the 
most extensively reported. The majority of hypermethylated CGIs identified in cancers are associated 
with genes involved in cell cycle regulation (such as p15 and Rb), DNA repair (BRCA1 and MGMT – 
a p53 related factor) or apoptosis and proliferative control (APC) (Dobrovic and Simpfendorfer 1997; 
Stirzaker, Millar et al. 1997; Esteller, Garcia-Foncillas et al. 2000; Virmani, Rathi et al. 2001; Harden, 
Tokumaru et al. 2003). The methylation of these CGIs results in loss of expression of such genes and 
progression of a cancer state. As such the protection of CGIs from the methylation machinery is of 
great importance towards to progression of tumour formation.  
 
1.4 The CXXC proteins  
By analogy with the MBD domain which specifically targets proteins to methylated CpG 
dinucleotides, there exists a domain which instead targets proteins to non-methylated CpGs. This non-
methyl CpG binding domain, more commonly referred to as a CXXC domain, forms a zinc finger 
structure which contains a series of highly conserved cysteine residues. This domain is found in a 
small group of proteins termed the CXXC family of proteins (Figure 1.4-1). Many of these CXXC 
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proteins have roles linked to the regulation of epigenetic state, including a DNA methyltransferase 
(Dnmt1), histone methyltransferases (Mll1 and Mll2), a histone demethylase (Kdm2a), a methyl 
binding protein (Mbd1), a candidate DNA demethylase (Tet1) as well as several proteins with as yet 
unknown functions. As these proteins all contain a CXXC zinc finger domain which specifically bind 
to non-methylated CpG dinucleotides, this family of proteins may act in a similar (albeit opposite) 
fashion to the MBD family and exert an effect on the local chromatin.  
 
The CXXC domain itself binds to DNA through interactions with zinc cations and replacement of 
these with any other metal leads to loss of binding (Lee, Voo et al. 2001). Mutation of any of the 
conserved cysteine residues abolishes DNA binding and as yet no true consensus sequence has been 
identified other than for the presence of an unmethylated CpG dinucleotide (Lee, Voo et al. 2001). In 
depth investigations into the structure and DNA binding properties of the CXXC domain from Mll1 
reveal that the domain makes up a crescent like structure incorporating two zinc ions (Figure 1.4-2, 
A). Each of these ions is contacted by three highly conserved cysteine residues (Figure 1.4-2, B) 
forming a loop like structure thought to interact with the underlying non-modified cytosine nucleotide. 
The overall DNA binding interface is made up of a groove of positively charged residues (Figure 1.4-
2, C) (Allen, Grummitt et al. 2006).  Mutation of any of these residues (R1154, K1176, K1178, K1186 
or K1193) results in loss of DNA binding without the unfolding of the protein whilst mutation of any 
of the conserved cysteines results in complete unfolding of the protein (Allen, Grummitt et al. 2006). 
The structure appears to only be able to bind to non modified CpG dinucleotides as methylated CpGs 
may sterically hinder the binding of the extended loop around the zinc ion. 
 
The specific affinity of the CXXC domain from MBD1 towards non-methylated CpG rich DNA has 
been used as a mechanism to isolate a CGI DNA library allowing thorough investigation of CGI 
distribution and properties (Illingworth, Kerr et al. 2008). This result however is unlikely to represent 
Mbd1 binding in vivo as the CXXC domain alone may not represent the true distribution of Mbd1. As 
the CXXC domains within several proteins are highly conserved (see chapter 5.2), specificity of 
binding to particular regions of the genome may arise through either the total structure of these 





Figure 1.4-1. The CXXC family of proteins. The nine members of the CXXC protein family aligned through 
their conserved CXXC domain (yellow). These proteins convey a variety of epigenetic roles ranging from the 
modification of histone tails (Kdm2a, Mll1 and Mll2) to the methylation of DNA (Dnmt1). Several of these 
proteins including Cfp1, Mll1 and Mll2 contain chromatin binding PHD domains (green). Additionally Mll1 and 
Mll2 have histone methyltransferase SET domains (purple). Interestingly the Mbd1 protein, which has three 
CXXC domains (of which only one is functional – CXXC3) also contains a methyl binding domain (MBD – 

























Figure 1.4-2. Structure of the CXXC domain from the Mll1 protein.  A. The ribbon structure of the 
CXXC domain revealing the positions of the zinc atoms, represented as spheres, and the overall crescent shape of 
the domain. B. Close up of the extended loop (from 1181 to 1189) and second of the zinc atoms (blue sphere) 
contacted by cysteine residues (yellow bars). C. Representation of the molecular structure of the CXXC domain 
including the residues predicted to contact the DNA. Surfaces in yellow represent the contact surface between the 




1.4.1 CpG binding protein, Cfp1 
CpG binding protein 1 (Cfp1) was first identified in the year 2000 when the gene was cloned and 
found to contain two PHD domains as well as a CXXC, coiled coil and basic domains (Figure 1.4-1) 
(Voo, Carlone et al. 2000). Further studies found that this protein exclusively bound to non-
methylated CpG rich oligonucleotides as well as acting as a transcriptional activator as shown by its 
ability to activate luciferase promoters upon cotransfection into cultured cell lines (Voo, Carlone et al. 
2000). It has also been implicated as a component of the nuclear matrix and localises to euchromatic 
nuclear speckles (Lee and Skalnik 2002) again linking it to transcriptionally active chromatin. 





HMTase complexes (Lee and Skalnik 2005; Lee, Tate et al. 2007) and there is some evidence also that 
it may bind to two other CXXC proteins; the H3K4 HMTases MLL1 and MLL2 (Ansari, Mishra et al. 
2008). Interestingly Cfp1 is analogous to the yeast protein Spp1, a component of the yeast Set1 
complex (Voo, Carlone et al. 2000; Miller, Krogan et al. 2001; Takahashi, Lee et al. 2009). Sequence 
alignments of the two proteins reveal high sequence conservation barring a few regions, most notably 
the absence of a CXXC domain in the yeast protein. Furthermore Spp1 and can bind to H3K4me3 
modified histone tails via its PHD domain (Murton, Chin et al. 2010) and has been shown to interact 
with the origin recognition complex (ORC) through co-immunoprecipitation with the ORC2p protein 
(Kan, Zou et al. 2008). This Complex is implicated in many cellular activities including 
transcriptional control and the initiation of DNA replication foci.  
 
Targeted disruption of the Cfp1 gene leads to peri-implantation embryonic lethality in mice (Carlone 
and Skalnik 2001) which is the developmental stage during which the genome undergoes global loss 
and remodelling of cytosine methylation patterns (Reik, Dean et al. 2001; Li 2002). Cfp1 -/- ES cells 
are viable although they exhibit an extended doubling time, largely due to apoptosis (Carlone, Lee et 
al. 2005). These Cfp1 -/- ES cells fail to survive when stimulated to differentiate and therefore it is an 
essential factor in development. This may in part be due to a 60% reduction in the levels of cytosine 
methylation in these cells (Carlone, Lee et al. 2005). Although transcription of the major maintenance 
DNA methyltransferase enzyme (Dnmt1) is found to be reduced to around 50% of its wild type levels 
(Carlone, Lee et al. 2005) this alone cannot account for the dramatic phenotypes seen in the Cfp1 null 
cells. Dnmt1 -/- ES cells exhibit ~90% reduction in the expression of this protein with dramatic loss in 
DNA methylation levels, but are otherwise able to grow normally until differentiation (Lei, Oh et al. 
1996). Thus the Dnmt1 reduction alone in Cfp1 null ES cells cannot explain the growth defects seen. 
 
Not only are the epigenetic modifications to the DNA altered upon Cfp1 removal, so to are the histone 
modifications, specifically that of H3K4 methylation. However, there is some disparity regarding the 
relationship between the CXXC protein and the active histone modification. In one study, Cfp1 -/- 
murine ES cells exhibited a four fold increase in the levels of this active histone modification 
(Carlone, Lee et al. 2005). However this finding is somewhat contradictory to the results of a study 
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carried out in cultured human embryonic kidney cells (Ansari, Mishra et al. 2008). Levels of Cfp1 
were depleted in these cells by using an antisense transcript resulting in the reduction of H3K4me3 
signal from the HoxA7 gene. Such a large disparity may represent discrete roles for the protein 
between the pluripotent ES cells and the differentiated somatic cells (Ansari, Mishra et al. 2008). 
Alternatively this may simply represent a difference between RNA depletion and knock out methods 
of analysis.  
 
Alongside roles in the epigenetic control of both the DNA and histone tail modification, loss or 
removal of Cfp1 appears to result in the reduction of gene expression. The aforementioned study in 
human embryonic kidney cells found that transcription of the HoxA7 gene was reduced with a loss of 
both Cfp1 and H3K4me3 over the promoter region (Ansari, Mishra et al. 2008). Additionally, Cfp1 -/- 
ES cells exhibit both a susceptibility to DNA damage as well as an associated loss in the expression of 
AP endonuclease (Ape1) activity, an enzyme involved in DNA base excision repair (Tate, Fishel et al. 
2009). Interestingly, both the expression of this gene and the susceptibility towards DNA damage 
were returned to normal upon restoration of normal Cfp1 levels. Taken together, these findings reveal 
that the Cfp1 protein may be an important regulator of transcription. In the case of the HoxA7 




1.4.2 Trithorax group proteins, MLL1/2 
The MLL family of proteins are histone methyltransferases, acting on the fourth lysine of the histone 
H3 tail through their conserved SET domains. Like many of the histone modifying enzymes they exist 
in multi-protein complexes consisting of several shared subunits, and require these to exhibit their 
effect (Dou, Milne et al. 2006).  Two of the family members, Mll1 and Mll2, also contain a highly 
conserved CXXC domain, similar to the one seen in Cfp1. 
 
Mll1 (mixed-lineage leukaemia 1) is a 3969aa protein which has been shown to interact with 
components of the basal transcription machinery as well as human homologues of the yeast 
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COMPASS complex (Yokoyama, Wang et al. 2004). Chromosomal translocations that fuse MLL1 to 
other sites are often found in many myeloid and lymphoid leukaemias (Ayton and Cleary 2001) and 
there is evidence to suggest an important role in the regulation of the Hox genes during development 
(Ernst, Fisher et al. 2004).  Most interestingly, ChIP-Chip studies have revealed binding of Mll1 over 
promoters at sites of high H3K4me3 and RNA pol II (Guenther, Jenner et al. 2005). These peaks were 
largest at the most highly expressed genes suggesting that MLL1 is possibly a binding factor of active 
genes, either through its binding to the transcriptional machinery, to the H3K4me3 mark itself or via 
its CXXC domain depending on the methyl status of the promoter.  
 
There is some evidence that both MLL1 and MLL2 bind to the CXXC protein Cfp1 as flag 
immunoprecipitations co-purify MLL1, MLL2 and the hSet H3K4 HMTase proteins (Ansari, Mishra 
et al. 2008). Cfp1 may therefore interact with two or three independent H3K4 HMTase complexes. 
 
 
1.4.3 Other CXXC proteins 
A few of the other CXXC proteins also contain functions linked to the control of epigenetic 
modifications. The first of these is the lysine specific demethylase 2a (Kdm2a) which is responsible 
for the removal of methyl groups from histone H3K36 residues (Tsukada, Fang et al. 2006). As 
methylation of the H3K36 residues is important for the progression of transcription through the gene 
body, modulation of this mark must be tightly controlled. This control is imposed by Kdm2a by the 
removal of H3K36me3 marks from the body of genes once transcription has occurred, catalysed by 
Kdm2a’s highly conserved JumonjiC (JmjC) domain (Klose, Kallin et al. 2006). 
 
Another CXXC domain containing protein which has attracted much attention recently is the Ten 
eleven translocation 1 (Tet1) protein. Recent work has identified this protein as a potential 
demethylase through the conversion of 5-methyl cytosine into 5-hyroxymethylcytosine (Tahiliani, 
Koh et al. 2009). Although the functional significance of 5hmC is unknown  it might be acting as 
either a signalling module for the recruitment of specific proteins (in a similar vein to methylated 
cytosine and the MBDs) or existing as an intermediate in the demethylation of 5mC (Kriaucionis and 
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Heintz 2009). As the domain architecture of the Tet1 protein is still largely unknown further roles for 
this protein have not been identified. The protein is known to contain a CXXC domain which leads to 
the possibility that this complex can bind to non-methylated CpG rich DNA such as that found at 
CGIs, which may in turn infer CGI maintenance roles upon Tet1. 
 
 
1.5 Phd Aims 
To date, CpG island research has largely focussed on the mapping these regions within the genome 
along with the study of the methylation states of these CGIs across various tissues and cells types 
(Antequera and Bird 1993; Antequera and Bird 1999; Shen, Kondo et al. 2007; Suzuki, Sato et al. 
2007; Suzuki, Kerr et al. 2007; Illingworth, Kerr et al. 2008; Meissner, Mikkelsen et al. 2008; 
Straussman, Nejman et al. 2009; Illingworth, Gruenewald-Schneider et al. 2010). As CGIs are unique 
in their DNA sequence composition (significantly rich in CpG dinucleotides compared to the rest of 
the genome) and are known to associate with histone marks generally associated with an euchromatic 
state (Tazi and Bird 1990), CGIs may also contain a host of unique binding proteins.  
 
The focus of the work in this thesis will be to attempt to identify any proteins which specifically 
associate with CGIs. This study will be expanded to contain both the histone tail modifications as well 
as any chromatin binding proteins. It is hoped that by identifying any uniquely bound protein factors 
that we may better understand: i) how these CGIs remain stably non methylated compared to the 
remainder of CpGs in the genome which are mostly methylated, ii) attempt to understand any possible 
functional roles for these CGIs and iii) to investigate the effects (if any) that the underlying DNA 
sequence at a CGI exerts towards defining the local chromatin environment through the binding 
specific protein factors.  
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Chapter 2: Materials and Methods 
 
2.1 Materials 
All reagents stored at room temperature unless otherwise stated 
 
2.1.1 Nuclei and chromatin manipulation 
Nuclei Homogenisation Buffer: 10mM Hepes pH7.9, 25mM KCl, 0.15mM Spermine, 0.5mM 
Spermidine, 1mM EDTA,2M Sucrose, 10% glycerol. Stored at -4°C. 
 
Nuclei Storage Buffer:  50mM Tris-HCL pH8, 100mM NaCl, 5 mM MgCl2, 0.3mM EGTA, 
10mM sodium butyrate, 1mM β-metacaptoethanol or DTT, protease inhibitors. Stored at -20°C 
 
Nuclei Lysis buffer: 1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), protease inhibitors. 
Stored at 4°C 
 
 
2.1.2 Nucleic acid Manipulation 
TE buffer pH7.5: 10mM Tris HCl p7.5, 1mM EDTA 
 
TAE electrophoresis buffer (1x): 40mM Tris-acetate, 1mM EDTA 
 
TBE electrophoresis buffer (1x): 45mM Tris-borate, 1mM EDTA 
 
Blue DNA loading buffer (6x) 2.5mg/ml bromophenol blue, 0.3mg/ml glycerol, 120mM 
EDTA pH8.0, 4.2% (w/v) SDS. Stored  at -20°C (long-term) or r/t (short-term). 
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Orange G loading buffer (6x): 0.198% (w/v) orange G, 12% (w/v) Ficoll, 120mM 
EDTA pH8.0, 4.2% (w/v) SDS. Stored at -20°C (long-term) or r/t (short-term). 
 
DNA Sequencing Buffer (2.5x): 20mM Tris HCl (pH8) and 5mM MgCl2. 
 
Bisulfite modification solution (pH of 5.0): 3.8g sodium hydrogen sulfite 
(NaHSO3) was dissolved in 5ml dH2O and 1.5ml 2M NaOH (kept away from light). 110mg 
hydroquinone was dissolved in 1ml dH2O at 55°C for ten minutes. The sodium bisulphite and the 
hydroquinone solutions were then mixed. Solution is prepared immediately before use. 
 
RNA extraction: Tri- Reagent (Sigma-Aldrich)  
 
Oligonucleotides: Custom Oligonucleotides were purchased from Sigma-Genosys. All were 
resuspended in dH20 to 100 µM whilst working stocks were diluted to 10µM. All resuspended 




Table 2.1-1. ChIP PCR Primers  
 
ID forward reverse 
actb   
1.2 CAGTACATAATTTACACAG CCAAGTATCCATGAAATAA 
1.3 AAGCCATGCCAATGTTGTC AGCAGATGTGGATCAGCA 
2.1 TGAAGCTGTAGCCACGCTC CTGTCCCTGTATGCCTCTG 
3 GCAGAAACTGCAAAGATCC CCACACCTTCTACAATGAG 
3.1 CCAAAGTAACAGGTCACTT GTGTCTTGATAGTTCGCCA 
4 CCTAATACGGCTTTTAACA CCTGAGGATCACTCAGAAC 
4.2 CGAGCACTTAAGTGGATGA GCTTTCCGGCTATTGCTAG 
4.3 CAGTGGTCCAATAACTGGA CCAGGCTTAGTCTTGCCTG 
5 CCTTGTCTGGAAGAGGTGA CTGAGCAACTGAGAAATAC 
6 CCTAAGCTGCACATTTTCA GGCATTATGGCTGGATCTT 
   
   
Atg9b   
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1 GGCCTCTGTCTGTCCCTCT AATGCCTATGCCTTGCTCC 
2 GCGGAACCAGAAGAGCAGA GCTTCGGAATGAGTGGTTG 
3 GTCAGAGAAGGGGCACACA CTTCTCGGGAGCTCTCTTT 
4 CCCTTGTTGGCTAACGCTA GTCCCTAGGCTTCCCTGTT 
5 CAGCATCTTCCCCTCTGCT CCATCCTTTGCCTTCCTCT 
   
   
bdnf   
1 TTCCTGATCTATGAGCAGA GACAGCTAAGAAATCTCTC 
3 GTGCTCAACTCTGAAATTC CCTTTCTTGATTTCTCCCT 
4 GGAAAATATACACATGTGT CCTAAGAATGCTTCTTTAA 
4.6 GCACAGACAGTTCCGGGATCCAGG GGAGTTCCTTTGCAGCACGCTTGG 
5 CATTCTTAGGATAGGAGGG CGAAAAGGTGTAGGCTAGG 
6 CCTTTTCGCTCAGAGCTCC GTGTGACTTATGAATCTAA 
7 CGATCCACTGAGCAAAGCC CTCCAAAATCTGACTCTCT 
9 GCTTCATTGAGCCCAGGTC GCACGCTTGGAATTGCATC 
12 CTGATCTGTCAGTGCATTG GAGCCTCCAACTTTGAGAG 
14 GACAACAGATTTGGGACCT GCACTGATATAGTCTCTGA 
14.6 TGGAGAAGGAAACCGCCTGGGG AAAGCTCTCGGATCCCCGGCAG 
15 GGAAGTTAAGACAGAGATC GCTCAATTGAAGCACATAT 
17 CCATGACAATCTCTCTAGG CCTCATGTGACTTTAGCAT 
   
   
C-myc   
1 CCAGAAGCTTTCCCAGCAA CAGCTCAGCCTTGCTTGCT 
2 GCATGCCATGGCTAGCTTG GAGAAGCAGGAGACCCTAA 
3 AGTGACTGAATGAATGCTG TCTCATACTAACAGTCATG 
4 GTGATGTCATCAGGCTGGG CACCAACAGATATGACAGT 
5 AGGCAATAATAAGCTAATG GTGAAGGAGATCTAACAGA 
6 TGGTTAATAAGCTAGATTA CCTTCGTATGTGTGTGTTA 
7 CCTAGATAACTCATTCGTT CCCTGCGTATATCAGTCAC 
8 GCTGTTTGAAGGCTGGATT CAACTACTCTTGAGAAAAG 
9 CAGTGCTGAATCGCTGCAG CCGATTGCTGACTTGGAGG 
10 GGAAGAGAATTTCTATCAC ACATAGGATGGAGAGCAGA 
11 GGCTTATCTTTCAGCTCCA TGGGTCTTAGACAAACGTA 
12 CTCAACCCAAGGACTCTGC CCAGGATCAACTTAGCAGT 
   
   
Dlx5/6   
-2 TCCATGATCTCCTAGGTAT TGAAAGCTATTCAAATGAA 
3 CAAAGATGACACAGTCAAA CTCACTCCTTTCCACCTCT 
6 GGTTCTACCACCTGGATGT CTCTAATTATACACCAGTG 
7 GAGCTAAGGTGGCTGCAAA GGATTTGGACGAGTCCTGG 
8 CTTACAGCGCCACGGACTT GCTATACCACTGTGGGCAC 
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9 GTAATGCTACATTGTAGGT CTACCTCCTATGTTGCTTA 
12 GAGACTACAGCTCTATGCA GCAGTCAGCTATGGGGATG 
16 GCATAGGCTAGATATCTAC CTCTTTCAGGATCTCCTGT 
18 CCATCCTCAGATCATACAT GAAACACACAAGGTGAATA 
19 GTGCTGTCCTGTTTGCAGT CCCCTACCACCAGTACGGC 
21 CCTGAAGTGCTGAAAGACT ACTCGAGGCTGTCTATAGT 
23 CTTTGCAAACCAAAATCGT CACCTGACAGTTCCGTTCT 
   
   
Foxd3   
1 GCCTAGTCGGTGAGGAGTTG CAAGCCTGGGTAGTCGAAAG 
2 TCTTACATCGCGCTCATCAC TCTTGACGAAGCAGTCGTTG 
3 CGCTGATGATGCAGAGCTT CCCAGGGTGTTGAGCTGTAG 
4 CCGAATTTCCAAAAATGCAC AAACTGCGCAGAGTGAACCT 
5 CTCCTCTCGAGCCTTTCAGA AGAATTGATGCCGTTTGAGG 
6 GAGCCCTGCTGAAGAAGCTA GAAGCCCTGCCTTTCTCTTT 
7 CTCCCGAGCTGTTTTTGAAG AATTCGCCTCCAGACCCTAT 
8 AGGATGGGTCACAGAACCAG TCTTCCATTTCCCAACTTGC 
9 GACCTGGAACGCATTAGGAA TGGAGTGAGGGTGCTTCTTT 
10 TGACAGGGGACTCTTGCTCT GGAGAGGCGAGCTAACTGTG 
   
   
intergenic ch5  
1 GAAGGCACACACATGCAAA GCGGCTACTGTTAGAAGAA 
2 GACCAATGTCCGCTTAGCT GCCGTGGCTTAGTGAAGAG 
3 GATCCTGACTAGTGCCCCT GGATCGCTGGATTCAGACC 
4 GGGGAGAGGGAACAGTGGT TGACTGTGTCCTGAGTGTG 
5 GGAGCTGCCTGCTACTCAT CCAGTGGAATTAGAGGGGC 
   
   
Oprd1   
1 TTTTACGGGAAGCCACTTTG CCATGTTTTCCACCATGACA 
2 CAGATAGCTGTGAGCCACCA TGGATAAGAATGGCCCTCAT 
3 AGATGGCTCAGCGGTTAAGA GTTCATGAGCCTTCCCACTC 
4 GGCTGGATTGGAACTGGTTA TCTGGTTCTAGGGGCTCTGA 
5 GAGCAGTCGGGTGCTCTTAC GGATTTAGAGGTGGGGGAGA 
6 AGTTTTCATCCGGAGCCTTT AGGGTTTTGGGGAGATGAAG 
7 TTTCTTCATCGTGCAGTCACA GCTCCGCTGACTCCAGGT 
8 GCCCCTCGTCAACCTCTC GGACGATGCCAAACATGAC 
9 CGCCCCAAGTCACATTTAGT TATCCCGAGTTCCTGACCAC 
10 TGGGAGCACTAAGACCCTGT AGAGATCTGCTTGCCTTTGC 
11 ATGCTGCAGTTGGCTGTATG CTCTGATGATCCCGACCACT 
12 AGTCGCCAAGGACACAGAGT CAGCCTTGGCTACAGGAGAC 
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Sycp2   
1 CCAGCAGCTGTTCAGTGCA TTCCTTGGTTGGCTCCTTT 
2 GCAGTCCCCTGACAAAGCT ACGGAGTCCCCAAGTCCCT 
3 CAGCCGGAAGTGATGGAAA CTGGGCATGAGGATTGCCT 
4 AGCTCCAATGACAGCCCAA AAGGGTGCCTCAGGGAGTG 
5 CATGCATGCCAGACAAGTG CACCCTCTAAAAGCCTGTC 
   
   
Xist   
-3 GACAGCCTTATCCAGTGTC GAACAGCGTAAAACTGTAA 
-2 GTGGTCTCATTGGTTGGCA GGAACATTTTATGTGGATA 
1.21 GTCTTGAGGAGAATCTAGA TTCTATACCAGTTCAGGCT 
2 GAATTCAACAAGTAAGCAA GCCAGAGTCATAGTGGATC 
2.1 GCACTGTAAGAGACTATGA CGCATGCTTGCAATTCTAA 
3 CCTGTACGACCTAAATGTC GTATTAGTGTGCGGTGTTG 
3.1 CTCAGTTTAAGAGCAAAGT GCTTGGTGGATGGAAATAT 
4 AAAAAGTATGGAGGACATG CGTGCAACGGCTTGCTCCA 
4.1 AGGTCACACACCTGTCTAT CCAAGGAGCCATTTTGTGA 
5 GTCTCGTTGATTCACGCTG GTTTATTCAGTCTGTGTGC 
6 CCTCCATTCCTGTACACTT CTTAATGTTAAGAATATGC 





Table 2.1-2. Genomic DNA PCR Primers  
ID forward  reverse 
Oprd1 GCTTCTGGGCAACGTGCTCG CCTCATAATCTCAGAGGACC 





Table 2.1-3. Primers Used for expression analysis 
ID forward reverse 
Actb CCAAAGTAACAGGTCACTT GTGTCTTGATAGTTCGCCA 
Bdnf GTGCTCAACTCTGAAATTC CCTTTCTTGATTTCTCCCT 
Cfp1 CGAGAACGACAGTGATGACA AGTGCTCAGGACACAGCACC 
C-myc TGGTTAATAAGCTAGATTA CCTTCGTATGTGTGTGTTA 
Gapdh TACCCCCCAATGTGTCCGTCG CCTGCTTCACCACCTTCTTG 






Restriction digestion of DNA: 
Table 2.1-4: NEB restriction enzymes 











2.1.3 Protein Manipulation 
Proteinase K stock solution: 20mg/ml proteinase K (Sigma), 100mM EDTA pH 7.5, 2% 
(w/v) SDS. Stored at 20°C. 
 
Antibodies: stored at -20°C 
 
 
Table 2.1-5: Antibodies 
Antibody [Applications] Source/ Catalogue number 
WB 
conditions 
Primary Antibodies    































Anti-Histone H3K36me3 [WB] Rabbit polyclonal to Histone H3 K36me3 




Anti-Histone H3 pan acetyl 
[WB/CHIP] 











Anti-RNAP II [ChIP] Mouse monoclonal to unphosphorylated RNA 




Anti-Cfp1 Skalnik [WB] / ChIP] Rabbit polyclonal to CFP1 (kind gift of D. 
Skalnik) 1:1000 
Anti-Cfp1 H-120 [ChIP] Rabbit polyclonal to CGBP: H-120 (Sc-25391 – 




 Rabbit polyclonal to Kdm2a (ab31739 – Abcam) 1:500 
 
Anti-Mll1  Rabbit polyclonal to Mll1 (3798-100 – BioVision) 1:250 
 
Anti-Mbd1  Rabbit polyclonal to Mbd1 (ab3753 – Abcam) N/a 
 
Anti-Hdac1  Rabbit polyclonal to Hdac1 (ab7028 – Abcam) 1:2000 
      
Seconday Antibodies     
peroxidase antimouse IgGs 
[WB] 
 




Peroxidase antimouse IgGs 
[WB] 
 




Infra-red anti-rabbit 680 IgGs 
[WB] 
 
Licor – 32223 
 1:25,000 
Infra-red anti-mouse 800 IgGs 
[WB] 
 






2.1.4 Tissue culture and manipulation of Cells 
HeLa & P-M- growth medium:  Glasgow Minimum Essential Media (GMEM –Gibco), 1% 
Non Essential Amino Acids (NEAA –Gibco), 1% Sodium Butyrate (Gibco), 1% 
Pennicillin/Streptomycin (Gibco), 10% Fetal bovine Serum (FBS,Perbio) 
 
NIH-3T3 Growth medium: Same as Hela. Transfected cell lines supplemented with 2µg/ml 
puromycin (Invitrogen) for selection.. 
 







shRNA Vectors for Cfp1 depletion: synthesised and cloned by Oligoengine. Vector 
backbone is called “pSuper puro” and contained the following shRNA target sequences:  
 
Table 2.1-6: Sequences for Cfp1 shRNA depletion in pSuper vector 
ID Sequence 
Target 986 5’-GAAGGUGAAGCACGUGAAG-3’ 
Target 1250 5’-CAGCCAACCGAAUCUAUGA-3’ 
Target 1920 5’-CUUCACCAAACGAUCCAAC-3’ 
 
Transfection reagents: Lipofectamine reagent (Invitrogen) and Opti-MEM reagent (Gibco) 
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2.2 Methods 
All reactions were carried out at room temperature unless otherwise stated 
 
2.2.1 Mouse Work 
 
Extraction and storage of mouse organs 
Mice brains and livers were harvested from a variety of different wild type mouse strains, mainly 
BALB/C and C57 strains. These mice were aged between 1 and 6 months and were of mixed gender 
(unless required for gender depend experiments such as that in section 5.3). Within particular 
experiments (such as ChIP-PCR runs), the age and gender of mice were kept constant. Harvested 
brains were instantly frozen in liquid nitrogen and then kept at -80 until needed.  
 
 
Isolation of nuclei from mouse tissues 
Nuclei were extracted by first grinding 8 brains or 4 livers up into a fine powder using a mortar and 
pestle along with liquid nitrogen. This powder was then transferred into a 30ml dounce containing 
16ml of Nuclei buffer A. The mixture was then supplemented with fresh EDTA (final concentration of 
5mM) and EGTA (final concentration of 0.5mM) along with protease inhibitors. The ground brain 
was then mechanically dounced on ice at (10 strokes). 9ml of the resulting homogenate was then 
layered onto a 3ml cushion of Nuclei buffer A in a plastic 13 ml centrifuge tube before centrifuging in 
pre-chilled SW40 rotor (13ml tubes) @ 72,700g for 40mins at 3°C.  
 
The resulting pellet was then resuspended in 500µl of Nuclei storage buffer, prior to centrifugation at 
425g at 4°C for 5 minutes. This pellet, the cleaned nuclei, is resuspended once more in 500µl of nuclei 
storage buffer and kept at -80°C until required. Typical mouse brains would generate around 0.4mg of 
DNA (~4^10
8




2.2.2 Nuclei and chromatin Manipulation 
Nuclei digestion 
Harvested nuclei were resuspended in nuclei digestion buffer to facilitate their digestion. 
 
Sucrose gradients 
Sucrose gradients were constructed to separate out the chromatin fragments which resulted from the 
nuclei digestions. First a 60% weight/weight sucrose solution in “Buffer B” was made by heating and 
stirring 240g of sucrose powder in 160g of buffer B. This sucrose solution was the starting point for 
the generation of a range of sucrose concentrations. For a 5-30% sucrose gradient, 6 different sucrose 
concentrations were used and layered upon each other. Each of these stocks would weigh 10g and as 
such the following equation was used to determine how much of the 60% stock solution would be 
added:  
 
% gradient required (as decimal) x final weight / stock sucrose % (as decimal) 
 
1ml of each stock sucrose concentration was carefully layered on top of each other in a Beckman 
Pollyamer centrifugation tube capable of holding 13 mls. The sucrose gradients were then left for 1 
hour on ice to allow the fractions to settle. A maximum of 0.8mg of brain DNA in a 500µl volume is 
loaded on top of the gradients before ultra-centrifugation at 4°C for 3 hours at 20,200g using a 
Beckman SW-40Ti swing out rotor (Beckman). 300µl Fractions were carefully collected from the 
resolved gradient using cut off blue tips and each fraction split into two eppendorfs in order to study 
both the DNA and protein compliments.  
 
 
“DIGNAM” salt washing and methyl sensitive digestion of nuclei 
Nuclei were resuspended in 250µl of nuclei digestion buffer prior to the dropwise addition of 250µl of 
0.3M NaCl in digestion buffer. Washing the nuclei with this salt solution results in removal of any 
non specific or loosely bound factors from the chromatin into the supernatant. Centrifugation at 
1,700g for 5 minutes pellets the chromatin leaving these non-specific proteins in the supernatant. 
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Pelleted material is resuspended in 500µl of fresh digestion buffer. Nuclei were then subjected to a 
two fold over digestion with either the restriction enzyme HinPI (GCGC) or MseI (TTAA) for 45 
minutes at 37°C (both enzymes NEB). Centrifugation at 3,800g for 5 minutes retains the small 
digested fragments of chromatin within the supernatant. The DNA was then extracted from the 
supernatant by alcohol precipitation and the proteins by Trichloracetic Acid (TCA) precipitation. 
 
 
2.2.3 Chromatin Immunoprecipitation and analysis 
 
Protocol for Chromatin immunoprecipitation 
Chromatin Immunoprecipitation (ChIP) is used to enrich for fragments of DNA bound by a protein of 
interest. Protocols vary slightly between ChIP carried out on nuclei from tissue and cells from culture. 
These nuclei or cells are first washed and resuspended in PBS and proteins fixed to the DNA by 
crosslinking for ten minutes at room temperature with 2% formaldehyde. This reaction is quenched by 
addition of 125mM glycine before washing through PBS. Samples are then resuspended in 450µl cold 
lysis buffer for 10 minutes to release the DNA from the nuclei. 150µl of this solution is aliquotted into 
separate eppendorfs prior to the addition of 1350µl of dilution buffer along with 3mM CaCl2, 10mM 
MgCl2 and protease inhibitors. Nuclei from tissues such as the brain (not cultured cells) are then 
subjected to mild levels of micrococcal nuclease digestion in order to aid later sonication steps. As 
such, 12 units of micrococcal-nuclease are then added for 20 minutes at room temperature and this 
enzyme inactivated through addition of 10mM EDTA and 5mM EGTA. Both cell and nuclei samples 
are then subjected to sonication so as to shear the chromatin, generating fragments with an average 
size of 500bp. Conditions for sonication vary depending on the concentration and volumes used. A 
typical reaction would be carried out on a volume of 1ml for 2 minutes at 25% power at 5 second 
intervals with each blast lasting 2.5 seconds.  These fragments of chromatin were then added to 
blocked protein A sepharose beads (GE healthcare), blocked for an hour with 1mg/ml BSA and tRNA 
before washing through and resuspending in dilution buffer. This step is crucial in order to preclear 
the beads of residual chromatin binding. Like samples are then pooled and spun down gently at 400g 
for 15-20 seconds to pellet the beads and chromatin removed. Antibodies are then bound to this 
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material overnight at 4°C. Typical antibody concentrations used were between 1-2mg/ml per 25ug of 
chromatin. For a complete list of antibodies and working conditions used during ChIP see the 
materials section. 10% of the sample volume is kept back as an “input” control and does not undergo 
immunoprecipitation to allow for the comparison of the enrichment between IP’d material and non IP 
“genomic” enrichments. 
 
The following day the precleared beads (see above) are added to the IP samples and left at 4°C for 2 
hours. These beads bind specifically to the IgG chains of antibodies bound to the chromatin proteins 
of interest. Bead:chromatin complexes are spun down at 2,600g for 1 minute and undergo a series of 
washes followed by 2,600g spins as follows: 1xTSE1 buffer wash, 4x TSE2 buffer wash, 1x buffer 3 
wash and 3x TE wash. Beads are finally resuspended in 200µl of extraction buffer and placed at 55°C 
for 55 minutes before shaking at room temperature for a further 20 minutes. Chromatin fragments 
previously bound to the beads should now be in the supernatant and beads can be removed through a 
fast spin at 15,700g for 2 minutes. Chromatin samples are spun through QIAshredder columns 
(Qiagen) at 15,700g for 1 minute to remove any left over sepharose beads.  Finally 300mM NaCl is 
added to all samples, including the inputs and the samples placed at 65°C overnight to remove any 
crosslinks.  
 
The final steps of the ChIP protocol include proteinase K (Sigma) and RNAseA (Sigma) treatment at 
55°C for an hour before carrying out DNA precipitation and resuspension into 0.1M TE.  
 
Typically 4 mouse brains would be split for 5xIPs and Input material. Each IP would be resuspended 
in 1150µl of 0.1 TE (enough for 108 ChIP PCR reactions for each IP which equated to 9 runs with 12 
primer pairs). 
 
Analysis of ChIP qPCR results 
DNA fragments prepared by ChIP are tested for amplification across regions of the genome (see 
“DNA manipulation” regarding PCR). Regions of high amplification correspond to high levels of 
protein binding. Relative levels of binding are calculated against input, non IP material. iCycler iQ 
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software (BioRad) assigns a baseline fluorescence measurement based on the standard deviations 
calculated for cycles 2-10. This baseline bisects the fluorescence curves from each PCR in the linear 
amplification phase and indicates the cycle threshold value for that reaction (Lander, Linton et al.). An 
arbitrary measure of DNA quantity (Q) can be calculated using: Q = 2
-Ct
. Averages of the two 
readings for each primer pair are then calculated and compared to the input. ChIP profiles are 
representative of those from at least 3 independent PCR runs using separate ChIP experiments.  Often 
the relative levels of enrichment would vary quite significantly between IPs however, the overall 
profile generated would be nearly identical when plotted normalised to the average values over the 
region. 
 
ChIP-Seq for genome wide sequencing 
Immunoprecipitations are performed from a single mouse brain as described above prior to end repair 
by incubation at 20°C for 30 min with 3 U of T4 DNA Polymerase (NEB), 10 U of Polynucleotide 
Kinase (NEB), 2 U DNA Polymerase I Large (Klenow) fragment (NEB), 1x T4 DNA ligase reaction 
buffer (NEB) and 400 nM dNTPs. The enzymes were then heat inactivated at 75 °C for 20 min, after 
which the DNA was ethanol precipitated. A string of adenine bases were added to the 3’ ends of the 
DNA by incubation with 5 U Klenow Endonuclease (NEB), 200nM dATP and 1x buffer 2 (NEB) at 
37°C for 30 min. After heat inactivation of the enzymes, Ilumina paired end adaptors were then 
ligated to the processed ChIP DNA by incubation with 300 U of T4 DNA ligase (NEB), 1x T4 DNA 
ligase buffer (NEB), 7.5% PEG-6000 and 2 pmol of annealed Ilumina adaptors for 3 h at room 
temperature. Resulting ligated DNA was purified using MinElute PCR columns (Qiagen) and eluted 
in 10 µl water. 
 
Bioinformatic analysis of ChIP-Seq data 
Data files representing the genome wide binding sites for proteins of interest were received as 
processed files in which the DNA sequences had been mapped to genomic coordinates (known as a 
“wiggle” file). This data can be visualised against the genomic sequence using the Integrated Genome 
Browser (“IGB”; Affymetrix. Found at http://209.135.50.217/partners_programs 
/programs/developer/tools/download_igb.affx). The height of these reads indicates the depth of 
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sequencing, an increase of which raises the likelihood that the sequence amplified is indeed 
specifically enriched during ChIP. In order to attain meaningful statistics from this raw file a set of in 
house tools called were created by Alastair Kerr at the University of Edinburgh which can be found at 
http://bifx3.bio.ed.ac.uk:8080.  
 
Initial raw wiggle files tend to contain high levels of background noise likely due to non-specific 
binding events during sequencing. As such this noise was removed by normalising the signal across 
the entire data set. This normalisation process takes into account the height of a user defined 
acceptable background level (the “depth of sequence”), the minimum run of sequence below the stated 
depth required to maintain read data during background subtraction (the “length”), along with the 
maximum gap allowed between two sequencing reads (the “gap”). For the criteria used for each ChIP-




To generate a file capable to use in statistical analysis the normalised wiggle file must be converted 
into a “peak file” in which regions containing a high sequencing depth over a region of the genome 
Table 2.2-1. Parameters used for peak finding calculations 
 
Each individual ChIP-Seq data set is processed first by background subtraction and then by peak finding to 
identify significant peaks. Background subtraction “length” refers to the minimum run of sequence (in base pairs) 
below the stated depth required to maintain read data during background subtraction. Background subtraction 
“gap” is the allowed gap within this run of sequence. The peak finding “length” corresponds to the minimum run 
of sequence at the stated “depth” required for identification as an enriched genomic locus. Finally for the peak 
finding “gap” value, individual peaks that are closer together than this value are knitted together as a single locus.  
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are represented as a box. The criteria to determine a genuine peak is entirely user based and as such is 
open to some interpretation. Genuine peaks are found by selecting on the basis of i) the length in base 
pairs in which the peak in sequencing occurs over, ii) the height or depth of this region and iii) the 
length of the gap that separates sequencing peaks. These values vary depending on the antibody used 
(Table 2.2-1). Resulting peaks can then be counted to determine total protein binding sites or 
compared for overlap with other peak finding data sets to determine co-localisation between proteins.  
 
Access to ChIP-Seq data sets 
High throughput sequencing data for Cfp1, H3K4me3 and RNAPII has been deposited in the Gene 
Expression Omnibus (GEO) under the accession number GSE18578. 
 
H3K27me3 data sets published by Mikkelsen et al, 2007 were found in GEO under the accession 
number GSE12241  
 
The genome wide CGI data set is available in the “John Thomson Sep 2010” folder within the 




2.2.4  DNA Manipulation 
DNA extraction and precipitation  
DNA was extracted through mixing with 1 volume of phenol:chloroform:IAA before precipitation by 
either 1 part isopropanol at r/t or 3 parts 96% ethanol (EtOH) at -80°C along with 1/10
th
 volume of 
NaOAC. After centrifugation at 15,700g for 15 minutes pellets were washed with 70% EtOH before 
allowing to air dry in a fume hood for 5 minutes. Once all residual ethanol has evaporated the DNA 
pellets were resuspended in 0.1M TE and stored at -20°C. 
 
Restriction enzyme digestion  
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Digestion of DNA through the use of restriction enzymes was carried out as per instruction of the 
manufacturer. Typically a range of 2-10 units of enzyme were used to digest 1µg of DNA at 37°C 
diluted in the appropriate buffer. Generally these reactions were carried out over the period of 45 
minutes to an hour. Restriction enzyme recognition sequences are outlined in the materials section.  
 
Gel electrophoresis 
DNA was resolved by electrophoresis through the use of Sub-Cell system (Bio-Rad). Depending on 
the size of DNA fragments to be resolved, gels were made spanning 0.8-2% (w/v) agarose in either 
TAE or TBE (most often used if fragments were <300bp).  Gels contained 0.5µg/ml of ethidium 
bromide which intercalates with the DNA and allows fluorescent visualisation upon excitation with 
Ultraviolet (UV) light. DNA samples and a DNA ladder of known fragment sizes were mixed with 
either 6x blue loading buffer or orange G loading buffer. Gels were run in the same buffer that they 
were made from and were run at a constant voltage no higher than 80V. Visualisation of DNA 
fragments was carried out over a UV light and images taken if needed.   
 
Gel Extraction 
Where DNA fragments were further required to be purified, single bands were cut out of the gel and 
placed into an eppendorf tube. Extraction of DNA from the gel piece was then carried out using the 
Perfect Gel cleanup Kit (Eppendorf) following the manufacturers’ instructions. 
 
Measurement of DNA concentration 
DNA solutions were measured at OD260nm and OD280nm using a Nanodrop-1000 
spectrophotometer (Thermo Scientific). The purity of the DNA was determined using 
OD260nm:OD280nm ratio, with a value greater than 1.8 indicating the absence of protein or phenol 
contaminants from the sample. An automated read out of the DNA concentration was determined 
through the use of Beer’s law [Concentration in ng/ul = (Absorbance OD260nm x Extinction 




End labelling of DNA fragments with radioactive dNTPs 
1µg of DNA was typically labelled with 10µCi of radioactive dCTP (GE healthcare). Labelling was 
carried out by using the Klenow enzyme (Roche) which has 5’ to 3’ polymerase activity as well as 
some 3’ to 5’ exonuclease activity. To the DNA and radioactive dCTP mix was added 100mM dNTPs 
lacking dCTP as well as 1-5 units of Klenow enzyme. Reactions were carried out in the high salt 
buffer supplied (Roche). 
 
Standard Polymerase Chain Reaction (PCR) 
PCR reactions were used wherever it was required to amplify up DNA of interest from a DNA 
template. Reactions vary however typically were of a final volume of 25µl. In this reaction was the 
DNA template (1-100ng), 200-400µM dNTPs, Red Hot PCR buffer (ABgene), 5U Red hot DNA 
polymerase (ABgene) and 2.5mM MgCl2. If amplifying up GC rich regions, PCR reactions were 
supplemented with 3% DMSO and sometimes slight increases in MgCl2. Positive and negative 
controls were included by using a known amount of genomic DNA for the positive and dH20 for the 
negative control.   
For every set of primers, the number of cycles and annealing temperature (T
an
) were different. Typical 
reactions however would compromise of an initial denaturation step for 2 minutes at 94°C followed 
by 30-40 cycles of denaturation at 94°C for 50 sec, primer annealing at T
an 
for 50 sec, primer 
extension at 72°C for 50 sec with a final extension phase after the cycles had been complete, at 72°C 
for 2 mins. 
 
Quantitative PCR (qPCR) 
This procedure was used whenever the need for quantitative comparisons of relative DNA arose. The 
two main procedures requiring qPCR were expression analysis of the same gene between cell lines 
and in the profiling of binding proteins to DNA regions after ChIP purification. The principles of 
qPCR are the same as standard PCR but for the incorporation of a dye in the reaction. The dye used, 
called SYBR green, is a cyanine dye that absorbs light at a λmax of 488 nm and emits light at a λmax 
of 522nm when complexed with double stranded (ds) DNA. Measurement of emitted light (522nm) 
directly allows the real-time quantification of duplexed DNA as it is synthesised. 5-50ng of DNA was 
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typically used per reaction and a specialised master mix (Quantace) containing SYBR green, dNTPs 
and MgCl2 added. For expression analysis, one set of primers, typically designed to span an intron 
(thus remove DNA contamination, see RNA manipulation section for more), are then added to the 
reaction. Reactions are then carried out with a denaturation step at 96°Cfor 10 minutes, followed by 
45 cycles of denaturation at 96°Cfor 50 secs, primer annealing at T
an 
for 50 secs, primer extension at 
72°C for 50 secs with a final extension phase after the cycles had been complete, at 72°C for 2 mins.  
Ct values (see section on “analysis of ChIP qPCR results” above) are extracted from the post run data 
and compared between the two samples to determine relative expression levels. Internal controls are 
imposed to normalise the samples. This is usually accomplished through first normalising the Ct 
values to those of a stable housekeeping gene such as GAPDH.    
 
In the case of ChIP qPCR many of the same principles apply with regards to the PCR reaction mixture 
and program of amplification. 5 to 12 primers were designed over regions of interest. Amplicons were 
not to be shorter than 150 or exceed 350 base pairs in length to give optimal amplification. On each 96 
well plate profiles containing a maximum of 12 primer pairs were run in duplicate to limit rogue 
results. Each plate contained two rows of input (non IP) DNA. This would allow direct comparisons 
between the Ct values generated in the IP sample over a particular primer pair to no IP material, thus 
allow the calculation of an enrichment value of input. Each plate would typically contain 2 rows of 12 
primer pairs for input material, with the remaining 6 rows of 12 divided between 3 IP samples, or 2 
samples and a negative control, each run in duplicate. For more see the section on the analysis of ChIP 
results below. 
 
2.2.5  Protein Manipulation 
Whole cell protein extracts 
Whole cell protein extracts were used to investigate total cellular levels of proteins. Typically 3-8^10
6
 
cells are washed in PBS before removal from culture dishes through the addition of 2mls of 
recombinant trypsin (Invitrogen). Once cells have detached from the culture plates the reaction is 
stopped by the addition of 1ml of culture medium before centrifugation at 400g to pellet the cells. 
Cells are washed in PBS including protease inhibitors and pelleted before resuspension in 50-100µl of 
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SDS loading buffer (without bromophenol blue dye). This solution is boiled for 5 minutes and 1µl 
taken for quantification by Bradford assay. At this stage bromophenol blue can be added to the protein 
solution in order to visualise on SDS polyacrylamide gels. 
 
Trichloracetic Acid (TCA) precipitation of proteins 
Certain experiments, such as the collection of sucrose gradient fractions, led to the attainment of large 
volumes of protein samples at low concentrations. In order to analyse these protein samples they first 
had to be concentrated to detectable levels. The most common way of concentrating protein samples is 
through TCA precipitation. 1% SDS is first added to the samples before adding TCA to a final 
concentration of 20% and incubating at -20°C o/n. The following day samples were thawed on ice 
before cold centrifugation at 15,700g for 15 minutes. The resulting pelleted proteins are near 
impossible to visualise in the eppendorf at this stage however the supernatant is carefully removed 
before adding 500µl of ice cold acetone and incubating on ice for 15 minutes. The protein pellet is 
encouraged to disperse in the acetone through gentle flicking of the eppendorf before the material is 
repelleted by cold centrifugation for 15 minutes at 15,700g. Once more the supernatant is carefully 
removed and the protein pellet left to air dry for five minutes on ice. Once all traces of the TCA and 
acetone have evaporated the pellet is resuspended in SDS loading buffer, boiled for 5 minutes to 
denature proteins and either used or stored at -80°C until required. 
 
Bradford assay for protein quantification 
Bradford assays were used to determine the protein concentrations of samples prepared, following the 
protocols outlined by the manufacturer (Biorad). BSA standards were prepared over a range of 
concentrations encompassing those expected in the protein samples. Typical final BSA concentrations 
in diluted Bradford reagent would range from 0.1 to 10µg/ml. Bradford reagent (Biorad) is diluted 1:5 
in deionised water and added to the BSA standards and the samples in question to a final volume of 
1ml. 1µl of the protein sample to be tested is taken for quantification and mixed with the diluted 
Bradford assay. This mixture will turn blue depending on the concentration of protein and the 
intensity of this colour is quantified by absorption at 595nm in a spectrophotometer. The 
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concentration of the protein sample can then be calculated through comparisons to a standard curve 
using the absorbances of the known BSA standards. 
 
Protein Electrophoresis 
SDS polyacrylamide gel electrophoresis (SDS PAGE) was used to resolve proteins based on 
molecular weight using the Mini-PROTEAN 3 system (Bio-Rad). Stacking gels contained 5% (w/v) 
acrylamide and separating gels between 8 to 15% (w/v) acrylamide depending on the molecular 
weight of the proteins of interest. Protein samples, prepared in protein loading buffer, and Pre-stained 
broad range protein markers (11-170kD; NEB) were incubated at 100°C for 5min to denature proteins 
and disrupt any higher order structures. Samples were then chilled on ice and loaded into the wells of 
the stacking gel. Electrophoresis was carried out at 25mA (Mini-PROTEAN 3 system, Bio-Rad) in 
Tris-glycine electrophoresis buffer.  
 
Staining of gels to visualise proteins 
SDS PAGE gels were stained by using either Coomassie reagent for a quick check of protein content 
or Silver stained for a more thorough analysis. For coomassie staining, gels were incubated in 
Coomassie Brilliant Blue R-250 staining solution for 20 minutes with gentle agitation. Gels were de-
stained by rinsing several times in dH2O at 100°C resulting in the visualisation of all proteins as blue 
bands. The gels can then be scanned onto the LI-COR scanner (LI-COR) which not only creates an 
image file of the gel but allows for accurate quantification of specific bands as well as total protein 
levels. As such this approach can be useful in the quantification of protein samples to ensure equal 
loading on subsequent gels.  
 
If protein levels are too low for the use of Coomassie staining a more sensitive approach can be used 
such a silver staining. This approach is based off the rationale that proteins bind silver ions, which can 
be reduced under appropriate conditions to generate a stained gel. Protein samples are run on SDS 
PAGE gels as explained above prior to soaking in 50% and then 5% methanol for 10 minutes 
respectively. Gels are then washed in 125ml dH2O supplemented with 4µl 1M DTT for at least ten 
minutes. The gel can then be stained through a series of washes, firstly through a 10 minute incubation 
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in “silver solution” containing 0.2M silver nitrate, before washing off 3 times in dH2O. To visualise 
the protein bands on the gel, developer solution containing sodium carbonate is added until the desired 
intensity is achieved and the reaction quenched by adding 5% acetic acid to the solution. The gel was 
then washed several times in dH2O and visualised through scanning onto a computer or dried onto 
Wattman paper for archiving.   
 
Immunoblotting 
Once resolved on an SDS polyacrylamide gel, proteins were then transferred from the SDS PAGE gel 
to PVDF (Bio-Rad) or nitrocellulose membrane (Bio-Rad) using the Trans-blot SD semi-dry transfer 
cell (Bio-Rad) with constant voltage of 2mA for 70 minutes. PVDF was typically used for histone 
proteins due to its smaller pore size which do not allowing histones to pass through upon transfer. 
PVDF membranes are first blocked in TBS supplemented with milk powder, varying from 4 to 8% 
depending on the antibody in use. Membranes were blocked for 2 hours at room temperature before 
washing in TBS 3 times. Antibodies specific for the protein of interest were then diluted to their 
optimum working concentrations in blocking solution. Conditions for western blot are highly sensitive 
and vary between antibodies as well as between batches of the same antibody. Typical primary 
antibody concentrations ranged from 1:1000 for Skalnik-Cfp1 down to 1:5000 for Histone H3 (For the 
full list of antibodies and working concentrations see “Materials” section above). Primary antibodies 
were incubated on the membrane overnight at 4°C. The following day membranes were washed in 
TBS for 15 minutes before incubating for 2 hours at r/t with secondary antibodies specific for the 
organism the primary antibody was raised in. The majority of secondary antibodies were raised in 
rabbit or mouse. Typical concentrations in blocking solution range from 1:1000 for HDAC1 to 1:5000 
for Histone H3 (for the full list of antibodies used as well as working concentrations see “Materials” 
section above). Membranes were then washed three times for 15 minutes in TBS to remove all of the 
secondary solution. The secondary antibodies bound to the membrane are conjugated with horseradish 
peroxidise and as such emit a signal when activated by enhanced chemiluminescence (ECL). ECL 
solution was washed over the membranes for 30 seconds prior to detection on light sensitive film. 
Resulting films were then scanned into a computer and bands corresponding to proteins of interest 
analysed for relative quantity or abundance.    
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LI-COR fluorescence blotting  
The use of fluorescent secondary antibodies instead of the traditional horseradish peroxidase approach 
allows far greater sensitivity to be attained in a fully quantitative manner. Traditional western blotting 
approaches are difficult to quantify as saturation of resulting bands on the membrane occurs rapidly. 
Using the LI-COR scanner system in conjunction with fluorescent secondary antibodies can overcome 
this problem. However, this approach if not carried out efficiently can lead to high levels of 
background signal. Fluorencent blot protocols are the same as those for the western blot however the 
secondary used is fluorescent (typically at 680nm for red signals and 800 for the green). As this 
fluorescence is light sensitive, steps following the addition of this antibody are carried out in the dark. 
For a list of antibodies used and working conditions for each see the materials section). 
 
 
2.2.6 RNA Manipulation 
 
RNA extraction 
RNA was extracted using Tri reagent (Sigma-aldrich). Tri reagent contains phenol and guanidine 
isothiocyanate and serves to maintain RNA integrity during cell disruption and dissolution of cell 
components. Subsequent centrifugation with chloroform allows biphasic separation such that RNA 
may be retrieved from the aqueous phase whilst DNA and protein remains in the organic phase. 
Typically 1ml of Tri reagent (Sigma-aldrich) was added to a confluent 100mm dish of cells in culture 
leading to their dissociation.  200µl chloroform was added, mixed vigorously and incubated for 10min 
at R/T. The aqueous phase (RNA) was resolved from the organic phase (DNA and proteins) by 
centrifugation for 15min at 12,000g at 4°C. To precipitate the RNA the aqueous phase was 
resuspended in 500µl of isopropanol, mixed and left to stand for 10min at r/t. RNA was pelleted by 
centrifugation (10min at 12000g at 4°C), washed with 70% EtOH, air dried and resuspended in 50µl 
of nuclease free water (Ambion). RNA was resolved by RNA gel electrophoresis (see RNA 
electrophoresis below) to determine the quality of the preparation as indicated by sharp bands 





To achieve accurate amplification of cDNA, contaminating DNA must be removed from the RNA 
prior to cDNA synthesis. Typically around 500ng of RNA was used in a total volume of 40µl 
containing 3ul (6U) DNAse I (DNA-free kit; Ambion) in DNAse I reaction buffer (DNA-free kit; 
Ambion) and incubated for 30min at 37°C. DNase I was inactivated according to the manufacturer’s 
instructions. Primers for cDNA amplification were designed to span exonic sequences to reduce 
amplification of contaminating genomic DNA. These exons will only be close enough to amplify by 
PCR once processed into mRNA thus genomic products should be minimal. Prior to reverse 
transcription the RNA was denatured at 65°C for 5min and snap chilled on ice. 250ng of the RNA was 
prepared in a total volume of 25µl containing 5µM random hexamers (Roche), 1mM dNTPs 
(Abgene), 40U RNasin (RNase inhibitor; Promega), 200U of M-MLV reverse transcriptase (RNase H 
minus; Promega) and MLV reverse transcriptase reaction buffer (Promega). In addition a minus (-)RT 
reaction was set up in parallel containing all the components except for the reverse transcriptase to 
control for DNA contamination by PCR. Typical reactions would consist of 4 cycles each for 8min at 
20°C, 8min at 25°C and 30min at 37°C followed by final heat inactivation at 70°C for 15min. The 





RNA samples and size marker (281bp-6.58kb; Promega) were denatured in RNA loading buffer for 
10min at 70°C and chilled on ice. These were then loaded onto a 1.5% (w/v) non denaturing agarose 
gel containing 0.5µg/ml ethidium bromide. Agarose gels were run at constant voltage (80V) in TAE 







2.2.7 Tissue culture and manipulation of cells 
General culture of cells 
HeLa, NIH-3T3 and P-M- fibroblast cell lines were each cultured in their own growth medium as 
described in the “Materials” section. Cells were grown to confluency before washing in PBS and then 
splitting into new plates using recombinant trypsin (Invitrogen) to dissociate the cells from the plate. 
Cells are stored at –180°C stored in growth medium supplemented with 20% DMSO and an additional 
10% FBS (Perbio).  
 
Transfection of cells with shRNA 
NIH3T3 cells were transfected using lipofectamine reagent (Invitrogen) with three independent 
pSuper vectors containing short hairpin constructs directed against Cfp1 (Oligoengine) or vector 
alone. The target sequences for these sequences are described in the “materials” section above. 
Additionally transfections were carried out using a mixture of all three constructs. 20µg of vector 
DNA was mixed to a final volume of 800µl in Opti-Mem (Gibco) in an eppendorf whilst 45µl of 
lipofectamine reagent was taken to 800µl Opti-Mem in a second eppendorf. These two solutions were 
mixed after 5 minutes at 37°C and diluted to 8mls in Opti-Mem. This mixture was left at 37°c for a 
further 45 minutes to allow the lipid rich lipofectamine and the vector DNA to mix. A 90mm dish of 
NIH 3T3 cells at approximately 70% confluency were harvested and growth media removed prior to 
the addition of the mixed transfection solution. This solution was left on for 5 hours to allow 
transfection to take place. After 5 hours this solution was removed and replaced with standard growth 
medium once again. The following day these cells were placed under puromycin selection in order to 
kill all non-transfectant cells. Upon transfection and subsequent selection the majority of cells died 
leaving single cells to grow, forming colonies which were expanced for further analysis. This 
approach was carried out in triplicate with three vectors each containing a shRNA sequence designed 
to reduce the levels of Cfp1. Furthermore this shRNA transfection was repeated with a mixture of all 
three vectors in to attempt to create a superior knockdown effect. 
 
Resulting shCfp1 cells were cultured in 3T3 growth medium supplemented with puromycin at 2µg/µl 




Calculation of growth curves for shCfp1 cell lines 
Both control transfected (“pSuper clone 10”) and cfp1 deficient (“shMix clone 3”) 3T3 cell lines were 
seeded at 0.2x10
6 
cells each in 6 x 35mm tissue culture dishes. These cells were grown in GMEM 
supplemented with puromycin. Plates were trypsinised at selected time points (15, 19, 24, 48, 72 and 
90 hours) and the number of cells calculated using a haemocytometer. Dead cells were distinguished 
from live cells by staining with Trypan-Blue (Invitrogen) and removed from the analysis. Cell 
numbers were plotted against the respective time point in order to determine a growth curve over the 




Chapter 3: Isolation and purification of CGI 
chromatin  
 
3.1 Introduction  
 
Eukaryotic DNA is packaged into a higher order chromatin structure compromised of repeating 
protein structures called nucleosomes. Each nucleosome consists of ~146 base pairs of DNA wrapped 
around an octamer consisting of four core histone proteins (two of each histone: H2a, H2b, H3 and 
H4) which in turn can be modified on their N terminal tails by a multitude of modifying factors 
(Kornberg 1974). These histone tail modifications can affect the local structure of the chromatin 
resulting in either compact or accessible regions. Modifications of these histone tails can affect the 
accessibility of the genetic code through the regulation of chromatin compaction as well as through 
the recruitment or repulsion of enzymatic protein complexes. Particular regions of the chromosome 
tend to be associated with a certain chromatin state. For example, centromeric sequences tend to be 
found in a heterochromatic state (Pluta, Mackay et al. 1995) whilst certain regions of the genome such 
as the promoters of active genes have been shown to correspond with particular sets of histone 
modifications permissive to transcription (Barski, Cuddapah et al. 2007).  
 
Advances in techniques of chromatin purification along with mass spectrometry have allowed the 
sophisticated analysis of histone modifications to be carried out on a genome wide level. Further to 
this, recent advances in genome wide sequencing technology such as ChIP-Seq (see chapter 4.4) have 
lead to the high resolution mapping of histone modifications in a variety of cell types (Barski, 
Cuddapah et al. 2007). As investigations into the chromatin state and binding proteins associated with 
CpG islands are limiting (Tazi and Bird 1990), the use of such new technologies will not allow such a 
study to be carried out on a genome wide level. The most challenging aspect of the determination of 
CGI binding proteins lies not in the detection of the proteins themselves but in the purification of pure 
and stable CpG island chromatin in the first place. As CGIs are rich in non methylated CpG 
dinucleotides, purification strategies were devised to take advantage of this trait. This was 
accomplished through the use of methyl sensitive restriction of chromatin using enzymes which 




3.2 Digestion of chromatin with methyl sensitive restriction 
enzymes 
In order to generate a pure population of CGI chromatin these regions of interest must first be 
separated away from the bulk of the genomic material. An approach was devised which was heavily 
reliant on the earlier work of Tazi and colleagues (Tazi and Bird 1990).  This method took advantage 
of the methyl specific DNA digestion imposed by certain restriction enzymes which recognised and 
cut only at CpG rich sequences, resulting in the liberation of CGI chromatin from the bulk of the 
genome. Methyl sensitive restriction enzymes such as HinP1 (recognition sequence GCGC) or HpaII 
(CCGG) can only cut the DNA when the cytosine in the CpG dinucleotide is in an unmethylated state, 
resulting in the digestion of CpG islands (Figure 3.3-1, A). As digests are carried out in the context of 
chromatin many of the enzymes target sites will be occluded by the presence of nucleosomes. 
However, sites between nucleosomes or in nucleosomal free regions over trascriptional start sites will 
be readily digested by these enzymes. The smallest DNA fragments generated by this digestion range 
in size from a few base pairs to around 60 nucleotides (nts) and correspond to the non-nucleosomal 
regions of unmethylated DNA. The next in size are the mono-, di- and trimeric nucleosomal fragments 
where digestion has taken place around the nucleosome in “unprotected” DNA sequence. Any of the 
bulk genomic material, which is mainly methylated, will be significantly larger in size allowing for 
the separation from the small CGI fragments. A set of restriction digestions using the non-methyl 
sensitive CG recognising enzymes MseI (TTAA) and AluI (AGCT) provide an ideal control 
experiment as they cut throughout the genome without a preference for CpG island sequences.  
 
As CGIs only contribute to a small proportion of the genome (1-2%), it will be difficult to visualise 
the fragments released upon digestion by standard ethidium bromide staining.  To overcome this 
problem the DNA fragments were end labelled post digestion with radioactive α
32
P dCTP nucleotides 
using Klenow fragment of the DNA polymerase I enzyme. Incorporation of the radioactive base into 
these fragments allowed for detection by radiation sensitive phosphor screens after gel 
electrophoresis. Early work using HeLa cells as a substrate was not successful at visualising liberated 
CGI fragments due to the fact that a fraction of cells in culture routinely undergo apoptosis. As these 
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apoptotic cells contain degraded DNA this severely raises the background noise seen in the 
radioactive signals. A new approach using nuclei from mouse brains as a starting point for CGI 
liberation gave far clearer results (similar to that in Figure 3.4-1). 
 
3.3 Purification of CGI chromatin through sucrose gradient 
ultracentifugation 
As it was now possible to digest the CGI compartment of the genome away from the bulk through 
methyl sensitive restriction, the next step was to isolate and purify this fraction. The fact that the CGI 
fragments were much smaller (ranging from <60bp to mono- di- and tri nucleosomal in length) than 
the remainder of the genome meant that these CGI fractions could be selected for based on their 
relative sizes. One way in which to accomplish this is by the centrifugation of digested material on a 
sucrose gradient (Figure 3.3-1). Chromatin is added to columns in which the sucrose concentration is 
set in a gradient and ultracentrifugation applied which results in the separation of the smaller CGI 
fragments away from the larger bulk chromatin. Initial experiments were carried out on gradients 
ranging from 15% to 30% sucrose with later gradients spanning 5% to 30% sucrose. Digested 
chromatin was gently layered on top of sucrose gradient columns before ultracentrifugation at 20,200g 
to resolve fragment densities. Once spun, fractions were collected and either analysed for DNA 
(phenol-ETOH extractions) or protein content (TCA precipitation). 
 
3.3.1  Optimisation of the sucrose gradient for purification of CGI chromatin 
Primary analysis was carried out by investigating the distribution of DNA across the sucrose gradient 
fractions. Purified DNA fragments from the gradient were visualised on a gel through radioactive end 
labelling α
32
P dCTP using Klenow fragment of DNA polymerase I as before. The first set of DNA 
fragments were taken from a 15-30% sucrose gradient and revealed that the small CGI fragments can 
indeed be separated away from the rest of the genome (Figure 3.3-1). The results of the methyl 
sensitive (CGI liberating) HinP1 digestions reveal the presence of the small non nucleosomal 
fragments in fractions 1 and 2 at the top of the centrifugation tube (Figure 3.3-1, B). Fractions 2-5 
contain the mono- nucleosomal fragments, with di- and trinucleosomal fragments seen in fractions 3-5 
and 4-5 respectively. In fractions 6-9 faint bands are seen corresponding to mono-, di- and 
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trinucleosomal fractions. The higher fraction numbers correspond to collections from nearer the 
bottom of the gradient and contain heavy fragments of chromatin. As expected these fractions lack 
nucleosomes but associate with high molecular weight DNA. At the time of analysis the pellet at the 
bottom of the gradient containing the majority of very large material was not analysed.  
 
As a control experiment, nuclei digested with Mse1 were run on a 15-30% sucrose gradient. 
Subsequent precipitation and radioactive end labelling of the DNA reveals that a distinct pattern of 
fragments are generated in comparison to HinP1 digested material (Figure 3.3-1, B). In contrast to the 
HinP1 digests, the first 9 lanes of the MseI sucrose gradients contained far lower amounts of 
nucleosomal material. The majority of the material in this sucrose gradient was found from fractions 
10 onwards due to the larger sized of fragment generated through the MseI digestion.  
 
These 15-30% sucrose gradients revealed that some of the digested material was being found in 
fraction 1 and 2 at the top of the gradient (fractions 1&2; Figure 3.3-1, B). As the uppermost fractions 
tend to contain large amounts of nuclear proteins this presents a problem of protein contamination. 
The sucrose gradients were run once more this time over a 5-30% range of sucrose concentrations 
with the aim of shifting the distribution of these CGI fragments away from the top of the gradient. 
Ultracentrifugation of these gradients resulted in a similar pattern of fragments visualised to the earlier 
15-30% gradients however the CGI fractions were now seen to span fractions 3-9 (Figure 3.3-1, C). 
On these gradients the non-nucleosomal fragments were now seen to be enriched in fractions 3 and 4 
whilst the mono-, di and trinucleosomal fragments are seen primarily enriched in fractions 5-9. In this 
set of experiment the pellet found at the bottom of the gradient was also included and as expected 
contained the majority of the DNA corresponding to the bulk of the genome (“pellet”, Figure 3.3-1, 
C). The relative abundance of the DNA in the pellet is unsurprising when one considers the fact that 
CGIs represent around 1% of the genome. As a control the MseI digest was run over a 5-30% sucrose 
gradient and once again showed no preference for smaller fragments, with the majority of fragments 
enriched in the mid range of fractions and in the pellet (data not shown). 
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Figure 3.3-1. Methyl sensitive restriction digestion and Sucrose gradient purification of CGI 
chromatin. A. Non methylated CGI chromatin can be digested into nucleosomal fragments through the methyl 
specific restriction enzyme, HinP1. These are separated from non CGI chromatin based on the sedimentation of 
resulting fragments after ultracentrifugation. Mse1 (not shown) is used as a control for non CGI digests.  B. DNA 
profiles across the HinP1 and Mse1 15-30% sucrose gradients. Typical CGI sizes correspond to non nucleosomal (< 100 
bp), mono-,di- and tri- nucleosomal ( ~150bp, ~300bp and ~450bp). Fraction number is indicated along the top of the 
gel from the highest fraction (1) to the lowest (19 and pellet) along with 5% input DNA (5% in). Sucrose gradient 
density represented by the black slope. Several of the lanes appear to lack any signal, however this is likely due to a loss 
of DNA during precipitation. C. HinP1 5-30% sucrose gradients give a greater separation of CGI fragments away from 
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3.3.2  Verification of sucrose gradient purification procedure 
In order to verify that the predicted CGI fractions do indeed contain CpG island sequence, PCR 
reactions were carried out across the 15-30% gradients for two known unmethlyated CGIs Oprd1 and 
Ccne1. HinP1 digests reveal amplification of both CGIs in lanes 7-10 (Figure 3.3-2, A), 
corresponding to the predicted CGI fractions in 15-30% gradients (fractions 5-9; Figure 3.3-1, B 
upper panel). As the PCR product is around 200bp in length it will not amplify from fractions 
containing only the non nucleosomal (~60bp in size) or mono nucleosomal (~146bp) fragments. 
 
 
Figure 3.3-2. Verification of CGI liberation through sucrose gradient ultracentrifugation. A. PCR 
for the distribution of non-methylated CGI across the 15-30% sucrose gradient. Amplification of the Oprd1 and 
Ccne1 CGIs over the HinP1 gradient was compared to the amplification over an Mse1 gradient. The HinP1 
gradient shows the presence of CGIs over the same fractions predicted to contain Islands (fractions 2-10; figure 
3.3-1 B), with a minority still in the largely uncut fraction 19 (presumably due to inefficient digestion). In 
contrast the Mse1 digested sucrose gradient shows a lack of CGI enrichment over the fractions.  B. whole protein 
extracts were made across a 5-30% HinP1 sucrose gradient to test for protein content and distribution. Fractions 
corresponding to those enriched for CGI nucleosomes are seen to contain higher levels of histones by silver 
staining (red box). However as many of the lanes across the gradient appear to contain similar bands this may 
indicate background protein contamination. 
Oprd1 (HinP1) 
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By contrast analysis across Mse1 digested gradients reveals that no Ccne1 PCR product is found in 
the fractions, with the exception of the pellet which will contain all non digested DNA including CGIs 
(Figure 3.3-2, A).    
 
Although CGI DNA appeared to be successfully liberated from the bulk through sucrose gradient 
centrifugation, the distribution of proteins across the fractions were investigated to ensure that stable 
chromatin can be purified and not just DNA. Equal volumes of TCA precipitated material were 
resolved on a SDS polyacrylamide gel prior to silver staining (see materials and methods section 
2.2.5). Although high levels of proteins were seen in each of the lanes making it hard to define any 
unique CGI proteins, levels of histones were indeed enriched here as expected from the earlier DNA 
studies (Figure 3.3-2, B). The finding that each lane contained so many proteins was somewhat 
surprising as it was hoped that this approach would result in the visualisation of bands representing 
CGI specific binding factors. In fact this result highlights the potential problems with the sucrose 
gradient approach to liberate CGI chromatin which can be explained further after mass spectrometry. 
 
The fractions corresponding to the CGI fragments were analysed by mass spectrometry. Fractions 5-9 
of the HinP1 (suspected CGI chromatin) and MseI (control chromatin) digested nuclei (Figure 3.3-1, 
C) were run a small distance on a SDS polyacrylamide gel. These gel lanes were then cut out, 
trypsinised and analysed by mass spectrometry. Resulting lists of proteins attained for HinP1 (CGI 
chromatin), Mse1 (bulk chromatin) and uncut chromatin (as a control) failed to identify many CGI 
specific proteins. HinP1 fractions identified 841 proteins whilst the uncut control found nearly 
identical numbers of proteins. Comparative analysis of the three data sets revealed that 87 proteins 
were unique to the HinP1 digested chromatin fragments (Figure 3.3-3). However, closer inspection of 
these proteins found that around sixty of these appeared to have no relevance to CGIs or promoter 
function whilst seven were entirely unknown in function. Of the remaining twenty proteins twelve 
were transcription factors (e.g. LBX1) whilst three were associated more directly to transcription (e.g. 
Polymerase II polypeptide C). Other proteins of interest include the DNA replication origin licensing 





Figure 3.3-3. HinP1 specific proteins as revealed through mass spectrometry. The 87 proteins 
found to be unique for HinP1 digests (CGI specific) are represented on a pie chart, grouped by their cellular 
function. The majority (61 and 7) were either unidentifiable proteins or those with non-CGI or non-
promoter/transcriptional links.   
 
 
Due to the high number of non-CGI related proteins present in both the HinP1, Mse1 and uncut 
samples, this approach was unable to accurately determine the protein compliment at CGIs. The 
problem of protein contamination could be explained if the chromatin is unstable in the sucrose 
environment and the proteins dissociate from the DNA, sedimenting to their respective densities. This 
would explain why proteins such as MeCP2 (a protein shown to bind to methylated CpG rich DNA) is 
seen in all three samples (data not shown). It is worth noting that this experiment was carried out prior 
to the identification of the somewhat more efficient and simple restriction enzyme digestion method 
for the purification of CGI chromatin (chapter 3.5). Repeating this analysis with this improved 
purification method may reveal novel CGI binding factors without the background contamination. 
  















The results of the mass spectrometry reveal a high level of background protein contamination. To 
ensure that any non-specific background proteins were removed an approach was taken to liberate and 
purify stable CGI chromatin. This was accomplished through the combination of a high salt wash 
protocol (Dignam, Lebovitz et al. 1983) with methyl sensitive restriction. Mouse brain nuclei were 
washed thoroughly in moderate levels of salt (0.3M NaCl) to remove non-specific and low affinity 
chromatin binding proteins before incubation with the restriction enzyme of choice (be it the methyl 
sensitive HinP1 or insensitive MseI). During this incubation period, the restriction enzymes are able to 
gain access to and selectively digest the chromatin in the nucleus. The resulting small CGI chromatin 
fragments are released into the supernatant and can be separated from bulk and uncut chromatin by 
centrifugation at low speeds. A set of calibrations determined the optimal speed for the centrifugation 
to be around 3,800g in order to best separate the  smaller CGI fragments (non-, mono-, di- and 
trinucleosomal fragments) from the bulk (data not shown). Precipitated DNA from the supernatants of 
the digested nuclei were end labelled as before through the incorporation of a radioactive α
32
P dCTP 
(see section 3.2 and 3.2).  Half of this labelled DNA was then digested further by another methyl 
sensitive restriction enzyme HpaII (cleavage site CCGG). As this DNA is now deproteinised (as 
opposed to the earlier HinP1 digests which were carried out in the context of chromatin), novel non 
methylated CpG sites are now able to be digested by the HpaII enzyme (Figure 3.4-1, A). If CGIs are 
present this should reduce the size of the previously digested DNA fragments further, appearing as a 
“collapse” of the nucleosomal pattern as shown previously by Antequera and collegues (Antequera, 
Macleod et al. 1989).   
 
The results show that the HinP1 digested material is indeed rich in CGI sequences. Firstly HinP1 
digestion alone gives the characteristic non nucleosomal, mono-, di- and trinucleosomal pattern found 
associated with successful CGI release. In contrast the MseI digested nuclei do not give this pattern, 
instead generating a range of band sizes representing general digestion throughout the genome (Figure 
3.4-1, A). Furthermore, HinP1 (CGI) chromatin is collapsed further upon HpaII digestion revealing 
that this DNA is indeed unmethylated and CpG rich. By contrast the MseI digests is unaffected by 





Figure 3.4-1. DIGNAM salt wash and methyl sensitive digestion of nuclei successfully liberates 
CGI chromatin. A. Fragments of DNA from the digested nuclei are radioactively end labelled to allow 
visualisation on an agarose gel. HinP1 digests reveal the expected pattern of nucleosomal digestion (HinP1, HpaII 
–ve lane) implying the successful liberation of CGI material. As a control, Mse1 digestions give rise to genomic 
digestion patterns (Mse1, HpaII –ve lane). Deprotinization post liberation followed by further digestion with the 
methyl sensitive restriction enzyme HpaII reveals that the suspected CGI fraction (HinP1 digests) can be digested 
further due to exposure of further non methylated CpG sequences after protein loss. This collapse is not seen in 
the Mse1 digests implying that a pure population of CGI chromatin is indeed liberated through HinP1 digestion 
of nuclei. Marks corresponding to a 100 base pair ladder are shown on the left.  B. Total protein content from 
HinP1, Mse1 (at a range of concentrations) and mock cut reactions analysed by silver stained polyacrylamide 
gels. Digests reveal a strong proportion of the proteins liberated are histones (predicted histone sizes are shown 
on the left). Additionally it is apparent that the Mse1 digested nuclei liberate around five times as much protein as 
the HinP1 digests.  
 
 
However, as seen with the sucrose gradient experiments, it is important to test the protein compliment 
of this purified material to ensure that stable chromatin is being present. Silver stained gels containing 
proteins present in the supernatants of HinP1, Mse1 and uncut control nuclei reveal far lower overall 
protein levels when compared to those seen in the sucrose gradients (Figure 3.4-1, B). The Dignam 
salt washes have resulted in a loss of protein contamination as seen in the uncut nuclei lane of Figure 
3.4-1, B. It appears from these results that the MseI digestion releases around five times as much 





3.5  Summary of CGI chromatin isolation technique 
 
This adaptation of the original method of isolating CGI chromatin as described by Tazi and collegues 
(Tazi and Bird 1990) produced far clearer results. The work by Tazi and Bird showed similar patterns 
of DNA digestion and collapse of CGI rich DNA to that seen in figure 3.4-1, A. However as the work 
presented here was also interested in CGI specific proteins this method had to be adapted to remove 
the original sucrose gradient size selection (which was found to be determental for protein stability 
within the context of chromatin) for an alternative digestion and salt wash method (Dignam, Lebovitz 
et al. 1983). 
 
This adapted method of isolating CGI chromatin has  greatly reduced the level of “background” 
protein contamination found when samples were subjected to sucrose gradient centrifugation (figure 
3.3-2,B), although it is hard to see any differences between the proteins present in the “CGI” and 
“bulk” chromatin fractions by looking at a silver stained gels alone (figure 3.4-1,B).  Further 
investigations into the specific histone modifications enriched within the CGI fraction through 
techniques such as immunoblotting should help to better understand the chromatin modifications 
associated with CGIs. Potential CGI specific binding factors can also be tested for their distributuion 
between the HinP1 and MseI digested material. Overall this adaptation on a classical method has 
successfully liberated CGI chromatin from the rest of the genome.  
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Chapter 4: Investigating the Protein 
Compliment of CGIs 
 
Historically the majority of work on CpG islands has focused primarily on the study of the DNA. The 
hypothesis that these non-methylated CpG rich stretches of DNA are associated with a unique set of 
proteins has not been thoroughly tested. However, the identification of any CGI specific proteins 
could go some way to explaining any functions associated with these loci. Additionally any proteins 
found to bind over CGIs may be responsibly for the maintenance of these unmethylated sites within a 
largely methylated genome. 
 
Progress in such investigations have been hindered by the lack of powerful enough analytical 
techniques. However, recent advances in the sensitivity of mass spectroscopic analysis and the advent 
of high resolution whole genome sequencing may allow the identification of CpG island binding 
proteins. Whole genome sequencing technology has already led to a plethora of studies investigating 
the distribution of histone modifications and DNA binding proteins on a genome wide scale.  This 
technology has allowed the rapid generation of high resolution binding patterns for multitude of 
proteins in a wide variety of organisms (Barski, Cuddapah et al. 2007; Cronn, Liston et al. 2008; 
Whiteford, Skelly et al. 2009). As the earlier mass spectrometry approaches at determining CGI 
binding proteins had failed a more candidate driven approach was devised to identifying a true set of 
CpG island binding factors.    
 
4.1 Comparisons of CGI and genomic chromatin 
 
4.1.1 Candidate driven analysis of Global CGI protein compliment 
As CGI chromatin had been successfully liberated from the bulk through a series of salt washes 
followed by methyl sensitive restriction enzyme digestion (section 3.5), this chromatin could be used 




In order to correctly test for enrichment of any factors, each of the protein samples had to be 
calibrated to ensure equal loading. Histone H3 was used due to its abundance, ease of detection and 
relative consistency across the genome. However, nucleosomal depletion is often seen over the TSS of 
many genes in the mammalian genome (Heintzman, Stuart et al. 2007; Ozsolak, Song et al. 2007; 
Ramirez-Carrozzi, Braas et al. 2009). As CGIs co-localise to around 60% of annotated promoters this 
may result in lowered levels of H3 within population of CGI chromatin. However the use H3 as a 
loading control allows the direct comparison of histone tail modifications between CGI and bulk 
genomic chromatin.    
 
In order to calibrate the levels of H3 within the CGI and bulk genomic chromatin, a western blot was 
carried out comparing levels of the protein between HinP1 digested nuclei (CGI fragments) and 
several dilutions of MseI digested nuclei (control digests; Figure 4.1-1, A). Quantification of H3 
signals reveals approximately 5 fold less histone H3 in the CGI chromatin samples compared to the 
control Mse1 digests. Using this as a control for equal loading, histone modifications can therefore be 
confidently compared between CGI and bulk chromatin. The relative abundance of these 
modifications may lead to a greater understanding of CGI function and maintenance. 
 
Acetylated Histone H3 
The first modification tested was acetylated Histone H3, a mark tightly linked to the expression of 
genes (chapter 1.1.1 section iv). As this modification can be found at lysines 9, 14, 18, 23 and 27 on 
the H3 tail an antibody was selected which would recognise all such modifications (entitled a “pan-
acetyl” H3 antibody). This mark is found enriched over the promoter start sites of active genes 
(Kurdistani, Tavazoie et al. 2004) it was previously shown to be enriched withing CGI chromatin 
(Tazi and Bird 1990) . Accoridingly the modification was seen enriched in the CGI chromatin relative 
to bulk chromatin (Figure 4.1-1, B). Acetylation of the H3 tail is not only confined to CGI chromatin 
but is found in the bulk fraction, possibly due to the transcriptionally active non-CGI genes (around 




The next histone modification tested was that of H3K4 methylation. High resolution studies have 
shown that mono methylated H3K4 modification peaks between -900 and +1000bp over promoters 
whilst, di- methyl is found between -500 and +700bp at the promoters of active genes (Figure 1.1-2)  
(Barski, Cuddapah et al. 2007). Interestingly the tri- methylated version of H3K4 is seen to peak 
strongly directly over the transcriptional start site of a gene and this occurs regardless of the 
underlying transcriptional state although typically with lower values at inactive or lowly transcribed 
genes (Barski, Cuddapah et al. 2007). As CGIs are often found associated with the promoter regions 
of genes these H3K4 methyl modifications are predicted to be found in the HinP1 digested chromatin. 
Indeed western blots for both H3K4me2 and me3 reveal that both are enriched in the CGI chromatin 
relative to the bulk (Figure 4.1-1, B) 
 
Other histone modifications 
The next set of histone modifications investigated were those typically found associated either within 
the bodies of genes or with inactive regions of chromatin. The histone mark H3K36me3 for example, 
is a modification associated with transcriptional elongation. This mark is found to be depleted over 
promoter regions but enriched over the gene body, mainly in highly transcribed genes (Barski, 
Cuddapah et al. 2007). It is believed that this modification works in conjunction with acetylation to 
allow the RNAP II complex to pass along the gene body during transcriptional elongation (Lee and 
Shilatifard 2007). As this modification is known to be absent from promoter sites it is not surprising to 
find that it is depleted in the CGI chromatin relative to bulk (Figure 4.1-1, B). Interestingly this mark 
is not entirely absent from purified CGI chromatin, possibly due to the fact that around 25% of all 





Figure 4.1-1. The distribution of histone modifications between CGI and bulk chromatin. 
 A. Western blot for histone H3 levels to calibrate the equal loading of protein samples. Mse1 digests liberate 
around 5 times as much material as HinP1 digests. Samples were calibrated as relative volumes of TCA 
precipitated material (from equal numbers of nuclei). Dilution values are displayed across the top of the western 
blot. As a control 5µg of whole cell extract was loaded in the far right lane. B.   Selected histone modifications 
were compared between liberated CGIs (HinP1) and bulk chromatin (Mse1). Equal loading was established by 
H3 levels (left group, top panel). The “active” histone modifications including acetylated H3 and H3K4me2 & 3 
were all significantly enriched within the CGI fraction relative to the bulk. Non-active marks such as 
H3K36me3, H3K9me2, H3K27me3 and H4K20me3 are all depleted or completely absent from CGIs. Two 
candidate CGI binding factors, Cfp1 & Kdm2a, reveal enrichment within CGI chromatin  
 
 
Probing for the distribution of several other histone modifications which tend to have links to 
transcriptionally inactive chromatin gave similar results. The modifications H3K9me2, H3K27me3 
and H4K20me3 have all been shown to be enriched at the promoters of inactive genes and are 
associated with the formation of the heterochromatic regions of the genome. Western blot analysis 
using antibodies to these modifications reveal a striking depletion of all three of these marks within 
CGI chromatin when compared to the bulk of the genome (Figure 4.1-1, B).  
 
































In summary the CGI chromatin is enriched in the histone tail modifications typically associated with 
gene activation such as H3 acetylation and H3K4me2 and me3. Furthermore this CGI chromatin 
appears to be depleted in the transcriptional elongation mark of H3K36me3 as well as the silencing 
modifications of H3K9me3, H3K27me3 and H4K20me3. Therefore CGI chromatin does indeed differ 
from the rest of the genomic material with regards to the modifications of the associated histones. 
  
CXXC proteins at CpG islands 
After the histone modifications associated with CGIs had been investigated the next step was to 
investigate this chromatin for specific binding proteins which may play a role in the initiation or 
maintenance of the CpG islands state. One particular property of the CGI that may be important in the 
binding of proteins is that the DNA sequence is extremely CpG rich. The MBD group of proteins are 
known to bind to methylated CpG dinucleotides through interactions between the cytosine base and a 
conserved methyl binding domain. It would therefore be interesting to search for a group of proteins 
containing any domain with specific affinity for non-modified CpG dinucleotides. One such candidate 
is the CXXC domain which is found in a group of around ten proteins, many which have roles in the 
regulation of chromatin state (see chapter 1.4). This zinc finger domain has been shown to bind to 
unmethylated CpG rich DNA oligonucleotides through interactions with zinc cations (Voo, Carlone et 
al. 2000; Lee, Voo et al. 2001). Furthermore this domain was used in the Bird laboratory as a means 
of generating CGI data sets by CAP technology (chapter 1.3.2). These findings indicate that proteins 
containing this CXXC domain may have important roles at CGIs. 
 
The first of the CXXC proteins investigated was a protein called CpG binding protein, Cfp1 (also 
known as CXXC1 or CGBP) which had previously been shown to be a component of the hSet1 H3K4 
HMTase complex (Lee and Skalnik 2005; Lee, Tate et al. 2007). Western blot analysis reveals that 
Cfp1 is enriched within CGI chromatin (Figure 4.1-1, B).  A second protein containing the CXXC 
domain, Lysine specific demethylase 2A, KDM2a (also known as Jhd1a) was also tested for its global 
distribution. Kdm2a is the enzyme responsible for the removal of methylation at lysine 36 on the 
histone H3 tail. As discussed above, this mark is involved in transcriptional elongation and is depleted 
over gene promoter regions. Like Cfp1 this protein is greatly enriched within the CGI fraction of the 
genome (Figure 4.1-1, B). However low levels of Kdm2a are found outside of CGI regions, possibly 
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as non-CGI promoters (which presumably will be H3K36me3 free and KDM2A positive) will be 
found in bulk genomic fractions. 
 
4.1.2 Database analysis of histone modifications associated with CGIs 
In order to verify the results of the western blots, the findings were compared to high throughput 
histone modification ChIP data sets. Using the online database of epigenetic marks collected by the 
ENCODE consortium (Encyclopedia Of DNA Elements: http://genome.ucsc.edu/ENCODE), CpG 
islands were investigated for the same histone marks previously probed experimentally. The 
ENCODE database displays the profiles of histone modifications across a small region of the genome 
which will invariably contain CGI chromatin. 60 randomly selected promoter CpG islands were 
investigated for associated histone modifications. Human lymphoblast cells were selected as this cell 
type had the most thorough analysis of histone modifications documented within the ENCODE 
database. Histone modifications at these 60 CGIs were classed as either “present” (where peaks of 
modifications were strongly associated to CGIs), “low” (where trace or unconvincing peaks of 
modifications existed) or “absent” (where CGIs were totally devoid of the mark of interest). Although 
limited, this analysis allows for comparisons to be drawn between the western blot results and a high 






Overall this analysis verifies the results of the global western blot experiments (figure 4.1-1) (Table 
4.1-1). The methyl H3K4 modifications were seen to be tightly associated with CGIs increasing in 
association depending on the level of lysine methylation present (mono < di- < trimethylation). None 
of the 60 promoters CGIs investigated lacked the di- or tri- methyl mark. Acetylated H3 was seen to 
be somewhat enriched at CGIs; however a quarter of islands lacked this modification (Table 4.1-1). 
These findings raise the question as to what is maintaining this H3K4 mark at the CpG islands at 
promoter loci (which vary in their levels of H3 acetylation). Analysis of the histone modifications 
which are generally thought to be associated with an inactive chromatin state also follow the findings 
of the earlier western blot study. 80% of the CGIs investigated were completely devoid of the 
H3K36me3 modification previously show to be absent at CGIs. Other silencing marks such as 
H3K9me3 and K27me3 also follow this pattern with 92% and 80% of CGIs completely lacking these 
modifications. It is worth noting that all of these three modifications were seen at low levels at around 
10-20% of CGIs however this may be due to the somewhat loose nature of categorisation used to 






Table 4.1-1 –Distribution of histone modifications at predicated CGIs through database mining. 
The table represents the percentages several histone modification across the 60 CpG island promoters analysed. 
“Present” refers to modifications which peak at moderate to strong levels over CGI regions whilst “low” refers to 
small and possibly non-significant peaks. “Absent” marks were completely lacking across the CGIs investigated. 
Highlighted boxes denote the higher percentage group, thus a consensus for the mark of interest, e.g. H3K4me3 is 
typically found present at moderate to high levels in promoter CGIs whilst H3K4me1 is generally found only at 
low levels. As a comparison the results of CGI chromatin from the western blot in figure 4.1-2 are shown below 
(“WB CGI”).  
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4.2 Profiling of promoter CGIs for associated proteins 
As several histone modifications and CXXC proteins were shown to be enriched at CpG islands on a 
global level, individual islands were subsequently inspected in greater detail through the use of 
chromatin immunoprecipitation followed by quantitative PCR (ChIP PCR). This approach allows the 
quantification and distribution of candidate proteins and histone modifications across regions of 
interest such as a CGI at a particular locus.  
 
The recent generation of CGI data sets in the Bird laboratory reveals that around 50% of identified 
CGIs are found associated with the 5’ end of an annotated gene with the remaining 50% at non 
promoter defined regions (Illingworth, Gruenewald-Schneider et al. 2010). Approximately half of 
these are intra-genic and half inter-genic. Representatives of all three classes were analysed by ChIP-
PCR and the results compared. Four promoter CGIs were investigated, including “typical” non 
methylated promoters as well as a methylated CGI. The profiles shown are results from a single 
experiment which were “typical” of the profiles seen over at least three ChIP-PCR experiments. There 
were often variations in the immunoprecipitation values between experiments leading to large error 
bars when the data was combined. Although these IP values differed the patterns seen did not vary and 
the overall enrichment values of peaks relative to flanking regions remained consistent. 
 
Seven promoter CGI were tested in mouse brain. Six of these were non-methylated in mouse brain 
tissue: genes for Brain-derived neurotrophic factor (Bdnf) which contains 2 CGIs, β-Actin (Actb), C-
Myc, Opiod receptor delta 1 (Oprd1) and Forkhead box D3 (Foxd3). In addition to these somewhat 




4.2.1 Cfp1 profiles over promoter CGIs in the mouse brain 
 
The CXXC protein of Cfp1 was the first protein investigated and was seen to bind over four of the six 
non methylated CGIs tested. Little or no binding was seen over the methylated CGI at the promoter of 
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the Sycp2 gene and the CGIs at the Oprd1 and Foxd3 promoters (Figure 4.2-1). Typical profiles for 
this protein reveal low levels of background signal over the flanking regions with discrete peaks seen 
peaking over the regions corresponding to predicted CGIs. Focussing on the peaks of Cfp1, typical IP 
efficiencies for Cfp1 peaks were in the range of 0.15% and 0.2% for the bdnf CGIs, 0.5% for actb and 
0.3% for c-myc. However, a far more appropriate way to determine the relative enrichment of the 
protein of interest over CGIs is to compare the binding values at these loci to the surrounding flanking 
regions. Using this measurement Cfp1 is seen to be enriched 4.2 fold and 3.1 fold over the two CGIs 
of bdnf, 5.2 fold enriched over actb and 2.6 fold enriched over c-myc. This reinforces the earlier 
finding that the protein Cfp1 is indeed a CGI binding factor (see section 4.1). As mentioned above, 
two of the 6 non methylated CGIs (Oprd1 and Foxd3) appear to lack defined peaks of Cfp1. This 
raises the possibility that Cfp1 is not an ubiquitous CGI binding protein per se but can be targeted to 






Figure 4.2-1. ChIP-PCR profiles over promoter CGIs for the CXXC protein Cfp1. Each of the 6 panels 
represents a promoter region. Gene structures are shown below the profiles with grey boxes representing exons (“exons”). 
CpG density plots (“CpGs”) are shown above the gene structure with each vertical line representing a CpG dinucleotide. 
Refseq derived CGIs are shown above the CpG density plots as indicated by the black boxes (“CGIs”). The enrichment 
values of the ChIP-PCR results are represented as the % of immunopreciptated DNA enriched relative to the input 
material (“%IP/Input”). Midpoints of resulting PCR amplicons are plotted along the x axis. From these results, Cfp1 is 
seen to peak over the islands at bdnf, β-actin and C-Myc but not at Sycp2, Oprd1 and Foxd3. 
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The results of Cfp1 Chip over the methylated Sycp2 CGI add weight to the suggested role of Cfp1 as 
a non-methyl binding protein. This is not entirely unexpected as the CXXC domain within Cfp1 was 
show previously to only bind to non methylated CpG dinucleotides in vitro (Voo, Carlone et al. 2000). 
However the ChIP results over Sycp2 gives an indication in vivo that Cfp1 does not bind to 
methylated CpG rich islands.  A more thorough method of testing the in vivo binding behaviour of 
Cfp1 was carried out later (see section 5.2.2 for more). 
 
 
4.2.2  H3K4me3 profiles over candidate promoter CGIs in the mouse brain 
 
The active histone modification of H3K4me3 previously found to be globally enriched at CGIs was 
also seen enriched at several of the candidate islands through ChIP-PCR analysis (Figure 4.2-2). 
Furthermore H3K4me3 enrichment profiles closely matched those of Cfp1, peaking over the CGIs of 
bdnf, actb and c-myc. Enrichment values of binding over the CGIs show strong and well defined 
H3K4me3 peaks over these regions. For example, the bdnf locus shows 13.3 and 6.8 fold enrichment 
of this modification at the CGIs versus the flanking regions whilst actb and c-myc reveal 2.9 and 7.25 
fold enrichment values at CGIs. The enrichment value of H3K4me3 at actb is somewhat reduced due 
to the fact this modification spans a region greater than the CGI; however this modification is at its 
highest over the CGI region.   
 
The methylated CGI at the sycp2 locus shows no discernable peak of the H3K4me3 modification 
across its length, a finding made all the more interesting through the lack of Cfp1 binding at this loci.  
Additionally, the other two CGIs which were previously shown to be devoid of Cfp1 were also shown 
to lack the H3K4me3 mark. As Cfp1 is part of the enzymatic complexes responsible for the 
establishment of H3K4me3 patterns this provides a possible link between the CXXC protein and the 
histone modification at CpG islands. 
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Figure 4.2-2. ChIP-PCR profiles over promoter CGIs for the histone modification H3K4me3.  
ChIP-PCR profiling for the active histone modification H3K4me3 reveals a similar pattern of binding over CGIs to that 
of the Cfp1 protein. H3K4me3 is seen to peak over bdnf, β-actin and C-Myc but not at Sycp2, Oprd1 and Foxd3. 
 
General figure layout and abbreviations follow those outlined in figure 4.2-1.  
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4.2.3 H3K27me3 profiles over CGIs 
The histone modification H3K27me3 is generally associated with “silenced” regions of chromatin set 
up by the Ezh2 subunit of PRC2 (polycomb repressive complex 2) (Cao, Wang et al. 2002) and is in 
turn bound by the PRC1 complex (polycomb repressive complex 1) to maintain this silencing. 
Regions high in this histone modification tend to exist in large domains in contrast to the discrete 
peaks of the H3K4 methylation states (Boyer, Plath et al. 2006; Roh, Cuddapah et al. 2006; 
Mikkelsen, Hanna et al. 2008). Genome wide studies have revealed that the majority of this 
modification is seen to correspond to inactive or “silenced” gene promoters however domains of this 




Typically, non methylated CGIs tend to lack the H3K27me3 modification in differentiated cells with 
profiles tending to remain low over such loci (Figure 4.2-3). However, profiling of the Bdnf locus in 
mouse brain revealed that both of the CGIs at this promoter contain peaks of H3K4me3 (Figure 4.2-2) 
as well as H3K27me3. These H3K27me3 peaks are found to have 3 to 3.5 fold enrichment over both 
of the CGIs relative to the flanking regions. A possible explanation for this is that the brain material 
used for ChIP contains multiple cells types such as neurons, glia etc and represent a mixed population 
of cells in which this gene is either on or off (thus H3K4me3 positive/H3K27me3 negative or vice 
versa). However it cannot be ruled out that the two CGIs at bdnf are indeed bivalently marked by both 
H3K4me3 and H3K27me3 modifications. 
 
In contrast the β-Actin locus exhibits a far more typical H3K27me3 patterns with around a 4 fold 
reduction in the modification over the CGI relative to the flanking sites. It must be noted that the 
signal over this entire locus was nearly ten fold lower than that seen over Bdnf further highlighting the 











Figure 4.2-3. ChIP-PCR profiles over promoter CGIs for the histone modification H3K27me3.  
ChIP-PCR profiling for the silencing histone modification H3K27me3 over 5 CGIs at 4 different promoters. 
H3K27me3 was seen to peak over bdnf, Oprd1 and Foxd3 CGIs but not that at β-actin. 
 
General figure layout and abbreviations follow those outlined in figure 4.2-1.  
 
 
Interestingly the two Cfp1 and H3K4me3 negative islands of Foxd3 and Oprd1 reveal high levels of 
H3K27me3 modified histones. Whether or not this modification directly repels Cfp1 binding and 
H3K4me3 modification or is a secondary event in the formation of heterochromatin is not yet known. 
It is possible that the promoters of these two genes were initially bivalently marked with both 
H3K4me3 as well as H3K27me3 in ES cells, leading to a transcriptionally “poised” state which is lost 
upon differentiation (Guenther, Levine et al. 2007). Foxd3 is indeed a developmental gene which is 
not transcribed in the brain and therefore silencing modifications such as H3K27me3 are found here. 
The links between the H3K27me3 modification and both H3K4me3 and Cfp1 binding are somewhat 
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complicated by the results at the bdnf locus. Although these finding can be explained by assuming a 
mixed cell population leads to the portrayal of a “bivalent-like” pattern over the CGIs this needs to be 
tested. Repeating these experiments on a pure population of cultured cells may give rise to a more 





4.2.4 H3K9me3 profiles over promoter CGIs in mouse brain 
 
Both di- and Tri- methylation of H3K9 has been implicated in both heterochromatin formation and 
gene silencing events (Bannister, Zegerman et al. 2001). Global levels of this modification were 
shown above to be absent or non detectable within non methylated CGIs (Figure 4.1-2, B). Profiling 
of this modification over the CGI regions of Bdnf, β-Actin and C-Myc show this modification enriched 
across all of these loci (Figure 4.2-4). By contrast, the methylated (and silenced) promoter at the 
Sycp2 locus exhibited around a 2.5 fold peak of H3K9me3 over the CGI region of this gene with IP 
efficiencies peaking at around 5% of the input.  
 
The promoter CGIs at Oprd1 and Foxd3 which lacked Cfp1 and H3K4me3 but contained H3K27me3 
also contain peaks of H3K9me3. Both loci show peaks of this silencing modification although the 
Oprd1 locus contains a far less defined peak than the foxd3 CGI. However, these loci along with the 
CGI at the Sycp2 promoter show IP efficiencies which are around ten fold higher than those seen at 
bdnf, actb and C-myc. All three of the islands which lack Cfp1 (the methylated Sycp2 and non 
methylated Oprd1 and Foxd3) contain peaks of both the silencing histone modifications of H3K9me3 
and H3K27me3 whilst the islands that contain this CXXC protein lack these marks and instead 
containing the active histone modification H3K4me3.  
 
4.2.5 Profiles of other CXXC proteins over CGIs in the mouse brain 
 
Several other proteins contain a CXXC domain homologous to that found in Cfp1 (Figure 1.4-1). Due 
to the affinity of this domain for non-methylated CpG dinucleotides, these proteins may represent a 
family of CGI specific binding factors. To determine whether or not these proteins are enriched over 





Figure 4.2-4. ChIP-PCR profiles over promoter CGIs for the histone modification H3K9me3 in 
mouse brain. ChIP-PCR profiling for the silencing histone modification H3K9me3 reveals limited binding over 
the entire bdnf, β-actin and C-Myc regions tested. In contrast, this modification is dramatically enriched over the 
CGIs at Sycp2, Oprd1 and Foxd3. 
 
General figure layout and abbreviations follow those outlined in figure 4.2-1 
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The first of these CXXC proteins tested was Mll1. Not only does this protein contain a highly 
conserved CXXC domain, but it also contains a SET domain responsible for the di- and tri- 
methylation of H3K4 residues. This protein might therefore provide an alternative link between non-
methylated CpG dinucleotides and the H3K4me2/3 modification to that discussed above with Cfp1 
and the Set1a/b complexes (Lee and Skalnik 2005; Lee, Tate et al. 2007). There is also some evidence 
to argue that the Cfp1 protein directly interacts with the MLL1 protein (Ansari, Mishra et al. 2008). 
ChIP profiling of the Mll1 protein over the 7 candidate CGIs revealed similar binding patterns as 
Cfp1. The bdnf locus contains peaks of enrichment for the protein which corresponded to the CGIs 
with 4.3 and 7.5 fold enrichment relative to the flanking regions (Figure 4.2-5). Similar patterns were 
seen over the CGIs at Actb and C-Myc with peaks of MLL1 enriched 2.4 and 2.9 fold relative to the 
flanks.  
 
Similar to Cfp1, Mll1 is not enriched at the methylated island Sycp2 raising the possibility that Mll1, 
like Cfp1, may be acting specifically as a non methyl binding protein in vivo. Again Mll1 follows 
similar patterns to that of Cfp1 over the final two CGIs of oprd1 and foxd3. It is not known whether 
Cfp1 and Mll1 peak over the CGI regions by co-localisation to such loci or whether or not a genuine 
interaction exists although the findings by Ansari and colleagues would argue for the latter (Ansari, 
Mishra et al. 2008) 
 
The protein Kdm2a is another member of the CXXC protein family. This enzyme, responsible for the 
demethylation of H3K36me3 histone tails, was also enriched over CGIs (Figure 4.1-1, B). Profiling of 
Kdm2a across the Bdnf locus revealed enrichment over the two CGIs, although with less discrete 
peaks than Cfp1 (Figure 4.2-6). Enrichment values of 2 and 5.2 fold over these CGIs relative to the 
flanking regions imply that Kdm2a may also be a CpG binding protein. Further ChIP-PCR 
experiments were carried out in the laboratory of Dr Rob Klose with similar CGI specific binding 
patterns seen across the genome (Blackledge, Zhou et al. 2010). These findings along with the earlier 
enrichment of Kdm2a in the CGI chromatin fraction of the genome (Figure 4.1-1) support the role of 






Figure 4.2-5. ChIP-PCR profiles over promoter CGIs for the CXXC protein Mll1.  
ChIP-PCR profiling for the histone methyltransferase Mll1 reveals a similar pattern of binding over CGIs to that of 
the Cfp1 protein and H3K4me3 modification. Mll1 is seen to peak over bdnf, β-actin and C-Myc but not at Sycp2, 
Oprd1 and Foxd3. 
 
General figure layout and abbreviations follow those outlined in figure 4.2-1 .  
Bdnf locus   39kb 
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Another CXXC protein of interest is Mbd1 as this protein contains both a MBD for methyl CpG 
binding as well as three CXXC domains for non-methyl CpG binding (Figures 1.2-4 & 1.4-1). 
Although this protein contains three CXXC domains only one has been shown to be capable of 
binding to non-methylated CpGs (Jorgensen, Ben-Porath et al. 2004). ChIP profiling for this protein 
over the bdnf locus yielded no discernable pattern of binding at or around the two CGIs. Whether or 
not this result represents poor immunoprecipitation or is a true representation of in vivo binding it is 
not known. Recent work using the functional CXXC domain of Mbd1 (“CXXC-3”) to generate a non-
methylated CGI library argues that a portion of Mbd1 is able to bind to non methylated CGIs in vitro 
(Illingworth, Kerr et al. 2008). Further work is required to better understand what is preventing full 




Figure 4.2-6. ChIP-PCR profiles over Bdnf promoter CGIs for the CXXC proteins Kdm2a and Mbd1. 
ChIP-PCR profiling of the bdnf locus for Kdm2a and Mbd1 give rise to dramatically different results. Although 
both contain CXXC domains only Kdm2a is seen to bind over the CGIs at bdnf. Mbd1 shows no such binding 
pattern, however due to the fact that the CXXC domain from this protein is used to affinity purify CGI DNA this 
ChIP-PCR result may be as limited by the antibody used. 
  


























The CXXC domain containing protein Tet1 has been predicted to have roles in the conversion of 
methylcytosine to hydroxymethylcytosine (Tahiliani, Koh et al. 2009). As this process may represent 
an intermediate in the demethylation of DNA, the Tet1 protein is of great interest. ChIP-PCR studies 
over the CGIs at bdnf and actb were unable to detect any binding of the Tet1 protein. Subsequent 
consultation of expression data reveals that levels of Tet1 are relatively low in the brain and therefore 
repeating these experiments in a cell type known to contain higher levels of Tet1 (such as ES cells) 
may result in a different pattern of binding over CGIs. However, from these ChIP-PCR results it is 
impossible to determine whether or not Tet1 binds to non methylated CGIs. It cannot therefore be 
assumed that proteins containing this domain are intrinsically CpG island specific binding factors.  
 
 
4.3 Profiling of non promoter CGIs for associated proteins 
 
As the seven candidate CGIs interrogated above were found at promoters of known protein coding 
genes, one could argue that the results may be representing a promoter specific set of CGI binding 
proteins and modifications. PCR profiling of non-promoter associated CGIs was carried out to better 
understand the general protein complement. 
 
4.3.1 Analysis of an intragenic CGI in mouse brain: exon 6 of the atg9b gene 
The gene Autophagy related 9 homolog B (Atg9b) has been shown to be involved in vacuole 
formation in the cell (Yamada, Carson et al. 2005). Ensemble CGI predictions are reinforced by 
studies in the lab (Elisabeth Wachter, unpublished observations) revealing the presence of a CGI 
within the fourth exon of the gene. ChIP PCR was carried out over a 3.5Kb region encompassing this 
intragenic CGI to test for the presence of several histone modifications and CXXC proteins. 
 111 
 
Figure 4.3-1. ChIP-PCR profiles over the intragenic CGI at atg9b in mouse brain. ChIP-PCR 
profiling for Cfp1, H3K4me3, H3K9me3 and Mll1 over the intragenic island reveals a mild enrichment of both 
Cfp1 and H3K4me3. Both the silencing modification ofH3K9me3 and the CXXC protein Mll1 show no such 
enrichment. 
   
General figure layout and abbreviations follow those outlined in figure 4.2-1. The exon numbers are displayed 
underneath as “e” followed by the respective number. 
 
 
Resulting PCR profiles for the CXXC protein Cfp1 showed a two fold enrichment over the exonic 
CGI of Atg9b (Figure 4.3-1). This low enrichment value is largely due to the relatively high 
background signal seen across this region, as the IP efficiency of the Cfp1 peak is comparable to 
earlier values seen over the promoter CGIs. One likely explanation for this is that the region 
investigated is much smaller than the earlier promoter regions tested (3.5kb here compared to 10-20kb 
over the promoter CGI loci). Extension of the profiled region further from this CGI so as to 
incorporate more flanking regions may reveal lower background values and result in a more discrete 
peak of binding over the CGI. Similarly, the H3K4me3 modification also contains high levels of 
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CGI relative to flanking regions (Figure 4.3-1). Although low enrichment values are seen, both Cfp1 
and H3K4me3 peak over the middle of the CGI. By contrast, the silencing modification H3K9me3 
showed no preferential binding over the Atg9b exonic CGI region. Interestingly the other CXXC 
protein investigated, Mll1, did not appear to be enriched at this unmethylated CGI. This is in contrast 
to the earlier set of findings showing enrichment of that Mll1 at promoter annotated CGIs (Figure 4.2-
5). This result may indicate promoter specific or promoter CGI specific binding of Mll1. Indeed Mll1 
has been shown to have a tight association with promoter regions and the basal transcription 
machinery (Yokoyama, Wang et al. 2004) and as such may only be found at CGIs corresponding to 
promoter regions. However, due to the small region profiled and resulting background problem, no 
definite conclusions can be made with regards to Mll1 binding. 
 
4.3.2 Analysis of an intergenic CGI  
Around a quarter of all CGIs are found in intergenic regions, not associated with any identified gene. 
Such islands, termed “orphan CGIs” are likely to represent either promoters of non-annotated genes or 
non coding RNAs. To better understand the protein compliments at these sites and compare to 
promoter and intragenic CGI results, a CGI found at chromosome 5 at location 142,802,323 - 
142,885,868 was investigated by ChIP-PCR for CXXC proteins and histone modifications.      
 
Similar to the other classes of CGI investigated, the CXXC protein Cfp1 is enriched over the CGI, 
albeit at lower levels than the promoter CGIs (Figures 4.3-2 and 4.2-1). As was seen at the intragenic 
CGI at the Atg9b gene, these Cfp1 peaks were only enriched 2 fold over the flanking regions. Again 
this is possibly due to small size of the region analysed (5.1kb compared to 39kb at bdnf) and 
extension of the profiles to include more of the flanking regions may result in a reduction of the 
background signal. Subsequent profiling for the H3K4me3 modification reveals a similar pattern of 








Figure 4.3-2. ChIP-PCR profiles over an intergenic CGI in mouse brain. ChIP-PCR profiling for Cfp1, 
H3K4me3, H3K9me3 and Mll1 over the intergenic CGI once again reveals an enrichment of both Cfp1 and 
H3K4me3 over the island. Again, both the silencing modification of H3K9me3 and the CXXC protein Mll1 show 
no such enrichment. 
   




Analysis of H3K9me3 and Mll1 binding over the intergenic island revealed striking similarities to 
those seen at intragenic islands. Both the silencing modification and the CXXC protein showed no 
discernable binding over this site and therefore strengthen the view that these are promoter specific 
factors. The finding that Mll1 is not enriched at either of the non-promoter islands implies that the 
Cfp1/Set complex may be the H3K4 methyltransferase leading to the maintenance of the H3K4me3 
modification at these CGIs. It remains to be determined whether these examples are representative of 












































4.4 Genome wide ChIP sequencing of CGI binding factors 
Recent advances in genome wide sequencing has paved the way for extremely thorough and in depth 
in vivo DNA-protein studies. The ability to sequence fragments of DNA isolated by chromatin 
immunoprecipitation (ChIP-Sequencing or “Chip-Seq”) allows high resolution protein-DNA maps to 
be drawn up on a genome wide scale. In contrast to earlier techniques such as ChIP-ChIP (ChIP 
followed by microarray hybridisation), ChIP Seq gives a higher resolution of sequencing from as little 
as 10ng starting material. This in turn has led to a great advancement in our understanding of the 
binding sites and therefore potential roles for proteins and histone modifications within the cell 
(Barski, Cuddapah et al. 2007; Robertson, Hirst et al. 2007; Whiteford, Skelly et al. 2009).   
 
Methods of whole genome sequencing differ depending on the particular company and equipment 
used. One of the more advanced and therefore widely used whole genome sequencing approaches is 
that developed by Illumina. This technology relies on the sequencing of clusters of amplified 
immunoprecipitated DNA to build up an image of genomic protein binding sites (Figure 4.4-1, A). 
One sequencing run can generate more than 20 million sequence tags of up to 36 base pairs each 
which allows ChIP-Seq studies to be carried out with a positional resolution of +/- 50bp (Mardis 
2007). A more accurate set of protein binding sites can be determined than previous ChIP-ChIP 
methods in which a large number of tiling arrays would be required to gain a comparable resolution.  
 
4.4.1 Recent genome wide protein binding studies 
The advent of new sequencing technology has led to an influx of high resolution studies carried out on 
a genome wide level. Many of these have focused specifically on histone modifications as these 
proteins are highly abundant and can be immunoprecipitated along with associated DNA sequences 
with high efficiency. The profiles of several of the histone methylation modifications such as K4, K9, 
K36 and K27 of histone H3 as well as RNA polymerase II were produced by ChIP-Sequencing across 
the promoter regions in T cells (Barski, Cuddapah et al. 2007). Promoters were grouped based on the 
transcriptional state of the associated gene, allowing direct comparisons to be drawn between certain 
histone modifications and expression levels. Although the distribution of many of these modifications 
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had been previously determined, this study by Barski and colleagues was able to clarify these finding 
at a much higher resolution.  
 
 
Figure 4.4-1. An overview of ChIP-Sequencing and data analysis. A. Flow chart of the steps taking 
immunoprecipitated DNA (“ChIP DNA”) through to sequencing and mapping.  Universal adaptors are added to the 
ChIP DNA before amplification and subsequent clustering onto plates. These plates are read by the Illumina genome 
analyser machine and converted into the readable and presentable format seen in B (figure created using the Integrated 
genome browser – IGB – provided by Affymetrix). At this stage the data is in a somewhat raw format (B). Shown is a 
typical display window where the ChIP seq raw data can be compared to genomic entities such as CGIs or RefSeq 
predicted genes. In the figure, the blue peaks correspond to protein binding patterns. The y axis represents the intensity 
of binding through the number of sequenced reads whilst the x axis is the position within the genome, allowing the reads 
to be mapped accordingly. C. These raw data files can be processed to remove artefacts of sequencing as well as non 
specific background noise. These processed files can then undergo user defined “peak finding” steps to identify true 
regions of protein binding (represented by the blue box under the ChIP-Seq data file). The red arrow denotes a common 
issue with peak finding whereby two peaks are often classed as one depending on the distance between then (the “gap”) 
(Figure A taken from (Barski, Cuddapah et al. 2007) 
 
This new technology has also resulted in some rather interesting findings. Traditionally RNAP II was 
believed to be specifically recruited to the promoters of actively transcribing genes. However, the 




















the transcriptional start site of nearly all promoters be they active or silent. Closer inspection reveals 
that higher levels of binding are seen at the promoters of highly expressed genes than those of silent. 
 
Further sets of studies utilising the ChIP-Seq technology have been applied to a wide range of protein-
DNA interactions ranging from studies determining nucleosomal positioning over promoter regions 
(Schones, Cui et al. 2008) to the mapping of enhancer elements (Visel, Blow et al. 2009). The latter 
study in particular highlights the potential of ChIP-Seq to identify the binding sites of DNA binding 
proteins. Therefore, ChIP-Seq can be used to thoroughly investigate the distribution of candidate CGI 
binding factors discovered in earlier Western blot and ChIP-PCR experiments on a genome wide 
scale. 
 
4.4.2 Preparing Samples for ChIP sequencing and analysis 
Although insightful, the previous ChIP-PCR studies were somewhat limited as they represented only a 
small fraction of the CGIs. In these experiments both the CXXC protein Cfp1 and H3K4me3 were 
seen to bind specifically to the CGI (see chapter 4.2-1 and 4.2.2) unless this island contained 
H3K27me3 modified histone tails. In order to determine whether or not this was true globally, ChIP-
Seq for both Cfp1 and H3K4me3 was carried out on mouse brain tissue and compared to published 
H3K27me3 data sets. Although H3K4me3 has been previously sequenced through ChIP-Seq by 
Barski and colleagues (Santos-Rosa, Schneider et al. 2002), it was important to generate our own data 
sets as this would allow for the optimisation of ChIP-Seq protocols as well as to allow for the direct 
comparison to subsequent ChIP-Seq data sets. 
 
In a similar approach to ChIP-PCR protocols, DNA fragments associated with the protein of interest 
are immunoprecipitated with a specific antibody (Figure 4.4-1 A). Universal adapters are then 
attached to the ends up these fragments to allow PCR amplification of ChIP material (typically 12-20 
cycles).  Amplified material is then clustered into groups at the Sanger institute, Cambridge, followed 
by sequencing-by-synthesis on analyser machines.  Image files are made from these sequencing 
reactions which in turn are converted into DNA sequence data which can be plotted against the 
genome. Prior to analysis, the resulting raw sequence files undergo a round of normalisation followed 
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by background subtraction in order to remove non-specific noise. To these ends a set of in-house tools 
called GALAXY were used (found at http://bifx3.bio.ed.ac.uk:8080). The parameters for 
normalisation and background can be found in the Materials and Methods section. 
 
Processed data can be viewed as a series of sequence hits over the genome using the Integrated 
Genome Browser (IGB) software provided by Affymetrix, which allows multiple ChIP-Seq profiles to 
be plotted simultaneously against the genomes of many organisms. In order to carry out statistical 
analysis, peaks of enrichment were defined from the raw sequencing data (Figure 4.4-1, B & C). 
These regions of enrichment are represented by a box marking genuine binding sites for the protein. 
GALAXY tools were used to convert significant peaks into blocks which can be compared between 
samples. In this way, sites which contain a box (referred to as a “peak”) for two individual proteins 
could be said to be overlapping and therefore co localised. Each individual ChIP-Seq sample had a 
unique set of criteria for what would define a peak however some pragmatic rules apply to the length, 
height and gaps required to produce a box or peak. For the conditions used to determine peaks during 
analysis see table 2.2-1. 
 
4.4.3 Analysis of ChIP-Sequencing data 
In order to investigate the distribution of the histone modifications and Cfp1 throughout the genome, 
specifically with respect to the CGIs, an accurate CGI data set must be used. Predictive techniques 
vary wildly in content depending on the criteria selected these are not fully reliable. Fortunately a high 
resolution genome wide map of non methylated CpG rich DNA sequences (CGIs) was created in the 
Bird laboratory and would allow for the direct comparisons between ChIP-Seq results and CGI 
positioning (Illingworth, Gruenewald-Schneider et al. 2010). This data set was created through 
affinity purification using a non-methyl binding domain (a “CXXC” domain) from the Mbd1 protein. 
Mouse sperm DNA was used as the substrate due to the fact that resulting data sets should include all 
non-methylated islands. Bound DNA was eluted off the CXXC columns using salt washes and 
resulting fragments adapter ligated and amplified prior to ChIP-sequencing. Peak finding on this 
sequenced data set allowed direct comparisons and statistical analysis for overlap with later ChIP-Seq 
results for proteins and histone modification of interest. 
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Peak finding analysis on the sequenced data gave 13,348 islands, of which around 50% were found to 
be 5’ promoter associated (Illingworth, Gruenewald-Schneider et al. 2010; Thomson, Skene et al. 
2010). The remaining 50% were found to be distributed between 3’ ends of genes and at intergenic 
and intragenic loci. Whether or not these loci are actually the promoters of non-annotated genes or 
non-coding RNA is as yet unknown. 
 
i) H3K4me3 
The H3K4me3 Chip-Seq was carried out and the data was analysed as outlined above. Sequence reads 
were plotted against the mouse genome (Ensemble mm9 build: 
http://www.ensembl.org/Mus_musculus/Info/Index) revealing a high coincidence of H3K4me3 
enrichment over CGIs. Previous studies have shown by ChIP sequencing that the H3K4me3 mark is 
found enriched over promoter regions with a greater level found over active promoters than at 
silenced counterparts (Barski, Cuddapah et al. 2007). The data set produced here reinforces these 
findings as well as linking this histone modification to CGIs. The raw data was then processed so that 
further statistical analysis could be applied.  Statistically significant H3K4me3 peaks were determined 
through the use of user defined parameters and were validated through comparison to the earlier ChIP-
PCR results (Table 2.2-1). Once processed, the H3K4me3 data set gave 13,663 unique peaks over the 
entire genome. When restricted to the CGI positive data set (13,348 sites) there were 10,440 
occurrences of overlap (78.2%) between the histone mark and CGIs. This reinforces the earlier ChIP-
PCR and western blot studies regarding the enrichment of K4me3 modified histone H3 tails at CGI 
loci (Figures 4.1-1 & 4.2-2).  
 
ii) Cfp1 
Cfp1 ChIP was carried out by both myself and Pete Skene of the Bird lab using the Cfp1 Santa-Cruz 
H120 antibody and sequencing adapters ligated onto the purified DNA fragments by Robert 
Illingworth in the lab prior to sequencing by the SANGER institute. The resulting Cfp1 sequencing 
data contained greater levels of background “noise” than the histone H3K4me3 ChIP-Seq data set, 
largely due to the low IP efficiency (~0.5%) and enrichment values (2-5 fold over flanking regions) of 
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the Cfp1 antibody. The raw data was normalised as before (Table 2.2-1) resulting in a processed Cfp1 
data set (Figure 4.4-2). Due to the low IP values seen for this antibody, two individual ChIP-Seq 
experiments were run in parallel and the data combined into one file. Combining data in this way 
should lead to a greater signal to noise ratio assuming the background noise effect is random and 
binding specific. The resulting combined data file was then subjected to peak finding parameters 
(Table 2.2-1) in order to determine statistically significant Cfp1 binding sites. 
 
Peak finding revealed that the earlier correlation between Cfp1 and non-methylated CGIs holds true 
across the entirety of the genome. Of predicted CGIs, 81.5% contain a significant enrichment of Cfp1 
over their length. Direct comparison of these Cfp1 positive islands with peaks of H3K4me3 confirms 
the co-localisation seen in the candidate ChIP-PCR studies. In total the majority (92.5%) of CGIs 





Figure 4.4-2. Raw and processed data sets for H3K4me3 and Cfp1 ChIP-Seq in mouse brain. 
Wiggle files and processed peak finding data sets are plotted against the mouse mm9 build using the IGB programme. 
“Wiggle” files represent the raw sequencing data with the height of the signal corresponding to the depth of sequencing 
of IP’d fragments. “Peak” data sets represent user defined regions of significant binding from the processed wiggle files.  
Peaks for H3K4me3 and Cfp1 were seen to overlap with predicted CGIs. 
 




























In order to ensure that this Cfp1 data set is indeed accurate, chromatin immunoprecipitation was 
repeated with a second antibody donated by Dr David Skalnik at the Harvard medical school. 
Although this antibody appears to be more specific in its binding the efficiency of 
immunoprecipitation is ten fold lower than the original H-120 data set resulting in higher levels of 
background noise. To reduce this problem samples were sequenced twice from two independent 
immunoprecipitations prior to combination into one data file. This had the desired effect of increasing 
the signal to noise ratio and allowed peak finding to be carried out with greater confidence. Although 
this second Cfp1 data set closely mimics the H-120 set of ChIP-Seq experiments (Figure 4.4-3) it 
lacks 9.2% of the Cfp1 positive islands identified in H-120 results (Figure 4.4-3, B left panel). This is 
likely due to both an increased specificity imposed by the antibody (as seen by the greater signal to 
noise ratio of peaks) and a low IP efficiency. Overall, the Cfp1 data set generated using the Skalnik 
antibody overlap with the H-120 data set by 96% whilst the H-120 overlaps with the Skalnik set by 
85%. Combining both the H-120 and Skalnik Cfp1 data sets and scoring only for an identifiable peak 
in both data sets drops the percentage of Cfp1 positive islands at CGIs from 81.5% in the H-120 data 
set alone to 69.5% in the combined set. Comparing the Cfp1 bound islands (from both individual data 
sets as well as the combined set) to H3K4me3 peaks reveals that the tight correlation persists 
regardless of the Cfp1 antibody (Figure 4.4-3, B right panel). 96% of Skalnik Cfp1 positive islands are 
H3K4me3 positive which compares to the 92.5% of H-120 Cfp1 positive islands seen to contain the 
active histone modification. Furthermore, the combined Cfp1 data set reveals nearly 97% overlap with 
H3K4me3. Although the Skalnik Cfp1 antibody appears to miss many of the Cfp1 peaks identified in 
the previous H-120 ChIP-Seq experiments, this second ChIP-Seq experiment increases the confidence 
that Cfp1 is a CGI binding factor and that the protein is tightly linked to regions of H3K4me3 at CGIs 
genome wide. Due to the low IP efficiency associated with the Skalnik ChIP-Seq experiment, the H-







Figure 4.4-3. Comparison of two independent Cfp1 ChIP-Seq data sets. A. Commercial Cfp1 “H-
120” antibody produced data set (upper tract, dark green) reveals a highly similar pattern of enrichment as the 
“Skalnik” Cfp1 antibody (lower tract, light green) over the β-Actin CGI. B. Genome wide statistics for the two 
Cfp1 antibodies. The left panel represents the percentage of all CGIs that are positive for either, or both 
(“combined”) Cfp1 antibodies. The Skalnik antibody is less efficient at pulling down CGI fragments and as such 
combining the two data sets results in around 10% fewer CGIs than the commercial H-120 alone. The right panel 
represents the percentage of these Cfp1+ CGIs that are also H3K4me3 positive. In all cases the association of 
H3K4me3 with the Cfp1 antibodies is tight. Combining the two Cfp1 data sets gives rise to around a 97% 






The earlier ChIP-PCR studies found that not all non-methylated CGIs contain the CXXC protein Cfp1 
and the active histone modification H3K4me3 (chapters 4.2.1 to 4.2.3). Two such islands (Oprd1 and 
foxd3) were instead seen to contain an enrichment of the H3K27me3 modification across the length of 












































the CGI. The ChIP-Seq data reveals that as a proportion (18.5%) of CGIs lack Cfp1 binding 
(determined by the H-120 Cfp1 data set) and that these also appear to lack the H3K4me3 modification 
(17.3% of CGIs lack both). To test whether or not these islands are enriched the H3K27me3 
modification identified in the earlier ChIP-PCR experiments, the data sets generated for H3K4me3 
and Cfp1 were directly compared to previously published H3K27me3 ChIP-Seq data sets on whole 
mouse brain tissue (Mikkelsen, Hanna et al. 2008). As the raw data was not available, processed “peak 
finding” data sets were compared to our ChIP-Seq data for further analysis. Although this hinders 
direct comparisons between our data sets to the previously published sets it still allows for some 
general conclusions to be drawn.  
 
Analysis of this data reveals that enrichment of H3K27me3 occurs over larger domains than the 
histone modification H3K4me3 in mouse brain, with around 50% of these domains corresponding to 
defined CGIs. Direct comparisons to the H3K4me3 and Cfp1 data sets reveal that the patterns seen in 
the earlier candidate ChIP-PCR experiments are the same genome wide (Figure 4.4-4). Typically 
islands which lacked the H3K4me3 modification (2908 islands) also lacked Cfp1 (2704 islands). The 
majority (63%) of these H3K4me3 negative, Cfp1 negative islands were found to be enriched in the 
H3K27me3 modification (1697 of 2707 Cfp1-ve/H3K4-ve islands). The functional significance of this 
is unknown, but it will be interesting to test whether of not the H3K27me3 modification itself is 
refractory to Cfp1 binding or the presence of H3K4me3 modifications, or if this mark is a secondary 




Figure 4.4-4. H3K27me3 peaks are found over CGIs which lack Cfp1 and H3K4me3. A. IGB 
alignment of H3K4me3 (blue), Cfp1 (green), RNAP II (pink) and H3K27me3 peaks (red boxes). Typically CGIs 
co-localise to peaks of H3K4me3, Cfp1 and RNAP II but not H3K27me3 peaks. H3K27me3 positive islands are 
indicated by the red asterisks and lack all other marks. B. Venn diagram representing the overlap of the 
H3K4me3, Cfp1 and H3K27me3 peaks at islands. Once again it is apparent that the H3K4me3 and Cfp1 peaks 
are tightly co-localised over islands whilst the H3K27me3 modification is discrete. Numbers indicate numbers of 




iv) RNAPII  
One of the more prominent hypotheses for the initiation and maintenance of CGIs is that transcription 
and the associated transcriptional machinery may either protect the DNA from methylation or 
facilitate the recruitment of certain histone modifying enzymes resulting in a decompacted chromatin 
structure (Macleod, Charlton et al. 1994; Guenther, Levine et al. 2007). Studies in which the Sp1 
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transcription factor binding site was mutated over the aprt promoter resulted in loss of transcription 
and caused subsequent methylation of the CpG Island (Macleod, Charlton et al. 1994). As CGIs are 
often found at the 5’ ends of genes the process of transcription itself may be maintaining CGI state. To 
investigate the associations between CGI binding proteins, histone modifications and transcription, 
RNAPII occupancy must be investigated over CGIs. RNAP II ChIP-Seq was carried out by Pete 
Skene in the Bird laboratory using the non phosphorylated tail form of RNAP II. This form of the 
protein will be representative of recruitment of the transcriptional machinery but not of initiation or 
transcriptional elongation. These RNAP II peaks were found to co localise to 74.6% of all CGIs. Since 
only a fraction of these are expressed RNAP II appears to be pre-bound at the promoters of many 
genes and not simply recruited for transcription as originally thought (Figure 4.4-5,A). Direct 
comparisons between this data set and the H-120 Cfp1 and H3K4me3 data sets reveal an 88% overlap 
between all three marks (Figure 4.4-5, B). However this analysis reveals a subset of CGIs which 
contain both Cfp1 and H3K4me3 in the absence of RNAP II (7% of Cfp1+/H3K4me3+ islands) 
leading to the possibility that the non-methylated CpG sequence itself, and not transcription or the 
transcriptional machinery, results in peaks of H3K4me3 through the CXXC protein Cfp1. 
Alternatively, this finding can be explained if the ChIP-Seq experiment was missing lower affinity 
RNAPII binding sites. Further work on the links between RNAP II and CGI state is required to fully 




Figure 4.4-5. RNAP II ChIP-Seq data aligns to the majority of CGIs. A. IGB alignment of Cfp1 (green), 
H3K4me3 (blue) and non phosphorylated RNAP II (pink) along with CGIs and Refseq annotated genes. RNAP II 
rends to also be found associated with CGIs, however in a minority (7%) of cases is not at H3K4me3+ Cfp1+ 
islands (denoted by pink asterisk). B. Genome wide statistical analysis represented in a Venn diagram. All three 
proteins and modifications overlap at 88% of islands however discrete sets of CGIs exist for each. The number of 
peaks is represented next to each group. The total number of CGIs displayed in the box.  
 
 
4.4.4 Conclusions from ChIP sequencing 
The genome wide sequencing by ChIP-Seq on mouse brain material has allowed for a more expansive 
and high resolution set of results than the earlier candidate ChIP-PCR based experiments. However 
these two types of experiment give similar findings when compared directly (β-actin Figures 4.2-1, 
4.2-2 and 4.4-3). ChIP-PCR using antibodies specific for H3K4me3 and Cfp1 resulted in profiles over 
RefSeq Genes  
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β-actin locus which closely resembled those seen in the ChIP-Seq data sets, albeit at a far lower 
resolution.  
 
With regards to the findings, Both Cfp1 and H3K4me3 are found to be enriched over non-methylated 
CGIs, with 81.5% of islands containing Cfp1 and 78.2% the active histone modification. Furthermore 
the peaks of Cfp1 largely co localise to H3K4me3 peaks over CpG Islands, with a 93% overlap 
between the two data sets. In contrast the silencing modification H3K27me3 is generally only found at 
non-methylated CGIs lacking both of these proteins. As such one could argue that H3K27me3 
modification is refractory to the binding of Cfp1. Alternatively this modification may be a secondary 
effect of silenced chromatin which is itself unable to contain either the H3K4me3 modification of the 
CXXC protein Cfp1.  
 
Comparison of promoters lacking CGIs to those containing them may also delineate promoter and 
CGI specific factors. Although no genome wide analysis was carried out, inspection of several 
candidate CGI-less promoter reveals no H3K4me3, Cfp1, H3K27me3 or RNAP II signals at these loci 
(Figure 4.4-6, i). As promoters lacking CGIs tend to be associated with tissue specific genes, these 
genes may in fact be silenced in brain, although not by H3K27me3.  
 
Finally, the finding that RNAP II also co-localises with CGIs raises the possibility that transcription or 
the transcriptional machinery may be responsible for the formation and maintenance of the H3K4me3 
pattern at CGIs. However as a small subset of islands which contain both Cfp1 and H3K4me3 lack 
RNAPII, it is unclear whether or not RNAPII is required or if non-methylated CpG clusters are 





Figure 4.4-6. Comparison of a non CGI promoter to two non-methylated CGIs A. IGB alignment of 
H3K4me3 (blue), Cfp1 (green), RNAP II (Pink), H3K27me3 peaks (red boxes) along with CGI peaks (black 
boxes) and Refseq annotated genes. Group one (i) represents non-CGI promoters whilst group two (Shogren-




4.5 Summary of the CGI binding proteins identified 
In summary, several proteins and modifications have been found enriched at CGIs through a 
combination of western blotting on purified CGI chromatin, ChIP-PCR over candidate CGIs and 
genome wide sequencing studies. Overall it appears that CpG islands are not only unique in their 
DNA base composition and methylation state but also harbour a distinct set of proteins and histone 
modifications. 
 
Initially, the CXXC protein Cfp1 was found enriched at CpG Islands along with Kdm2a (Figure 4.1-
1). Subsequent ChIP-PCR profiling for Cfp1 over several promoter and non-promoter loci also 
revealed enrichment of this protein specifically over CGIs (Figure 4.2-1). Notable exceptions to this 
rule were the methylated island of sycp2, and the “H3K27me3” positive islands of Oprd1 and Foxd3. 
The fact Cfp1 is absent from the methylated sycp2 island strengthens evidence that it may indeed be a 
specific non-methyl CpG binding factor. The findings of this limited candidate-style study were 
expanded through genome wide ChIP-sequencing of Cfp1 binding sites (Figures 4.4-2 & 4.4-4, B) 
which found that Cfp1 binds to 82% of CGIs mapped through CXXC Affinity purificiation.  













The histone modifications found at CGIs were those associated with an active euchromatic state. 
Aside from acetylated H3 tails, H3 tails containing K4 di- and tri- methyl modifications were strongly 
enriched within CGI chromatin as detected by western blotting on purified CGI chromatin, candidate 
ChIP-PCR and ChIP-Seq. Interestingly, ChIP-PCR and ChIP-Seq both reveal that a subset of CGIs 
are enriched for histone H3 K27me3 modified tails. As these non-methylated CGIs were found to lack 
both Cfp1 and H3K4me3 this modification may be refractory for the binding of the Cpf1 protein in 
some way.  
 
Taken together, these findings suggest that the CpG rich sequence found at CGIs may be functionally 
important in the setting up or maintenance of the local chromatin state. As Cfp1 is a CGI binding 
factor containing a domain with in vitro affinity for non methylated CpG dinucleotides and is a 
member of a H3K4 HMTase complex, this protein must be investigated further for its role at CGIs.  
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Chapter 5: CXXC proteins as non methyl CpG 
DNA binding proteins 
 
5.1 Introduction 
To date two of the most widely investigated CXXC proteins are the DNA methyltransferase Dnmt1 
and the histone H3K4me3 methyltransferase Mll1; two proteins which have crucial roles in the 
establishment and maintenance of epigenetic marks. Dnmt1 is the enzyme responsible for the 
maintenance of methylation profiles in the mammalian genome and has been shown to harbour around 
a 50 fold preference for hemimethylated CpG dinucleotides (Fatemi, Hermann et al. 2001). Recent 
work by Pradhan and colleges has shown that the CXXC domain of Dnmt1 can bind to unmethylated 
CpG islands in vitro. Interestingly this domain appears to be vital for full enzymatic function of the 
Dnmt1 protein in vivo (Pradhan, Esteve et al. 2008). The histone H3K4 methyltransferase Mll1 has 
also been studied extensively not only because of its role in chromatin modification but due to the 
finding of chromosomal translocations which fuse the amino terminus of Mll1 to multiple loci in 
patients with aggressive myeloid and lymphoid leukemias (Ayton and Cleary 2001). This H3K4 
HMTase has previously been shown to regulate the Hox genes during development with chromosomal 
translocations resulting in Mll1 fusions leading to Hox gene deregulation (Milne, Briggs et al. 2002). 
The distribution and binding of Mll1 in normal tissue reveals that this protein is often found 
associated with the RNA polymerase II complex at the 5’ end of active genes (Guenther, Jenner et al. 
2005). Such sites are also known to be predominantly rich in the H3K4me3 modification (Barski, 
Cuddapah et al. 2007) linking the presence of this CXXC protein with its resulting modification. 
Whether or not Mll1 is responsible for the methylation of a unique set of H3K4 tails in comparison 
with the other histone methyltransferases such as Set1a and Set1b is unclear.  
 
In comparison to the aforementioned CXXC proteins, relatively little is known regarding the protein 
Cfp1 (see chapter 1.4.1). Early co-transfection experiments revealed that this protein acts as a 
transcriptional activator (Voo, Carlone et al. 2000) and later was shown to bind at the Hox promoter 
(Ansari, Mishra et al. 2008) which as stated above, is a MLL1 target promoter. Cfp1 -/- ES cells are 
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viable until stimulated to differentiate and show 60-80% reduction in DNA methylation with slightly 
elevated levels of the H3K4me3 histone modification (Lee and Skalnik 2005).  More recently it was 
shown that Cfp1 is part of the Set1a and Set1b histone H3K4 methyltransferase complexes (Lee and 
Skalnik 2005; Lee, Tate et al. 2007; Ansari, Mishra et al. 2008). This could go some way to 
explaining the earlier ChIP PCR findings linking H3K4me3 patterns with Cfp1 occupancy (Figures 
4.2-1 & 4.2-2).   
 
Interestingly, none of these studies have linked the non methyl CpG binding of Cfp1 to CGI binding. 
As the earlier western blotting and ChIP experiments in brain had revealed that Cfp1 binds only at 
unmethylated CpG rich regions such as CGIs it is now important to further interrogate the role of this 
protein, if any, at CpG islands. 
 
 
5.2 Bioinformatic analysis of the CXXC domain and Cfp1  
To reach a greater understanding of the functions of the CXXC domain containing proteins, 
specifically with regards to the protein Cfp1, bioinformatic analysis was carried out. This was 
accomplished in two parts. Firstly, the alignment of sequences for the annotated CXXC domains in 
mouse was carried out to determine conservation and to allow the prediction of residues involved in 
non methylated CpG rich DNA binding. This analysis was followed by the alignment of the CXXC 
domain of Cfp1 across several organisms ranging from mouse and human to Drosophila and yeast. 
 
Searching of the Uniprot protein sequence database UniProt (EMBL-EBI: www.uniprot.org) 
identified annotated CXXC domain-containing proteins in mouse tissues. In an attempt to better 
understand the amino acid residues of importance in non methyl CpG DNA binding these sequences 
were compared for conservation using the “Muscle” application of Jalview (www.jalview.org). These 
alignments highlight the high levels of cysteine conservation within the CXXC motifs across all 13 of 
these sequences (Figure 5.2-1) as these cysteine residues are essential in forming the CXXC zing 
finger structure. The carboxy- terminal end of the CXXC domain appears to vary the most across the 
identified sequences (denoted by the asterisk in Figure 5.2-1). Closer inspection of this region 
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between Cfp1 and the CXXC-3 of Mbd1 (domains which have both been shown to bind unmethylated 
CpGs) and the CXXC-1 and 2 of Mbd1 (shown to be unable to bind unmethylated CpG) reveal 
differences in sequence over this region.  The fact that both Cfp1 and the third CXXC domain of 
Mbd1 contain a set of highly conserved residues (particularly the conservation of the residues KFGG) 
whilst the cxxc1 and 2 domains of Mbd1 lack these might represent a set of residues important in the 






Figure 5.2-1. Alignment of identified mouse CXXC domains. CXXC domains from proteins in the 
mouse were found through database searches were aligned and scored for conservation. Residues are coloured as  
follows - red: R K, green: N S T, pink: C, magenta: E D, orange: G, gold: P, Blue: A I L M F W V. Conservation 
of residues is shown below with yellow bars representing high levels of conservation. A general CXXC 
consensus sequence is displayed below in black. Nucleotides which varied between the CXXC domains shown to 
bind to non-methylated CpGs to those which cannot is highlighted by the red bar and asterisk.  
 
 
In an attempt to better understand the non methyl CpG binding nature of the CXXC domain of Cfp1, 




CXXC domain along with the presence or absence of methylation. Figure 5.2-2 shows that the Cfp1 
CXXC sequences of both human and mouse, as well as those found in the rat, zebrafish, Xenopus, the 
sea squirt (Ciona), Strongylocentrotus and the bee are all highly conserved. Interestingly these 
organisms all contain the epigenetic modification of DNA methylation. In stark contrast to these 
sequences are the “CXXC-like” domains found in C.elegans, Drosophila and S.cerevisiae which are 
all organisms in which DNA methylation is absent. Although these sequences appear to contain the 
highly conserved cysteine residues the rest of the sequence varies greatly (Figure 5.2-2). It therefore 
appears that a fully functional CXXC domain has arisen in Cfp1 during evolution, possibly to aid 
specific non methyl CpG protein binding in organisms containing DNA methylation. 
 
 
Figure 5.2-2 Alignment of the Cfp1 CXXC domain across organisms containing and lacking DNA 
methylation. The CXXC domains (or “CXXC like” domains) were aligned for organisms containing DNA 
methylation (A) and lacking the epigenetic modification (B). Residues are coloured as described in figure 5.1-1. 
Figure A reveals high levels of CXXC conservation across organisms in which DNA methylation has been 
identified which is in stark contrast to the CXXC-like domains found in organisms which lack DNA methylation 
(B). As the CXXC domain is important for non-methyl specific binding this may have arisen through evolution to 







5.3 In vivo verification of methyl sensitive DNA binding 
In vitro experiments have previously shown that the CXXC domain of Cfp1 is only able to bind to 
double stranded DNA which is both rich in CpG dinucleotides and unmethylated (Voo, Carlone et al. 
2000). These observations along with the multiple sequence alignments described above that Cfp1 
may indeed be a non methyl CGI binding protein. This view is strengthened when one considers the 
results of the earlier ChIP PCR experiments in mouse brain; in particular the finding that Cfp1 is 
bound over the non methylated islands but absent over the methylated island at the Sycp2 promoter 
(Figure 4.2-1). We therefore set out to test whether Cfp1 protein is indeed a specific non methyl DNA 
binding protein in vivo.  
 
A simple system in which to test this further is to perform ChIP-PCR over the Xist gene in male and 
female mouse brain. Xist is an X linked gene found on the X chromosome of mammals which 
contains a strong CGI over its promoter (Norris, Patel et al. 1994). In females there are two copies of 
the gene, one of which is active thus non methylated and containing active histone modifications, the 
other is silenced and contains a methylated CGI (reviewed by (Ng, Pullirsch et al. 2007). By contrast 
males contain a single copy of the gene on its sole X chromosome, which is silenced and the CGI 
methylated (Figure 5.3-1, A). PCR profiling over this region using Cfp1 immunoprecipitated material 
should reveal any specificity of binding to either the methylated or non-methylated CGI. 
 
ChIP-PCR was performed for both male and female mouse brains using antibodies against the Cfp1 
protein. Figure 5.3-1 reveals that Cfp1 is bound over the CGI at the female Xist locus with 4.8 fold 
enrichment relative to the flanking regions. Cfp1 profiles over male brains gave no significant 
enrichment presumably due to the methylated island here. As the earlier studies in mouse brain 
revealed a potential link between the Cfp1 protein and the H3K4me3 histone modification, this mark 
was also profiled over the Xist locus. Patterns for H3K4me3 were similar to those for the Cfp1 
protein. Female mouse brains contain a strong peak of enrichment over the non methylated CGI with 
3.6 fold enrichment relative to the flanking regions. Taken with the in vitro CXXC domain studies 
(Voo, Carlone et al. 2000) this provides evidence that Cfp1 is indeed a non methyl CpG binding 







Figure 5.3-1. In vivo analysis revealing non-methyl CpG specific binding of Cfp1. The rationale 
behind the experiment is outlined in (A) whereby Cfp1 will only bind to the non-methylated CpGs found in 
female tissues. B. Results of the ChIP-PCR experiments over Xist in male (blue lines) and female (pink lines) 
tissues. CpG plots are represented by vertical lines under the PCR profiles whilst the CGIs are represented by 
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As Cfp1 has been shown to bind specifically to non-methylated CGIs in mouse brain in vivo, it is 
interesting to determine what role, if any, the abundance of CpG dinucleotides found at such CGI loci 
plays in the binding of this protein. Calculations were carried out on the basis that a typical human 
genome of 3x10
9
 base pairs contains 25,000 CGIs, each taken as around 1000 base pairs in length. As 
CGIs are typically C+G rich (~65%) the probability of the numbers of cytosine or guanine bases in 
1000bps was calculated at 0.35 ([0.65/2]/1000). The number of CpGs in a typical 1kb island was then 
calculated at 105 (0.35x035x1000bp). Assuming these parameters, the human genome will contain 
2.5x10
6
 CpG dinucleotides within CGIs. In contrast, a similar set of calculations predict that 3x10
7
 
CpG dinucleotides occur out with such islands. This means than as few as 8% of CpG dinucleotides 
are in both a non-methylated state and at present within CGIs. The remaining 92% of dinucleotides 
are found largely methylated (70%) or non methylated (22%) at low frequency (less than 1 CpG per 
10bp) throughout the genome. This argues that if the binding effect of Cfp1 is density dependant, then 
it can bind to approximately 8% of all the CpG dinucleotides it can encounter within the genome 
(those found at high densities in islands). Removal of methylation may lead to an increase in potential 
Cfp1 binding sites outside of CGIs which were previously CpG dense (relatively speaking) and 
methylated. To test the distribution of Cfp1 in such a way, P53 -/- Dnmt1 -/- (“P-M-”) mouse 
embryonic fibroblasts were cultured prior to ChIP-PCR analysis. Due to the loss of Dnmt1, these cells 
have globally lost ~90% of their DNA methylation levels but require the subsequent removal of the 
P53 gene for viability (Cedar, Lande-Diner et al. 2007).  
 
In the majority of the genome, the frequency of CpG (in a non-methylated state) is around 1 every 500 
bases increasesing to around 1 every 10 bases within CGIs. This fifty fold increase in CpG density 
may be an important factor restricting the binding of Cfp1 to islands. In cells lacking DNA 
methylation (such as the P-M- cells) frequency of non-methylated CpG dinucleotides in the bulk of 
the genomic material increases to 1 every 100 bases whilst the frequency at islands remains the same 
at 1 in 10 bases, representing a ten fold increase in CpG density at the islands when compared to 
control cells. This change in the relative CpG densities between islands and bulk may facilitate new 
Cfp1 binding sites outside of CGI loci. 
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ChIP-PCR for Cfp1 and H3K4me3 was carried out over the Bdnf locus in P-M- cells with a P53 -/- 
MEF cell line used as a control. ChIP-PCR binding patterns for Cfp1 in the control cells closely 
follow those seen in the earlier mouse brain studies (Figure 4.2-1) with peaks of Cfp1 occurring 
directly over the predicted CGIs. However these Cfp1 peaks were not seen in the P-M- cell line 
(Figure 5.4-1). This can be explained if Cfp1 is now recruited to the newly available CpG 
dinucleotides outside of the CGIs which were previously methylated. Somewhat confusingly, the 
patterns of the histone modification H3K4me3 which peaks over the islands in the control cell line are 
only slightly reduced in the P-M- cell line in which Cfp1 has been completely removed. Whether or 
not the maintenance of H4K4me3 is facilitated by a protein complex distinct from the Cfp1-Set1 




Figure 5.4-1. ChIP-PCR for 
H3K4me3 and Cfp1 in 
methylation deficient 
cells. ChIP PCR across the 
bdnf locus reveals a slight loss 
of H3K4me3 signal over the 
CGIs in the P53-/- Dnmt1-/- 
(“P-M-”, light purple lines) 
cells relative to the P53-/- 
control cells (“P-”, dark lines). 
Cfp1 by contrast is seen to be 
completely lost from these 
islands when methylation is 
lost globally, presumable as 
additionally CpG sites now 













































5.5 Summary of Cfp1 non methyl CpG DNA binding studies 
From these results it can be concluded that the CXXC protein Cfp1 can bind specifically in vivo to 
high densities of non-methylated CpG dinucleotides, characteristics which are hallmarks of CpG 
island DNA. Taken together with the earlier western blot (chapter 4.1) and ChIP-PCR results (chapter 
4.2), ChIP-PCR studies over the Xist locus verified this hypothesis revealing that Cfp1 is indeed a 
specific non methyl CpG DNA binding protein in vivo. Further to this, multiple sequence alignments 
reveal that the CXXC domain sequences of Cfp1, Mll1 and Kdm2a are highly conserved. Furthermore 
these sequences show significant levels of similarity to the sequence of the MBD1 CXXC3 domain 
which has previously been shown to bind non methyl CpGs in vitro (Illingworth, Kerr et al. 2008). 
Closer inspection of the CXXC domain of Cfp1 finds that it is highly conserved in organisms which 
contain DNA methylation, indicating that this domain may have evolved for the function of directing 
this protein to the unique regions of non methylated CpG rich DNA.    
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Chapter 6: Investigating the role of Cfp1 at CpG 
islands 
  
6.1 Generation of Cfp1 stable knockdown cells 
In an effort to better understand the role of Cfp1 at CGIs, cells deficient in the CXXC protein were 
generated to investigate the effects upon cell viability and growth rates as well as for any changes in 
the chromatin state at CGI loci. To ensure that a stable reduction of Cfp1 was achieved over a long 
period of time, short hairpin RNA oligonucleotides (shRNAs) specific for Cfp1, were transfected into 
NIH-3T3 cells. Once transcribed, the short sequences form an RNA hairpin structure which is bound 
by protein complexes such as DICER and converted into short interfering RNAs (siRNA). These 
siRNAs then bind to their complimentary sequences on the Cfp1 mRNA resulting in a cleavage event 
and subsequent gene silencing. As shRNA sequences remain on the transfected vector and are usually 
passed onto daughter cells this results in the stable and long term silencing of Cfp1 
 
Three unique shRNA sequences averaging 19 nucleotides in length were synthesized by Oligoengine 
which would recognise the Cfp1 gene in mice. The resulting sequences were then cloned into a vector 
so that the sequences were under the control of the polymerase-III H1-RNA gene promoter which 
produces a small RNA transcript lacking a polyadenosine tail (“pSuper” vector). These sequences 
were designed to recognise the following regions on the cfp1 mRNA: 986-1005 (termed sh986), 1250-
1269 (sh1250) and 1960-1979 (sh1960; see Materials and Methods section 2.1.4 for sequences). 
Successful transfections were selected for through puromycin resistance which was encoded in the 
vector. Each of the three shRNA vectors were individually transfected into NIH-3T3 cells and grown 
in puromycin containing media to select for successful transfectants.  Additionally all three shRNA 
vectors were mixed and transfected to see if there was either a greater transfection efficiency or 
knockdown of Cfp1 when combined together to that seen with the individual transfections. Puromycin 
selection lead to loss of around 90% of the cells with survivors growing to form small colonies within 
24 to 48 hours. Colonies were picked and grown up further to produce 40 cell lines in total (ten clones 
for each of the individual and mixed set of shRNA vectors). 
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6.1.1 Verification of Cfp1 deficient cell lines 
 
For each transfected cell line, protein was taken for western blot analysis at the same time as RNA for 
quantitative PCR (qPCR) and chromatin for ChIP-PCR. As it was the simplest approach, qPCR for 
Cfp1 expression was carried out first to identify the levels of Cfp1 reduction in the cell lines (Figure 
6.1-1). As it was believed that the cell lines most likely to be depleted in Cfp1 were those which were 
transfected with a mixture of all three short hairpin RNA sequences (“shMix” cells), these cell lines 
were tested first (Figure 6.1-1). 
 
 
Figure 6.1-1. qPCR verification of Cfp1 levels in “mix” transfected cell lines.  qPCR results for the 
expression of Cfp1 relative to the control cell line (PS10 vector - blue) and knockdown cells (red: successful 
knockdown, grey: unsuccessful knockdown). The cell line selected for subsequent ChIP-PCR studies is denoted 
by an asterisk. All data is normalised to the expression of GAPDH in each cell line. 
 
Although ten cell lines were initially selected for growth after transfection with the mixture of short 
hairpin constructs, only five survived expansion for analysis.  One possibility is that the knock down 
of Cfp1 in these cell lines may have been above a critical level for survival. However, this argues that 
the surviving cell lines are likely not efficiently reduced in Cfp1 levels. Alternatively the failure to 
expand may be due to the fact that these cell lines may have not taken up (or have lost) the puromycin 

























Closer inspection of the surviving mixed transfected cell lines by qPCR reveal that three out of the 
five cell lines expanded were deficient for Cfp1 when compared to the “pSuper10” vector control cell 
line (Figure 6.1-1). Of these two were significantly reduced to around 13% and 15% of control Cfp1 
mRNA levels. The lowest of these (termed shMIX3) was expanded and qPCR repeated a further two 
times resulting in an average of 87% reduction in Cfp1 levels. In order to ensure this level of 
knockdown was reproducible these mixed pool transfections were repeated at a later date with near 
identical levels of Cfp1 reduction (data not shown). 
 
 
Figure 6.1-2. Western blot verification of Cfp1 levels in shRNA transfected cell lines. Results of 
western blots over the most Cfp1 deficient cell lines. Shown are cell lines in which individual shRNA constructs 
have been used (sh986 and sh1920) along with the mixed shRNA cell line previously characterised by qPCR 
(Figure 6.1-1) all compared directly to the vector control “pSuper10” cell line (“Ve”). HDAC1 is used as a 
control to ensure equal levels of protein are loaded. The mixed shRNA cell line used in subsequent ChIP-PCR 
experiments is highlighted by an asterisk. Graphical representation of Cfp1 levels through quantification carried 
out using ImageJ software on the western blot are shown directly below (blue boxes represent control vector  
whilst red the knockdown cell lines)  
 
 
To ensure that the qPCR results measuring Cfp1 mRNA are correct, western blot analysis was carried 
out on the shMix3 cells to test for Cfp1 protein levels. Further to this, cell lines transfected with only 
one of the three shRNA constructs (“sh986” and “sh1920”) were also tested for Cfp1 levels (Figure 
6.1-2). Quantification of signals was carried out using ImageJ software. In concordance with the 
earlier qPCR results, the mix3 cell line contains around an 85% reduction in the Cfp1 protein. The 986 













cells whilst the sh1920 clone 4 had around a 75% reduction in Cfp1 levels. In conclusion NIH-3T3 
cell lines were successfully knocked down for Cfp1 at the level of mRNA as well as protein in both 
individual and mixed transfected cell lines.  
  
 
6.1.2 Growth and morphological changes associated with Cfp1 deficient 
cells 
As Cfp1 had been successfully reduced in several cell lines, the next step was to investigate the effect 
that this depletion placed upon the growth rates and cellular morphologies of the NIH-3T3 cells 
themselves. To this end, the Cfp1 deficient cells which showed the greatest knock down (“shMIX3”) 
were grown alongside Vector only controls (“pSuper10”) and WT 3T3 cells. It was noted that the wild 
type NIH-3T3 and pSuper10 vector control cells required splitting almost twice as often as the Cfp1 
deficient cells (Figure 6.1-3, A). Equal numbers of cells were seeded for both vector control and Cfp1 
deficient cell lines and the numbers of cells counted over a period of 90 hours (for a detailed 
procedure see Materials and Methods section 2.2.7). When represented graphically it can be seen that 
the Cfp1 deficient cells grow at a lower rate than vector only cells (Figure 6.1-3, A).  From these 
values the doubling time for vector control 3T3 cells was found to be around 13 hours which 
compares to around 18 hours for Cfp1 deficient cells (a 38.5% slower growth rate). Likely 
explanations for this lowered growth rate are that Cfp1 may be involved in cell cycle progression or 
that Cfp1 is required for viability in some way. This could be investigated further through FACS 
analysis in order to test whether or not the cells were arresting at a certain stage in the cell cycle. 
Interestingly Cfp1 -/- ES cells generated in the lab of Dr Skalnik are reported to have increased 
doubling times due to an increase in apoptosis (around 33% of all Cfp1 -/- cells (Carlone, Lee et al. 
2005). 
 
Closer inspection of the Cfp1 deficient cells reveals that they are morphologically different from the 
control transfected NIH-3T3 cells (Figure 6.1-3, B). Vector control cells look like their normal wild 
type counterparts with long flat bodies contacting neighbouring cells. This indicates that the process 
of transfection does not alter the structure of the cell. In contrast the Cfp1 deficient cells appeared far 
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more rounded in shape and clump together with reduced contacts between the cells. Therefore the 
removal of Cfp1 leads to an overall change in both the structure of the cell as well as the rate of 
growth in culture. 
 
 
Figure 6.1-3. ShCfp1 cells exhibit growth and morphological changes.  Figure A highlights the 
differences in growth rates between control cells (blue line) and shCfp1 mix cl3 cells (red line). Overall these 
Cfp1 deficient cells grow around 40% slower than the control cells. B. Cell morphology differs greatly between 
the control and Mixed shCfp1 cells (original magnification x200). 
 
 
6.1.3 Western blot analysis of histone modifications in Cfp1 deficient cell lines  
As Cfp1 has a positive correlation with the H3K4me3 modification (chapters 4.2.1 and 4.2.2) and a 
negative correlation with the H3K27me3 modification in chromatin (chapter 4.2.3), global levels of 
these two marks were investigated through western blot analysis to compare control and Cfp1 
deficient 3T3 cells. In order to assess the relative levels of global histone modifications between the 
cell lines, a range of concentrations of vector control cell extract was loaded alongside the shCfp1 cell 
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lines sh986 cl4 and sh1920 cl4 and the mixed hairpin cell line (Figure 6.1-4). As the analysis was 






Figure 6.1-4. Global analysis of H3K4me3 and H3K27me3 in shCfp1 cell lines. In A, LI-COR 
western blotting for H3K4me3, H3K27me3 and HDAC1 (as a loading control) is shown with the quantification 
shown underneath in B. a ten fold dilution range (1/10, 1/3 and equal levels) of vector whole cell extract are 
loaded to facilitate accurate quantification of signals. In the 986 clone 4, 1920 clone 4 and mixed clone 3 cell 
lines (all shown to be Cfp1 deficient – figure 5.3-1) H3K4me3 levels are slightly decreased whilst H3K27me3 
remains constant. Quantification of the signals in B reveals that H3K4me3 levels (blue bars) fall to an average of 
around 70% of that seen in the vector control. H3K27me3 levels (red bars) do not appear to fluctuate. 
 
Quantification revealed modest levels of H3K4me3 depletion in all three knockdown cell lines, 
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lines contained very similar levels of H3K4me3 (73, 66 and 71% wild type levels respectively). In 
contrast to the reduction in H3K4me3 levels, no such change was noted for the silencing modification 
H3K27me3 in each of the three cell lines. 
 
 
6.2 ChIP profiling of genes using Cfp1 deficient cells 
As the global levels of both H3K4me3 and H3K27me3 had been investigated in the Cfp1 deficient 
cell lines, ChIP-PCR profiles for these modifications along with Cfp1 were carried out to better 
understand any changes taking place specifically at CGIs. The same promoter CGIs that were earlier 
selected for analysis in the mouse brain (see chapter 4.2) were now investigated in the vector control 
and mixed short hairpin (“shMix cl3”) cfp1 deficient cell lines (Figures 6.2-1 & 6.2-2). Furthermore, 
the ChIP profiles generated from the cell lines transfected with a mixture of short hairpin constructs 
(“shMix cl3”) were compared to the profiles from the individually transfected cell lines (“sh986 cl4” 
and “sh1920 cl4”) in order to investigate the possibility of any off target effects which can occur with 
shRNA silencing (see Figure 6.2-4 below). 
 
6.2.1 Cfp1 profiles over CGIs 
The Cfp1 depleted “shMix cl3” cell line was expanded prior to ChIP PCR analysis over the six CGIs 
previously investigated in mouse brain. As a positive control, a vector transfected cell line containing 
wild type levels of Cfp1 (“pSuper10”) was tested along with the Cfp1 deficient cells. These control 
cells gave similar results to wild type NIH-3T3 cells (data not shown) with peaks of Cfp1 seen to 
correspond to the predicted CGIs whilst remaining low over flanking regions (blue plot, Figure 6.2-1). 
Typically the enrichment values of these peaks relative to flanking regions are similar to the values 
determined earlier in the mouse brain (Figure 4.2-1). For example the enrichment values for Cfp1 over 
the CGIs at Bdnf are 3.2 and 4.4 fold enriched in the control vector NIH-3T3 cells and 4.1 and 3.2 fold 
enriched in the brain (Figures 6.2-1 and 4.2-1). ChIP-PCR profiles over the same CGIs in “shMix3” 
cells reveal a loss of Cfp1 from these islands providing a further conformation of Cfp1depletion. 
Quantification of the loss of the Cfp1 signal results in a 93 and 66 fold drop over the CGIs at the Bdnf 
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locus, a 23.6 fold reduction over the island at β-Actin, a 41.5 fold reduction over the island at C-Myc 






Figure 6.2-1. Cfp1 binding is dramatically reduced over CGIs in shCfp1 mix3 cell lines. ChIP-PCR 
profiles for four loci containing 6 CGIs. pSuper10 Control 3T3 cells (blue lines) contain previously described 
patterns of Cfp1 binding over CGIs. These peaks of Cfp1 are lost or dramatically reduced in the Cfp1 deficient 
cell line “mix3” (red lines). Profile shown represents one experiment with results typical for n=3 runs. 
General figure layout and abbreviations follow those outlined in figure 4.2-1. 
 
   
6.2.2 H3K4me3 profiles over CGIs 







































Both candidate ChIP and ChIP-sequencing in mouse brain highlighted a potential link between the 
H3K4me3 modification and Cfp1 occupancy at CGIs. With this in mind, the patterns of H3K4me3 at 
CGIs were investigated in the vector control and “shMix3” Cfp1 deficient cell lines. Again the 
patterns of H3K4me3 in the pSuper10 vector control cells followed those seen earlier in the mouse 
brain (Figure 4.2-2) peaking specifically over the predicted CGIs (Figure 6.2-2). Enrichment values 
for the H3K4me3 modification over the CGIs were calculated at 11.4 and 10.7 over the CGIs at Bdnf, 
12.6 fold over Actb, 10.3 fold over C-myc and 2.5 and 2.4 fold over the islands at the Dlx5/6 locus.  
Although total levels of the H3K4me3 modification are only slightly reduced in the Cfp1 deficient 
cells (Figure 6.1-3) the association of this histone modification to CGI loci appears to be greatly 
reduced. Quantification of the ChIP-PCR results reveals that levels of the H3K4me3 modification 
over the CGI at the bdnf locus are 6.6 and 4.8 fold lower than those seen over the island in the control 
cell line. The other regions profiled also reveal a precipitous drop in the H3K4me3 signal over the 
predicted CGIs with patterns at β-actin, C-myc and Dlx5/6 falling by 3.6, 3.7, 2.8 and 4.3 fold 
respectively. 
 
From these results it is clear that depletion of Cfp1 leads to a dramatic loss of the H3K4me3 peaks 
normally associated with CpG islands. As eluded to earlier, Cfp1 is part of the Set1 complex 
responsible for setting up the H3K4me3 modification and as such may provide the enzymatic complex 
with a CXXC domain to aid targeting to CGIs. Depletion of Cfp1 with concomitant removal of the 
CXXC domain from the Set1 complex may result in the reduction of H3K4me3 patterns over islands. 
Any redistribution of the H3K4me3 mark throughout the genome due to lack of targeting via the 
CXXC domain of Cfp1 coupled with loss from islands may explain the earlier finding that global 
levels of H3K4me3 are only slightly reduced (Figure 6.1-4). Alternatively as Cfp1 is a core 
component of the Set1 complex, removal may destabilise or lead to the loss of activity of the 
enzymatic complex resulting in a reduced H3K4me3 signal. Studies in yeast with the Cfp1 homologue 
Spp1 argue against this hypothesis as removal of this protein does not affect global levels of the Set1 
protein but does result in a lower level of H3K4me3 globally (Takahashi, Lee et al. 2009). Further 
work on the interactions between Cfp1 and the Set1a and b complexes in both the wild type and Cfp1 








Figure 6.2-2. H3K4me3 modified histone tails are depleted over CGIs in shCfp1 mix3 cell lines. 
ChIP-PCR profiles for four loci containing 6 CGIs. pSuper10 Control 3T3 cells (blue lines) once again reveal 
patterns of binding similar to those in the mouse brain. These peaks of H3K4me3 are dramatically reduced in the 
Cfp1 deficient cell line “mix3” (red lines).  
 
General figure layout and abbreviations follow those outlined in figure 4.2-1.  
 
 
6.2.3  H3K27me3 and H3K9me3 profiles over CGIs 
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The histone modifications H3K27me3 and H3K9me3 were also investigated over the CGI loci 
outlined above. Genome wide analysis reveals that H3K27me3 is enriched over less discrete regions 
than the H3K4me3 modification. Analysis of the H3K27me3 ChIP-Seq data generated by the 
Bernstein lab (Mikkelsen, Hanna et al. 2008) reveals that this modification is not frequently found 
over CGIs (chapter 4.4.4). Notable exceptions to this rule included a minority of islands which lack 
both Cfp1 and H3K4me3. 
 
Analysis of H3K27me3 patterns over the Bdnf promoter locus in pSuper10 control 3T3 cells found no 
identifiable peaks of enrichment for this histone modification (Figure 6.2-3). Subsequent analysis of 
the β-actin, C-Myc and Dlx5/6 loci also reveal little or no enrichment of this modification over either 
the CGI or flanking regions. Cells deficient for Cfp1 did not display any changes in the H3K27me3 
profiles to those seen in the vector control cells (Figure 6.2.3, A).  As a further control H3K9me3 
levels were analysed over the CGIs at the Bdnf and β-actin loci. In both cases the H3K9me3 profiles 
revealed no enrichment over the predicted CGIs. These patterns remained low and consistent in both 
the vector control and the Cfp1 depleted cell lines (Figure 6.2-3, B).  
 
In conclusion, the reduction of H3K4me3 signal in the Cfp1 depleted cells (without a reduction of the 
H3K27me3 and H3K9me3 signal) furthers the argument for a specific link between the active histone 
modification and the CXXC protein, possibly facilitated through the Set1a and Set1b complexes of 







Figure 6.2-3. Patterns of H3K27me3 and H3K9me3 modified histone tails are unaffected in 
shCfp1 mix3 cell lines. ChIP-PCR profiles for H3K27me3 (6 CGIs, A) and H3K9me3 (3 CGIs, B). Both 
H3K27me3 and H3K9me3 patterns in the pSuper10 Control 3T3 cells (blue lines) closely match those seen in the 
Cfp1 deficient cell line “mix3” (red lines). As such loss of Cfp1 does not affect H3K27me3 levels globally or 
locally at CGIs.   
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6.2.4 Comparisons of 2 individual shRNA constructs by ChIP-PCR 
In order to ensure that the ChIP profiles seen in the “shMix3” cell line were not due to off target 
effects, ChIP-PCR was carried out over the Bdnf and β-actin loci on cell lines transfected with just the 
sh986, sh1250 or sh1920 constructs. Earlier immunoblotting had revealed that the cell lines 986 clone 
4 and 1920 clone 4 both resulted in high levels of Cfp1 depletion (Figure 6.1-2). The sh1250 construct 
was not able to reduce levels of the Cfp1 protein (Figure 6.1-2) which was verified through the ChIP-
PCR profiles (data not shown).  
 
ChIP-PCR profiles for Cfp1, H3K4me3 and H3K27me3 were carried out in both the vector control 
“pSuper10” cell line as well as in the sh986 cl4 and sh1920 cl4 cell lines (Figure 6.2-4). Both of these 
cell lines show high levels of reduction in the Cfp1 signal over CGIs when compared to the pSuper10 
vector control cells. Interestingly the sh986 cl4 cells revealed lower levels of Cfp1 reduction than the 
1920 cl4 cell line. Furthermore, both of these cell lines contain higher levels of Cfp1 than the 
“shMix3” cell line possibly due to a combinatorial effect of the two short hairpin sequences. 
 
Both the “sh986 cl4” and “sh1920 cl4” cell lines reveal a precipitous drop in the levels of the 
H3K4me3 modification at CGIs when compared to the vector control cell line. This analysis also 
reveals that the level of Cfp1 binding is somewhat proportional to the histone H3K4me3 modification 
over the islands. This is most pronounced at the β-Actin locus where the sh1920 cell line shows both 
increased Cfp1 depletion and H3K4me3 reduction when compared to the sh986 cell line (Figure 
6.2.4). Analysis of the H3K27me3 modification over these loci in the two Cfp1 deficient and vector 
control cell lines reinforced the earlier results in the shMix3 cells. Both the vector control and the 
individually transfected cell lines failed to contain peaks of the H3K27me3 modification over the 
regions profiled, once more distancing the H3K27me3 modification from the Cfp1 protein. 
 
In conclusion, the results of the earlier ChIP-PCR experiments of the “shMix3” cells were repeated 
using two independent short hairpin constructs. As such the knockdown effect is likely due to a joint 





Figure 6.2-4. Two independent Cfp1 deficient cell lines derived from individual shRNAs give 
identical results to the shMix3 cell line. ChIP-PCR profiles for Cfp1, H3K4me3 and H3K27me3 repeat the 
earlier findings in which a mixed shRNA cell line was used. pSuper10 cell lines were compared to both 986 clone 
4 and 1920 clone 4 cell lines. Each individual shCfp1 cell line shows a reduction in both Cfp1 and H3K4me3 
levels comparable to the mixed cell line. Again the H3K27me3 patterns are unchanged at both bdnf and β-actin. 
Cfp1 immunoprecipitations were carried using a different antibody from the previous ChIP-PCR studies (“Cfp1-
Skalnik” rabbit polyclonal). As such these experiments not only verify the individual knockdown cell lines but 
also the specificity of two separate antibodies for Cfp1.  
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6.3 Long term culture of Cfp1 shRNA cells 
Although transient transfection is often used to reduce protein levels in the short term, the decision 
was taken to use short hairpin RNA constructs to stably reduce levels of Cfp1. This should result in a 
long term reduction in the Cfp1 transcript allowing thorough investigations to be carried without a 
reduction in silencing. However, under particularly stressful conditions such as loss or reduction of 
important proteins or complexes, cells have been known to lose this silencing whilst maintaining the 
selectable resistance markers usually associated with successful knockdowns. This behaviour may be 
arising as selection prefers the faster growing “normal” cells which are able to escape suppression and 
become the predominant cell type with respect to the slow growing deficient cells. This was indeed 
the case during long term culture of the Cfp1 deficient cell lines.  
 
Figure 6.3-1. Reversion of shCfp1 cell lines. A. Expression of Cfp1 returns to wild type over time in 
culture. The graph shows that the initial 87% reduction returns to a 12% reduction over 12 months. Expression 
levels of Cfp1 are normalised to Gapdh. B. ChIP-PCR for H3K4me3 over the 2 CGIs and a flanking region of the 
bdnf promoter. As Cfp1 levels return to wild type (A) so do the H3K4me3 levels over the islands. Vector control 
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Levels of Cfp1 transcript were analysed through qPCR quantification at certain time points over a 
twelve month culture period. Levels of Cfp1 expression increase from 13% to 70% of wild type over 
this time period with reversion occurring as quickly as two months (Figure 6.3-1, A). The increase in 
Cfp1 was matched by an increase in the H3K4me3 levels seen over the islands, once again 
highlighting a potential link between this modification and Cfp1. These ChIP results also reveal that 
the H3K4me3 modifications over CGIs can be restored upon reintroduction of the Cfp1 protein 
(Figure 6.3-1). As the magnitude of the changes in the Cfp1 and the H3K4me3 signals appear to be 
closely linked this might represent a direct interaction between the CXXC protein and the 
modification through the Set1 complex.  
  
This reversion to wild type-like levels of Cfp1 was also noted by Skalnik and colleagues during their 
work on human PLB-985 myeloid cells transfected with a shCfp1 construct. Initial results revealed 
that the 70% reduction in Cfp1 expression was reduced to just 15% after twenty passages (Young and 
Skalnik 2007). The authors argue that this is most likely to be as a result of the loss of silencing from 
the short hairpin construct leading to an “outgrowth of spontaneously rescued cells”. Taken together 
these findings imply that Cfp1 plays an important role in normal cell viability.  
 
      
6.4 Cfp1 and links to transcription  
One of the more prominent models to explain the maintenance of CGIs in an unmethylated state is 
that these loci are regions high in transcriptional activity. Indeed CGIs are often found at the 5’ ends 
of genes and frequently (76% of CGIs) associated with the binding of the non-phosphorylated form of 
RNAP II (Figure 4.4-5). Experiments in ES cells reveal that disruption of the transcription factor 
binding site for Sp1 over the aprt gene resulted in loss of expression and subsequent methylation of 
the gene in resulting mice. As CGIs are found over the TSS of many genes, disruption of CGI binding 
factors along with the histone modifications may in some way alter the transcription from underlying 
genes. Indeed the levels of Dnmt1 expression were also reduced to around 50% of wild type in Cfp1 
null ES cells (Carlone, Lee et al. 2005). In order to test whether or not expression levels of genes are 
altered in the shCfp1 cells, the expression from candidate genes were quantified by qPCR analysis 
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between vector control and knockdown cells. Two of the individually transfected cell lines (sh986 and 
sh1960) as well as a cell line transfected with mixture of all three constructs show reduction in gene 
expression across several candidate genes when compared to the vector control cells (Figure 6.4-1). 
Interestingly the sh1250 cell line did not show any change in expression when compared to the vector 
controls and this backs up the finding that these cell lines did not show any depletion in the protein 
levels of cfp1 (data not shown). As the promoter regions of the genes analysed in Figure 6.4-1 were 
also investigated in the ChIP-PCR experiments (Figures 6.2-1 to 6.2-3) the results of this 
transcriptional analysis can be linked to changes in the histone modification profiles. The loss of 
transcription could be as a result of reduced H3K4me3 modifications over the CGIs at these 
promoters, tying the process of CGI maintenance with a functional role in transcription. These 
preliminary findings imply that loss of Cfp1 results in a loss of H3K4me3 from many if not all CGIs 
resulting in a change in the level of transcription from many CGI containing genes.  
 
   
 
Figure 6.4-1. Gene expression for four genes in shCfp1 and control cell lines. Quantitative PCR 
results reveal that the expression of several genes is reduced upon reduction of Cfp1. Both the vector control 
(blue) and sh1250 cl2 (yellow) cell lines contain wild type levels of Cfp1 and shown no discernable differences in 
the expression of Cfp1, bdnf, β-actin or C-myc. In contrast, cell lines deficient in Cfp1; 986 cl4 (tan), 1960 cl4 





































However, this in itself poses a problem towards the normalisation of the data. As the expression data 
is normalised to the expression of the housekeeping gene Gapdh (which has its own 5’ CGI) it is hard 
to properly quantify the signals. Nevertheless the fact that the s1250 transfected cell line doesn’t show 
any changes in expression whilst the cell lines known to be Cfp1 deficient (sh986, 1920 and mix3) do, 
argues that transcription is likely reduced in the absence of wild type Cfp1 levels 
 
Cfp1 deficient cell lines generated previously by other laboratories also reveal links between Cfp1 
levels to transcription and differentiation. Human myeloid cells stably transfected with a short hairpin 
construct directed against Cfp1 resulted in a loss of granulocytic differentiation (Young and Skalnik 
2007). Restoration of Cfp1 levels also restored the differentiation potential of the cell line. Taken 
together with the above findings, loss of Cfp1 may be leading to a loss in H3K4me3 levels at 
promoters, affecting the genes responsible for differentiation.  
 
However, as RNAP II is found at the majority of CGIs alongside Cfp1 and H3K4me3 (see chapter 
4.4.3 section iv) one may argue that RNAP II itself or the act of transcription (not Cfp1) is recruiting 
the H3K4 HMTase complexes such as Set1. To test this further experiment was carried out by Pete 
Skene and Jim Selfridge in the Bird laboratory in which an artificial promoterless CGI was 
interrogated for its protein content (Thomson, Skene et al. 2010). The insertion of an enhanced green 
fluorescent protein (eGFP) reporter gene (containing 60CpGs in 720bp of sequence) and a puromycin 
resistance gene (containing 93 CpGs in 600bp sequence) into the TβC44 ES line results in the 
generation of two promoterless and largely unmetylated CGIs (Chambers, Silva et al. 2007; Thomson, 
Skene et al. 2010). As these CGIs are separated from a promoter they allow for the investigation of the 
proteins and histone modifications recruited to a CGI in a promoterless environment. As RNAP II is 
found at the majority of CGIs in our sequencing analysis this experiment can investigate any links 
between Cfp1 and H3K4me3 at CGIs in the absence of RNAP II (although one may argue that 
transcription is occurring across the CGI as these sequences are found at the 3’ end of the gene for 
Nanog). Interestingly, the insertion of these two CGI-like sequences was enough to generate two 
novel H3K4me3 peaks. Furthermore the pattern of H3K4me3 modification followed that of the 
CXXC protein Cfp1. As this occurs without the recruitment of RNAP II one can argue that Cfp1, and 
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not RNAP II, is the protein responsible for the recruitment of the H3K4 HMTase complexes such as 
Set1 to CGIs through specific interactions with its CXXC domain (Thomson, Skene et al. 2010).  
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Chapter 7: Discussion and future work 
The dinucleotide sequence CpG varies in both its modified state and distribution throughout the 
mammalian genome. Although this dinucleotide is generally found methylated at low density 
throughout the bulk of the genome, discrete regions rich in non-methylated CpGs form around 1% of 
the total genomic sequence. Not only are these regions of interest due to their increased CpG densities, 
they remain stably non-modified in a genome rich in CpG methylation 
i
. These regions, termed CpG 
islands, were found to co-localise to the 5' ends of around 60% of annotated genes (Robert 
Illingworth, unpublished observations). As the majority of these genes are housekeeping in function 
this implies that CGIs may have a link with the regulation of a transcriptional state. Indeed CGI 
methylation has importance in the silencing of genes during X inactivation as well as imprinting 
(Norris, Brockdorff et al. 1991). Additionally, several genes involved in tumour suppression and cell 
cycle regulation have been found to acquire methylation of their CGIs (Dobrovic and Simpfendorfer 
1997; Stirzaker, Millar et al. 1997; Esteller, Garcia-Foncillas et al. 2000; Virmani, Rathi et al. 2001; 
Harden, Tokumaru et al. 2003). As CGIs have the ability to become methylated during these processes 
it suggests that some factor or factors may be protecting these dinucleotides from becoming 
methylated. 
 
7.1 CGIs may be bound by an array of CGI specific proteins  
Previously the study of CGIs has largely focused on the DNA sequence itself and the distribution of 
these CGIs throughout the genome. However, the majority of work has failed to investigate what 
proteins, if any, are specifically bound to CGIs. A notable exception to this was a study carried out by 
Dr Macleod and colleagues in 1994 which investigated the possibility that the transcription factor Sp1 
was in fact a CGI binding protein (Macleod, Charlton et al. 1994). In this work it was found that 
mutation of the Sp1 binding site within the 5’ CGI of the aprt gene in transgenic mice resulted in a 
gain of methylation in resulting mice. Subsequent work on the effect of CpG rich DNA sequences to 
the stability of associated nucleosome raised the possibility that one of the major functions of the CGI 
  
i. Although the majority of CGIs remain methyl-free some are seen to gain methylation in concordinace with gene silencing 
events (<0.1% genome). 
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is to destabilise nucleosomes over promoter regions to allow transcription factors (such as Sp1) to 
bind (Hargreaves, Horng et al. 2009; Ramirez-Carrozzi, Braas et al. 2009; Singh 2009). Although this 
destabilisation effect may assist in the binding of transcription factors, the work presented in this 
thesis along with a recent study by Klose and colleagues (Blackledge, Zhou et al. 2010) reveals that 
CGIs are also bound by a unique set of binding proteins which can in turn affect the local chromatin 
state. These proteins were identified as potential CGI binding factors due to their highly conserved 
CXXC zinc finger binding domain which has previously been shown to bind specifically to non-
methylated CpG dinucleotides in vitro (Voo, Carlone et al. 2000). Further to this, the third CXXC 
domain from the Mbd1 protein was used previously by Dr Rob Illingworth in the laboratory of Adrian 
Bird to purify out non-methylated, CpG rich DNA sequences resulting in a high resolution map of the 
CGIs in both the human and mouse genomes (Illingworth, Kerr et al. 2008; Illingworth, Gruenewald-
Schneider et al. 2010).  
 
In mammals around ten proteins contain this CXXC domain (Figure 1.4-1) of which several have 
roles in the regulation of chromatin state such as the protein DNA methyltransferase Dnmt1 (Pradhan, 
Esteve et al. 2008), the H3K4MTases Mll1 and Mll2 (Birke, Schreiner et al. 2002) and the H3K36 
demethylase Kdm2a (Tsukada, Fang et al. 2006). The work outlined here identifies the CXXC domain 
containing protein as an important CGI specific binding factor within the mammalian genome. As 
Cfp1 is a core component of the Set1 H3K4HMTase, this protein appears to link the underlying DNA 
sequence rich in CpG dinucleotides, to changes in the local chromatin state through modification of 
histone tails.  
 
Early work by Dr Skalnik revealed that Cfp1 can bind to non-methylated CpG rich probes in vitro 
(Voo, Carlone et al. 2000) which was verified in this thesis by in vivo ChIP-PCR experiments over the 
Xist locus. Although other laboratories have studied the Cfp1 protein none had proposed that it may be 
able to bind to CGIs. This was somewhat surprising given the fact that its CXXC domain was known 
to have a preference for non-methylated CpG rich sequences. Instead the majority of work on Cfp1 
has focused on its interactions with other proteins such as the Set1a (Lee and Skalnik 2005) and Set1b 
(Lee, Tate et al. 2007) complexes or the Dnmt1 protein (Butler, Lee et al. 2008). 
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The finding that both Cfp1 and Kdm2a bind to CGIs raises the possibility that the other CXXC 
domain containing proteins may also behave similarly. Indeed Mll1 was shown to bind over CGIs and 
has previously been shown to bind preferentially to non-methylated CpG rich DNA by its CXXC 
domain (Birke, Schreiner et al. 2002). It will be interesting to find out whether Tet1, a protein with 
demethylase activity as well as a CXXC domain, can bind to CGIs in the same way. These CXXC 
domain containing proteins appear to be acting in a similar yet opposing manner to the methyl binding 
domain (MBD) containing proteins; each binding to a particular state of CpG within the genome. This 
ability to bind and interpret modified or non-modified forms of the cytosine base may have arisen 
during evolution as an efficient method to increase the coding potential of the mamalian genome.  
 
7.2 The effects of Cfp1 binding at CGIs 
The evidence presented in this thesis suggests a significant association between the Cfp1 protein and 
the H3K4me3 modification at CGIs. Although the high resolution profiles for several histone 
methylations such as H3K4me3 and H3K27me3 have been collected (Barski, Cuddapah et al. 2007; 
Mikkelsen, Ku et al. 2007) this analysis has not been restricted to CGIs themselves. Upon doing so it 
appears that in addition to containing a unique set of proteins such as Cfp1 and Kdm2a, CGIs are also 
unique in the histone modifications present. This was most noticeable for the enrichment of H3K4me3 
tails and depletion of H3K9me3 and H3K27me3 tails directly over CGIs.   
 
One of the most striking findings of this work has been the intimate association between the CXXC 
domain containing protein Cfp1 and the active histone modification H3K4me3. Both marks were 
found throughout the genome to co-localise to CGIs and depletion of the Cfp1 protein was followed 
closely by levels of H3K4me3 modifications over CGIs. This direct link appears to be facilitated 
through the enzymatic complex responsible for setting up the levels of the histone H3K4me3 
modification. Cfp1 is in fact a subunit of the Set1a/b and yeast COMPASS H3K4 HMTase complexes 
responsible for the setting up and maintenance of the H3K4me3 modification (Lee and Skalnik 2005; 
Lee, Tate et al. 2007; Takahashi, Lee et al. 2009). The homologue of Cfp1 in yeast (Spp1) is not 
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essential for the overall viability of the yeast Set1 complex (Takahashi, Lee et al. 2009); however 
removal of Spp1 results in loss of H3K4me3 levels.  
 
Interestingly Spp1 in yeast lacks the CXXC domain found in its mammalian counterpart, possibly as 
this organism lacks DNA methylation. Therefore the CXXC domain may have arisen in organisms 
containing DNA methylation as a means of targeting the Set1 complex to specific loci (non-
methylated CpG rich regions often occurring at the 5’ ends of genes: CGIs). Indeed sequence 
alignments of the Cfp1 CXXC domain from several organisms reveals high levels of conservation 
within the organisms in which DNA methylation has been detected (Figure 5.2-2). In this regards, the 
CXXC domain within Cfp1 may target the Set1 HMTase complex to CGIs resulting in H3K4me3 at 
these loci (Figure 7.2-1). Loss of this targeting to the 1% of the genome occupied by CGIs would 
reduce the occupancy of the complex at such sites resulting in a CGI specific loss of H3K4me3 marks 
without a disruption on a global level.  
 
The functional significance of the H3K4me3 modification at CGIs is largely unknown however it is 
largely thought to be required to form transcriptionally permissive chromatin (Bannister, Schneider et 
al. 2002; Bernstein, Humphrey et al. 2002; Santos-Rosa, Schneider et al. 2002; Schubeler, MacAlpine 
et al. 2004). As around 60% of promoters contain a CGI, these regions (and their associated 
H3K4me3 modifications) may be important in the regulation of transcription. As the promoters of 
housekeeping genes contain an associated CGI, these non methylated CpG rich regions may be 
required to ensure high levels of transcription.. Although poorly understood, it has been proposed that 
the methylation of H3K4 residues may facilitate the formation of a euchromatic state through the 
attraction of specific H3K4me3 binding factors (Ruthenburg, Allis et al. 2007). Several of these 
H3K4me3 binding proteins have roles in epigenetic regulation such as the protein ING which attracts 
histone acetyltransferase complexes or BPTF which is part of the NURF nucleosomal remodelling 
complex (Mizuguchi, Tsukiyama et al. 1997) and TFIID which is a member of the transcriptional 
machinery associated with RNAPII (Vermeulen, Mulder et al. 2007). The latter of these H3K4me3 
binding proteins may represent a link to the recruitment of the RNAPII complex at CGIs (Figure 7.2-
1, B). The enrichment of H3K4me3 modified histone tails over CGIs may also act to reinforce the 
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binding of Cfp1/Set1 complex at these loci. Studies in yeast have found that the homologue of Cfp1, 
Spp1, contains a PHD domain with a particular preference to histones H3 tails containing the me2 and 
me3 modifications (Murton, Chin et al. 2010)     
 
Alternatively, H3K4me3 modified tails may be refractory to the binding of certain proteins or 
occupancy by “silencing” histone modifications. Indeed the de novo DNA methyltransferase cofactor 
Dnmt3L is unable to bind to histone tails with this modification in vitro (Ooi, Qiu et al. 2007). As 
such, regions of the genome rich in the H3K4me3 modification such as CGIs would remain 
inaccessible to these methyltransferases and would thus remain free of methylation (Figure 7.2-1, A). 
This may therefore go some way to explain how CGIs remain methylation free in a genome which is 
largely methylated. Further analysis of the methylation status of the CGIs in the Cfp1 deficient cell 
line should result in a greater understanding of this model. 
Figure 7.2-1. Potential models for the maintenance of CGI chromatin state. Figure A. shows a 
proposed model whereby the underlying CpG rich non-methylated DNA influences the overlying chromatin state. Cfp1 
(green) is proposed to bind to non methylated CGIs through interactions with its CXXC domain. As Cfp1 is a part of the 
Set1a/b complexes (light blue) this results in the trimethylation of H3K4 residues on the surrounding histones (histone 
octamers represented by grey circles). As histone tails containing this modification has been shown to be antagonistic to 
the binding of Dnmt3 and 3L (yellow) this may represent a model for the maintenance of a non-methylated CGI state.  
Figure B. represents how the H3K4me3 modification at CGIs may affect transcription and the recruitment of RNAPII. 
Specific proteins such as the TFIID factor (purple) bind to H3K4me3 modified tails and may in conjunction with the 
binding of specific transcription factors (“TFs – light blue”) to recruit RNAPII to islands. Therefore both the non 
methylated CpG dinucleotide and the H3K4me3 modified histone tails act as platforms for the binding of chromatin 























As CGIs are often found associated with the 5’ ends of genes it was not surprising to find that many of 
these CGIs co-localised to a peak of RNAP II. However this co-localisation with peaks of H3K4me3 
at CGIs may reflect indirect recruitment of the Set1 complexes by RNAPII itself. Another of the 
mammalian H3K4 HMTases, MLL1 (which also contains a CXXC domain) was found to be tightly 
associated with the RNAP II protein at the 5’ ends of active genes (Guenther, Jenner et al. 2005). The 
ChIP-Sequencing data presented above revealed that around 7% of the Cfp1/H3K4me3 rich CGIs 
were seen to lack RNAPII. This argues that the transcriptional machinery is not a required element for 
the generation of the H3K4me3 peaks over islands. This was tested further by Pete Skene and Jim 
Selfridge in the Bird Laboratory by investigating promoterless “CGI-like” constructs in ES cells. 
Using the TβC44 ES cell line (Chambers, Silva et al. 2007) in which the genes encoding eGFP 
(containing 60 CpGs in a 720bp sequence) or Puromycin (93 CpGs in a 600bp sequence) had been 
inserted into the genome resulted in DNA sequences with the typical CpG density of a CGI with no 
associated promoter. ChIP-PCR over these promoterless CGIs revealed that the non methylated CpG 
rich sequence was sufficient to recruit Cfp1 and to generate a peak of H3K4me3 in the absence of 
RNAPII (Thomson, Skene et al. 2010). As proposed in Figure 7.2-1 B, RNAPII may be recruited to 
CGIs through association with the H3K4me3 binding factor TFIID as well as specific transcription 
factors. This model would go some way to describing the finding that 88% of Cfp1/H3K4me3 
enriched islands also contain the RNAPII protein and suggests that CGIs may have important roles in 
the preparation of promoter regions (at least for the housekeeping genes) for transcription.  
   
7.3 The ES cell discrepancy 
The bulk of the investigations described above were carried out in somatic cells of the mouse brain or 
cultured NIH-3T3 fibroblasts. However, to better understand how these CGIs are initially created it 
may be important to study Cfp1 in the context of the pluripotent stem cell. Cfp1 -/- ES cells have been 
generated in the lab of Dr Skalnik which reportedly contain a four fold increase in the levels of 
H3K4me3 when compared to wild type cells. This is somewhat confusing as our findings along with 
those of Ansari and colleagues reveal a loss of H3K4me3 from CGI loci. This may be in part due to 
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the difference in Cfp1 depletion as the work outlined above and studies carried out by Ansari and 
colleagues reduced Cfp1 levels by antisense transcription whereas Skalnik and colleagues generated a 
knock out cell line. However, this may also be due to the fact that Skalnik’s work was carried out on 
ES cells compared to the HEK293 cells used by Ansari and colleagues and the somatic cells used in 
our own work.  
 
To test if there were any differences in the behaviour of Cfp1 in ES cells, a series of experiments were 
carried out by Thomas Clouaire in the Bird laboratory. ChIP-PCR in WT ES cells gave results similar 
to those shown above for the 3T3 cells (with peaks of binding occurring over the CGIs), however 
when repeated on Cfp1 null ES cells (gifted by Dr Skalnik) this signal failed to disappear. As these 
immunoprecipitations were carried out with the same antibody which detected the reduction of Cfp1 
levels in the shCfp1 3T3 cells this was a surprising result raising the question as to what the antibody 
was recognising in ES cells. To ensure that this finding was an ES cell specific issue, the earlier ChIP-
PCR studies on the shCfp1cells were repeated using an antibody generated by Dr Skalnik raised 
against the full length protein. This antibody gave similar results to those seen using the commercially 
available “H-120” antibody with peaks of enrichment for Cfp1 over the CGIs lost in the knockdown 
cell line (Figure 6.2-4). Genome wide ChIP-Seq with the Skalnik antibody generated data sets which 
closely matched that of the initial antibody (Figure 4.4-3). Therefore it can be concluded that for 
somatic cells both the H-120 commercial antibody and the full length Skalnik antibody specifically 
recognise Cfp1. However, as studies in the Cfp1 null ES cells using the Skalnik antibody resulted in 
the expected loss of signal over CGIs, this raises the possibility that the H-120 antibody is non 
specific in ES cells. As this antibody is raised to a portion of the CXXC domain it might represent the 
detection of another CXXC protein specifically in ES cells. Further work into any ES cell specific 
CGI factors will go some way to better understanding how these islands are initially set up. 
 
7.5 Concluding remarks 
The dinucleotide sequence CpG can be found in both modified and non-modified forms throughout 
the mammalian genome, the distribution of which increases the coding potential of the genome. 
Typically CpG is found to contain a methylated cytosine base at low density (typically 1 per 100bp) 
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throughout the majority (~99%) of the genome. This modified base is bound by a group of proteins 
containing methyl binding domains which in turn recruit enzymatic complexes capable of regulating 
the local chromatin state. Typically these MBD recruited proteins aid the formation of a repressive 
heterochromatic state, linking the modified CpG dinucleotide to a compact chromatin environment. In 
contrast to these methylated CpGs, a fraction of the genomic sequence (approximately 1-2% of the 
total sequence) is seen to contain high densities of the non methylated form of the CpG dinucleotide 
over approximately 1kb stretches of the genome (known as the CpG islands). Furthermore, these CGIs 
are often found associated with the 5’ ends of annotated protein coding genes. In the same way that 
the methylated CpG dinucleotide recruits MBD containing proteins, the work presented here reveals a 
group of proteins containing a CXXC domain which bind specifically to the non-methylated CpG 
dinucleotide. Several of these CXXC proteins have roles in the modulation of the chromatin 
environment. The protein Cfp1 for example is a component of the Set1a and Set1b H3K4 HMTase 
complex responsible for the formation of euchromatin. Additionally the CXXC proteins Mll1 and 
Kdm2a are important for the modulation of the H3K4me3 and a H3K36me3 marks respectively. As 
such these non-methylated islands may be acting as “beacons” for the recruitment and binding of 
factors which modify the chromatin state, simplifying the genome by the restriction of potential 
binding sites to around 1% of the total sequence.  
 
The majority of the work presented here focused upon the protein Cfp1. Although this protein was 
shown to localise to CGIs and be sufficient to establish chromatin rich in the H3K4me3 modification 
the precise mode by which this is accomplished is still unknown. The hypothesis raised is that the 
Set1a and Set1b complexes are recruited to CGIs by Cfp1, resulting in the targeting of the complex 
specifically to non methylated CpGs. Indeed comparisons between Cfp1 and its yeast homologue, 
Spp1 reveal a similar function within an H3K4 HMTase complex. As the yeast lacks methylation, the 
yeast protein lacks any CXXC motif for potential targeting to non-methylated “beacons”. One could 
argue that in the shRNA experiments (chapter 6) depletion of Cfp1 is not resulting in a loss of 
targeting of Set1 complexes but in a reduced functionality of stability of the complex itself. This 
would explain the loss of the H3K4me3 peaks over the CGS however it would not account for the 
near wild type levels of global H3K4me3 seen (Figure 6.1-4). To test this possibility, the CGIs of cell 
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lines containing Cfp1 DNA binding mutants (with mutations in the CXXC domain to remove any 
CXXC specific targeting to islands) could be investigated. If H3K4me3 modifications are lost from 
the islands in the DNA binding mutant cell lines it would indicate a CXXC targeting model for the 
Set1a/b complex. Further experiments could be devised in which the shCfp1 cells could be 
investigated for potential rescue of Cfp1. By adding back either wild type or a DNA binding mutant of 
Cfp1 one could investigate the effects on H3K4me3 levels at islands. If for example the introduction 
of a DNA binding mutant of Cfp1 was able to restore H3K4me3 levels at islands it would argue that 
the loss of Cfp1 targeting is not the main reason for the reduction in H3K4me3 peaks seen in the 
shCfp1 cell lines. Investigations into the precise roles for Cfp1 within the Set1a/b complex are vital in 
the understanding of the functional importance of the proteins associated with CpG islands.    
 
In addition to these studies it is important to attempt to understand the roles of additional factors at 
CGIs such as the possible involvement of another CXXC protein, Mll1. As this H3K4me3 HMTase 
complex was also seen to peak to CGIs, although mainly over promoter regions, it may also be 
responsible for the maintenance of the overlying epigenetic state. Indeed work by Ansari and 
colleagues found that shRNA depletion of Cfp1 also reduced the binding of the Mll1 protein at the 
Hoxa7 CGI along with a reduction of the H3K4me3 signal (Ansari, Mishra et al. 2008).  
 
Overall the findings of this work reveal that the CXXC protein Cfp1 is found specifically at CpG 
islands. Through its specific non methylated DNA binding ability this protein is recruited to the CpG 
islands, modulating histone modifications at such sites. As such this represents a mode whereby DNA 
sequence can drive the overlying chromatin state. Further investigations of Cfp1 and its role at CpG 
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